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Abstract 
The aim of my Ph. D. thesis is to generalize a method for targeted anti-cancer 
drug delivery. Hydrophilic polymer-drug conjugates involve complicated synthesis; drug-
encapsulated polymeric nanoparticles limit the loading capability of payloads. This thesis 
introduces the concept of nanoconjugates to overcome difficulties in synthesis and 
formulation. Drugs with hydroxyl group are able to initiate polyester synthesis in a regio- 
and chemo- selective way, with the mediation of ligand-tunable Zinc catalyst. Herein, 
three anti-cancer drugs are presented to demonstrate the high efficiency and selectivity in 
the method (Chapter 2-4). The obtained particles are stable in salt solution, releasing 
drugs over weeks in controlled manner. With the conjugation of aptamer, particles are 
capable to target prostate cancer cells in vitro. These results open the gateway to evaluate 
the in vivo efficacy of nanoconjugates for target cancer therapy (Chapter 5). Mechanism 
study of the polymerization leads to the discovery of chemosite selective synthesis of 
prodrugs with acrylate functional groups. Functional copolymer-drug conjugates will 
expand the scope of nanoconjugates (Chapter 6). Liposome-aptamer targeting drug 
delivery vehicle is well studied to achieve reversible cell-specific delivery of non-
hydoxyl drugs e.g. cisplatin (Chapter 7). New monomers and polymerization mechanisms 
are explored for polyester in order to synthesize nanoconjugates with variety on 
properties (Chapter 8). Initial efforts to apply this type of prodrugs will be focused on the 
preparation of hydrogels for stem cell research (Chapter 9). 
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CHAPTER 1 
INTRODUCTION 
 
1. Background 
1.1 Nanomedicine and cancer therapy 
Small molecule chemotherapeutics often have undesired physiochemical and 
pharmacological properties, such as low solubility and narrow therapeutic index.[1] These 
drawbacks limit their applications for clinical cancer treatments.  Two strategies have 
emerged over the past 2-3 decades to address these intrinsic drawbacks of 
chemotherapeutics.[2]  One approach is to design and develop new derivatives of 
chemotherapeutics with improved physiochemical and pharmacological properties so that 
they can be used to precisely and specifically modulate the molecular processes and 
pathways associated with tumor progression.[3]  The other widely used approach is to 
modify the existing chemotherapeutic agents using drug delivery technologies.[4]  
Most drug delivery vehicles of chemotherapeutics have particles size below 
200nm and usually contain many therapeutic agents per vehicle.  Nowadays these new 
anticancer modalities were often also termed nanomedicine.  The first generation of 
anticancer nanomedicine has been focused on the preparation of delivery vehicles using 
well-developed biomaterials and methodologies, and on targeting and treating primary 
tumors based mainly on the Enhanced Permeation and Retention effect (EPR effect).[5]  
The EPR effect refers to the accumulation of nanoparticles (NPs) in tumor facilitated by 
the highly permeable nature of the tumor vasculature and poor lymphatic drainage of the 
interstitial fluid surrounding a tumor. Nanocarriers based on passive targeting mechanism 
have been evaluated in clinic since the mid-1980s; the first sets were approved for 
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clinical use in the mid-1990s.[6] The second generation of nanomedicine, however, placed 
a greater emphasis on novel strategies, such as bypassing biological barriers at the 
systemic, tissue, and cellular levels, and targeting metastatic lesions (active targeting).[4c] 
Recent development of new chemistry (e.g. click chemistry[7]) and fabrication 
technologies[8] is expected to allow for unprecedented, precise control of nanomedicine 
formulation, making it possible to evaluate nanomedicine with the variation of one 
parameter (e.g. size, surface property, and shape) at a time.[9]   
In the construction of nanomedicine, lipid and polymer-based systems are 
amongst most extensively explored, accounting for more than half of the nanomedicines 
approved for clinical disease treatment.  I mainly focus on polymeric nanomedicine, 
especially those with the use of poly(lactide) (PLA) based polyesters and their 
copolymers.  
 
1.2 Development of polyester 
Since 1970s, much effort has been focused on developing different polymers for 
drug delivery to improve therapeutic efficacy. The main criteria of the eligibility of 
polymers used in drug delivery involve bioavailability, biocompatibility, straightforward 
production, sustained release of drug and degradation rate.[10] Polyester, alone or in 
combination with other polymers have been widely adapted for the formulation of NPs. 
Poly (lactic acid) (PLA) and poly(lactic-do-glycolic acids) are among the most well 
known choices due to their highly biocompatibility and biodegrade property. These 
aliphatic polyesters have been used for surgical sutures since its first file as resorbable 
suture in 1967 (Schmitt, E. E.; Polistina, R. A. In U.S. Patent, 1967). Drug delivery 
research using PLGA and PLA polymers first confined in low molecular weight steroids 
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for contraception and small peptides such as LHRH analogues in 1970-80s. This area of 
research for slow release of small peptides showed the clinical impact. In 1989, the U.S. 
Food and Drug Administration (FDA) approved the first PLGA system to slowly release 
a peptide[11]. These PLGA matrix slowly release luteinizing hormone releasing hormone 
(LHRH) analogues, which are of about 1200 Da molecular weight. This later becomes 
the most widely used system for treating advanced prostate cancer, endometriosis, and 
precocious puberty. Meanwhile, serious delivery problems for the emerging of large-
molecular-weight drugs (e.g. recombinant proteins) required a sustained dosage system to 
continuously release drugs in unaltered form. PLGA was first investigated by Langer 
group to delivery high molecular weight proteins in 1990[12]. PLGA microspheres with 
diameters of 55-95 µm can encapsulate more than 90% of proteins and slowly release 
them over 100 days in vitro. Later in 1994, Langer group sophisticatedly apply PLA-PEG 
copolymer system for small molecule drug delivery with control release and long 
circulation profiles within simply formulation step and nanometer sizes[13]. The inclusion 
of PEG into the copolymer aims to reduce non-specific effects of protein adsorption and 
colloidal aggregation, and further facilitate circulation. The molecular origins of these 
phenomena are still under investigation [14] . Rapidly growing area to apply PLA and 
PLGA and their combination with other copolymers microparticles and NPs for 
biomedical therapeutics delivery, including small molecules[15], proteins[16] and genes[17]. 
The delivery routes have also been substantially expanded, from injection[13] to 
pulmonary[18], oral[19], and recently targeting delivery strategy[20]. Progress in the 
nanotechnology and microfabrication [21] produced many advanced nanodevices based on 
PLGA and PLA with PEG copolymer for smart drug delivery [22]. Additionally, the 
morphology of nanocarriers is beyond spherical shapes due to the development of 
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microscale technology. In 2005, DeSimone and coworkers [23]  prepared polymeric NPs 
(including PLA copolymer) of various shapes (e.g. cylinder and cube) using the PRINT 
technique and demonstrated in vitro that shape greatly impacted the cellular uptake of 
NPs.  In 2009, Mitragotri and coworkers engineered an intriguing type of nanoparticles 
based on PLGA mimicking the nature shape and size of red blood cells[24]. These new 
particles, similar to their nature counterpart, possess the ability to carry oxygen and flow 
through capillaries smaller than their own diameters. Another area under intense 
investigation is to study the self-assemble of amphilphlic copolymers. The increasing 
understanding in this area eventually creates new delivery vehicles such as polymersomes 
[25] (polymer based liposome) and filamicelles [26]. The flexible cylinder-shaped 
filomicelles (20-60 nm in cross-sectional diameter and a few micrometers in length) in 
rodents could persist in the circulation up to one week after intravenous injection, which 
is about ten-times longer than their spherical counterparts. One trend is to dedicate PLA 
and PLGA in novel biomedical area, such as emerging stem cell areas and siRNA 
regarded as promising therapy. In 2002, human embryonic stem cells could be cultured 
onto supportive 3D PLGA scaffolds, and could be induced to early differentiation [27]. In 
2009 Saltzman and coworkers apply PLGA as siRNA delivery vehicles for in vivo gene 
silencing therapy [28]. A single dose of high amount siRNA-loaded NPs to the mouse 
female reproductive tract caused efficient and sustained gene silencing. Another 
intriguing work published in 2009 by Cheng group showed that PLA-mPEG micelle can 
effectively repair traumatically injured spinal cord through intraveneously injection. 
Substantial attention was recently also focused on designing smart biomaterials on the 
basis of simple structure of PLA and PLGA, including thermosensitive hydrogel 
composed of PLA and PLGA[29], and PLA/polyurethane [30] possessing with shape 
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memory as its similar aliphatic ester PCL[31]. It witness the extensive investigation of 
PLA/PLGA polymers and rapidly growth of their biomedical application, largely 
influenced by the concurrent development in technology and understanding of chemistry, 
biology, and materials science.  As one of the most important and materials for 
nanomedicine, PLA was selected as the basis of my research. The exploration of the 
chemistry, properties, application of PLA leads me to understand the nanomedicine field, 
to synthesize new materials for various applications, and to design new biomaterials and 
chemistries to contribute for the biomedicine society. 
 
1.3 Cancer targeting 
To achieve tumor targeting, nanocarriers must first overcome systemic barriers, 
especially clearance via phagocytic uptake and hepatic filtration. Then they are expected 
to extravasate the tumor vasculature and penetrate the tumor microenvironment so that 
even cancer cells situated distal to the tumor vessel can be exposed to the anticancer 
agent at high enough concentrations.  
The first examples of targeted NPs were reported in 1980, and despite nearly three 
decades of research, targeted NPs have made a limited impact on human health. This, in 
part, is because the optimal bio-physicochemical properties of NPs, including the choice 
of a suitable targeting ligand, have remained elusive. Aptamers (Apts) or single-stranded 
DNA or RNA that can fold into unique conformations capable of binding to specific 
targets with high affinity and specificity recently emerged as a new class of targeting 
ligands that showed some unique abilities unattainable from antibodies or small 
molecules. Apts are non-immunogenic and exhibit remarkable stability in a wide range of 
pH (4–9), temperature, and organic solvents without the loss of activities. The synthesis 
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of Apts is an entirely chemical process that can decrease batch-to-batch variability.[32] 
These advantages of Apts are superior to immunogenic or labile antibodies, which have 
significant batch-to-batch variability due to the dependence on biological systems. 
Farokhzad, et al. demonstrated for the first time that intratumorally administered 
polymeric NPs with surface-coated aptamers specific for prostate-specific membrane 
antigen (PSMA) could successfully recognize and target PSMA-positive lymph node 
carcinoma of prostate (LNCaP) cells and eradicate the tumor more effectively than the 
NPs without aptamers.[33] When injected systemically, the nanoparticle-aptamer 
conjugates could target subcutaneously implanted LNCaP tumor.[20] One of the ultimate 
research goals for my projects is to fabricate delivery vehicles which can efficiently 
target tumors, eventually, in vivo. 
 
2. Scope and Organization 
The aim of my thesis work is to develop potential polymeric drug delivery 
vehicles for the treatment of cancers (e.g. prostate and breast cancers).  Although 
polymeric nanoparticles are attractive vehicles for the delivery of anticancer drugs to 
solid tumors by selective penetration through leaky tumor vessels, many current 
nanoparticle formulations exhibit low drug loading and encapsulation efficiency, bimodal 
particle distributions, and undesirable drug “burst” release kinetics. Our new developed 
technology, described in Chapter 2 to Chapter 5, is expected to overcome the above 
limitations and permit the clinical translation of nanoparticles for polymeric targeted 
cancer therapy. 
The nanoconjugation technique I developed that allows for the efficient 
preparation of PLA-drug conjugated nanoparticles, termed nanoconjugates (NCs).  These 
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nanoconjugates are 100 nm or less in size, have exceptionally high drug loading (up to 
37%), 100% drug loading efficiency and controlled release profiles without the so-called 
“burst” effect.  The comprehensive development of nanoconjugation chemistry are 
documented in Chapter 2, 3, 4, organized by the increased complexity of the drug 
structures from camptothecin to paclitaxel and doxorubicin. Chapter 2 described this 
simple, unique chemistry that allows for one-step conjugation of camptothecin to the 
terminus PLA by the nanoconjugation technique.  The tertiary less reactive hydroxyl 
group on the CPT was activated for LA polymerization by the selection of asymmetric β–
diiminate Zinc (BDI-Zn) catalysts, overcoming conventional tedious coupling chemistry. 
These findings are also reported in one published paper. 
 Chapter 3 showed the efforts to incorporate paclitaxel, a significant potent drug 
for cancer therapy with multi hydroxyls, on PLA. We demonstrated, for the first time, 
anticancer drugs like paclitaxel can be incorporated into polymers in a regioselective 
manner via a well-controlled living polymerization process. The most reactive 2’-OH 
group in paclitaxel can readily initiate the living polymerization of PLA mediated by 
BDI-Zn catalyst. The paper published on 2008 on the development of PLA-paclitaxel 
conjugates set up the basis for our NCs projects. This chapter also includes the work to 
use various cyclic lactones and carbonates as the monomers for living polymerization 
initiated by the combination of paclitaxel/BDI-Zn, expanding the scope of 
nanoconjugates synthesis. 
Addiontionally, doxorubicin, another cancer therapeutic agent which containing 
one amine and three hydroxyl groups, can be incorporated into polymers in a regio- and 
chemo-selective manner via the well-controlled living polymerization process. The 
comprehensive study on the preparation of PLA-doxorubicin NCs, described in Chapter 4, 
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was also reported in the published paper. Therefore, a handful of complicated 
chemotherapeutics with hydroxyl groups widely used in clinical settings have been 
readily incorporated into the biodegradable NCs.   
Successively, Chapter 5 showed the initial efforts to address the translational 
barriers for NCs. We first addressed the formulation issues of NCs. A unique method was 
developed to store NCs in solid form for potential clinical translation. NCs with targeting 
ligands for bone tumor and prostate tumors, respectively, are developed.  Preliminary in 
vivo radiolabeling imaging study showed the potential for tumor targeting. Pre-clinical in 
vivo trials for tumor prevention using PLA-paclitaxel NCs further confirmed the potential 
application of NCs. We published two papers on this topic, nevertheless, to date the 
understanding and improvement of our NCs systems for clinical translation are still 
undergoing. 
Inspired by our new chemistry on the PLA polymerization with regioselective 
initiation on drugs (in Chapter 3 and 4), in 2009, I explored the O-acylation chemistry for 
drugs/ anhydride reaction, catalyzed by the BDI-Zn catalyst. The objective of this project 
is to introducing functional groups in regioselective manner for further modification. 
Chapter 6 concluded the initial efforts for this project. In addition to many drugs we 
studied before, rapamycin, one of the most significant drugs for both immunotherapy and 
cancer treatment, was found to react with various anhydrides with regioselecitivity using 
the developed methods.  This intriguing reaction is expected to provide another elegent 
facile strategy to synthesize new prodrugs for both medicinal chemistry and 
bioconjugation.  
Current cancer targeting strategies use antibodies to recognize specific markers on 
tumor cell surfaces.  However, the resulting antibody-drug delivery systems are often 
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ineffective in vivo as they suffer from inconsistent binding affinity for cancer cells and 
can be potentially immunogenic.  The collaborative work (with Dr. Yi Lu and Dr. Gerard 
Wong group) on liposome –aptamer for targeting delivery of cisplatin to breast cancer 
was documented in Chapter 7. We incorporated aptamers with liposome-based delivery 
systems and successfully delivered cisplatin, an important chemotherapeutic agent, to 
breast cancer cells without significant damage to regular cells.  Furthermore, because 
each patient responds to chemotherapeutics differently, over-dosage of drugs can lead to 
severe consequences. We showed for the first time that a complementary DNA of the 
aptamer can function as “antidote” to prohibit or even disrupt aptamer-mediated targeted 
drug delivery, and one paper was published based on these encouraging findings. The 
results described in Chapter 7 suggested that aptamer-mediated cancer-targeting strategy 
can be highly specific in terms of targeting and dosage modulation.   
Aforementioned six chapters are comprised as the main focus in my graduate 
research.  
It is also demanding to expand the scope of the monomer for polyester not only 
for biomedical use, such as drug conjugates, but also for the plastic engineering. In 2010 
we adapted the monomer O-carboxyanhydride, with the mediation of BDI-Zn catalysts 
and additional co-catalyst (HMDS) to achieve controlled living polymerization of new 
polyesters. Chapter 8 reported the undergoing research of this direction. We expect drugs 
can be potentially incorporated the new polyesters, in order to modulate nanoconjugates 
properties for further biomedical applications. 
Chapter 9 briefly summarized the initial efforts to utilize biomaterials for stem 
cell engineering on regenerative medicine in past one year, through the collaboration with 
Dr. Jennifer Lewis group and Dr. Fei Wang group. The ultimate goal for this project is to 
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delivery biological active cues in controlled manner for regulate stem cell fate. The 
preliminary is involved with the protein delivery and fabrication of scaffolds for 
cultivation stem cells. 
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CHAPTER 2  
NANOCONJUGATES: INCORPORATING CAMPTOTHECIN  
 
 
1. Introduction 
1.1 General consideration of polymer-drug conjugates 
Polymeric nanomedicine, an emerging field that involves the use of drug-
containing polymeric nanoparticles (NPs) for cancer treatment, is expected to alter the 
landscape of oncology. Although the nomenclature of nanomedicine emerged only a few 
years ago, the practice of applying nanotechnology to cancer drug delivery dates back to 
the 1970s. Through numerous efforts, a handful of polymeric NPs have been developed 
and evaluated in various preclinical or clinical studies, some of which have been 
approved for clinical cancer treatment.  
The application of nanotechnology to conventional chemotherapy has obvious 
benefits. In general, the incorporation of chemotherapeutic agents in NP delivery vehicles 
has improved water solubility, reduced clearance, reduced drug resistance and enhanced 
therapeutic effectiveness. However, the drawbacks of the incorporation of 
chemotherapeutic agents in delivery NPs are also obvious. Compared to conventional 
chemotherapy, where all therapeutic agents have identical structures and molecular 
weights, polymeric NPs are heterogeneous in their composition, structure and size. 
The heterogeneities of polymer-drug conjugates, a class of well-known polymeric 
NP delivery vehicles, may result from (1) the polydispersity of the polymer; (2) the lack 
of control over the site on the polymer backbone to which the drug is conjugated; and (3) 
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the lack of control over the regio- and chemoselective conjugation of the therapeutic 
agents containing multiple conjugation-amenable functional groups. These 
heterogeneities are not easily addressable and may present bottlenecks to the clinical 
translation of polymeric NPs. Without eliminating the heterogeneities inherent in 
polymeric-drug conjugates, it will be difficult, if not entirely impossible, to achieve 
advanced drug delivery for targeted or even personalized cancer therapy. In the past 
several decades, there have been numerous efforts to reduce these heterogeneities by 
developing polymers with low polydispersities, conjugating therapeutic agents to the 
termini of polymers or to specific sites along polymer backbones and blocking the 
undesirable conjugation of competing functional groups on therapeutic agents through the 
use of protection and deprotection chemistries.  
Ring-opening polymerization (ROP) for the preparation of polyesters, such as 
polylactide (PLA), which is used in this study, has been investigated extensively. This 
polymerization typically involves lactide (LA) ring opening by a metal-alkoxide (RO-M) 
to form a RO-terminated LA-metal alkoxide (ROOCCH(CH3)O-M), followed by chain 
propagation to form RO-terminated PLA. The RO is connected to the PLA terminus 
through an ester bond.  This process is well understood and has been used extensively for 
the incorporation of hydroxyl-containing small molecules, macromolecules and NPs to 
the termini of PLA. We hypothesis with judicious choices of the metal catalyst, it is 
likely we can incorporate drugs containing hydroxyl group onto the terminus of PLA by 
hydroxyl initiated ROP. Here we first used the drug containing one hydroxyl group to 
demonstrate the concept. 
 
1.2 Incorporation of camptothecin 
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20(S)-Camptothecin (CPT), a topoisomerase II inhibitor isolated from the Chinese 
tree Camptotheca acuminate in the 1960s, exhibits a broad range of anticancer activity in 
various animal models.  CPT has low aqueous solubility in its therapeutically active 
lactone form.  Once placed in an aqueous solution at physiological pH, the lactone form 
of CPT is quickly transformed to its carboxylate form, which is highly toxic and 
therapeutically inactive. Serum albumin preferentially binds to the carboxylate form of 
CPT and serves as the driving force of shifting the lactone-carboxylate equilibrium 
(shown in Scheme 2.1) toward the formation of the carboxylate. These pharmacological 
properties of CPT result in rapid deactivation and fast clearance of CPT from the 
circulation after it is intravenously administered.  To overcome these drawbacks, CPT has 
been conjugated to various polymeric carriers for improved solubility, enhanced stability 
of its lactone form and reduced renal clearance. 
Polymer-CPT conjugates prepared with conventional coupling chemistry have 
various heterogeneities that may impact their pharmacological and pharmacokinetic 
properties in vivo.  For instance, various polymers used for the conjugation of CPT were 
prepared via condensation reaction with molecular weight distributions (MWDs) over a 
range of 1.5 to 2.5.  It is also difficult to control the site of CPT conjugation to polymers 
with pendant functional groups. Furthermore, the direct conjugation of CPT through its 
C20-hydroxyl groups is difficult mulistep reaction; the CPT must first be converted to a 
CPT-amino ester and then conjugated to a polymer that contains carboxylate groups via 
the amine end group of the CPT-amino ester. 
Here, we report a simple, unique chemistry that allows for one-step conjugation of 
CPT to the terminal carboxylate group of polylactide (PLA).  Instead of using coupling 
chemistry, we developed a ring-opening polymerization method to facilitate the 
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incorporation of CPT to PLA.  Through a living polymerization, both the initiation (drug 
incorporation) and the chain propagation proceed in a well-controlled manner and result 
in materials with pre-defined drug loadings and MWDs as narrow as 1.02.  The resulting 
CPT-PLA conjugate was nanoprecipitated to form CPT-PLA conjugate nanoparticles, 
termed nanoconjugates (NCs), around 100 nm in size with narrow polydispersities and 
controlled antitumor toxicities.   
 
 
2. Materials and Methods 
2.1 General 
D,L-Lactide (LA) was purchased from TCI America (Portland, OR), recrystallized 
three times in toluene and stored at -30oC in a glove box prior to use.  The BDI ligands 
and the corresponding metal catalysts ((BDI)MN(TMS)2, M = Mg, Zn) were prepared by 
following the published procedures and stored at -30oC in a glove box prior to use.  All 
anhydrous solvents were purified by being passing through dry alumina columns and 
were kept anhydrous by using molecular sieves.  Doxo·HCl was purchased from Bosche 
Scientific (New Brunswick, NJ) and used as received.  Removal of HCl of Doxo·HCl 
was achieved by following the procedure reported in the literature.  Docetaxel (Dtxl) was 
purchased from LC Laboratories (Woburn, MA) and used as received.  Cy5 was 
synthesized according to the published procedure. All other chemicals were purchased 
from Sigma-Aldrich (St Louis, MO) and used as received, unless otherwise specified.  
The MWs of PLA and Doxo-PLA were determined by a size-exclusion chromatography 
instrument (SEC) equipped with an isocratic pump (Model 1100, Agilent Technology, 
Santa Clara, CA), a DAWN HELEOS 18-angle laser light scattering detector (Wyatt 
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Technology, Santa Barbara, CA) and an Optilab rEX refractive index detector (Wyatt 
Technology, Santa Barbara, CA). The wavelength of the HELEOS detector was set at 
658 nm.  The size exclusion columns used for the separation of PLA and Doxo-PLA 
conjugates were serially connected to a SEC (Phenogel columns 100 Å, 500 Å, 103 Å and 
104 Å, 5 µm, 300 × 7.8 mm, Phenomenex, Torrance, CA) equipped with a 126P solvent 
module and  a System Gold 128 UV detector (Beckman Coulter, Fullerton, CA).  THF 
(HPLC grade) was used as the mobile phase of SEC with a 1-mL/min flow rate. The low 
resolution electrospray ionization mass spectrometry (LR-ESI-MS) experiments were 
performed on a Waters Quattro II Mass Spectrometer.  The high resolution electrospray 
ionization mass spectrometry (HR-ESI MS) experiments were performed on a Micromass 
Q-TOF Ultima system. Matrix assisted laser desorption/ionization-time of flight mass 
spectrometry (MALDI-TOF MS) spectra were collected on an Applied Biosystems 
Voyager-DETM STR system.  HPLC analyses were performed on a System Gold system 
(Beckman Coulter, Fullerton, CA) equipped with a 126P solvent module, a System Gold 
128 UV detector and an analytical pentafluorophenyl column (Curosil-PFP, 250 × 4.6 
mm, 5 μ, Phenomenex, Torrance, CA) or an analytical C18 column (Luna C18, 250 × 4.6 
mm, 5 μ, Phenomenex, Torrance, CA).  The UV wavelength for detecting Pyr-OH or Pyr-
NH2 was set at 300 nm.  The UV wavelength for detecting Doxo was set at 450 nm or 
500 nm, depending on the signal-to-noise ratio in corresponding studies.  The NMR 
experiments were conducted on a Varian U500, a VXR500 or a UI500NB (500 MHz) 
NMR spectrometer.  The sizes and particle polydispersities of the PLA-drug (dye) NCs 
were determined on a ZetaPlus Dynamic Light Scattering (DLS) detector (15-mW laser, 
incident beam = 676 nm, Brookhaven Instruments, Holtsville, NY).  The PC-3 cells 
(ATCC, Manassas, VA) used in the MTT assay were cultured in Ham’s F12K medium 
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containing 10% fetal bovine serum, 1000 units/mL aqueous penicillin G and 100 μg/mL 
streptomycin.   
 
 
2.2 Synthesis and characterization of CPT-PLA nanoconjugates 
2.2.1 General Procedures for the Preparation of CPT-PLA Conjugate via CPT-
Mediated Ring-Opening Polymerization of LA    
(BDI-3)ZnN(TMS)2 (5.5 mg,  8.9 μmol) was dissolved in anhydrous THF (300 
μL).  The solution was added to a vial containing CPT (3.0 mg, 8.6 mmol) and the 
mixture was stirred for 15 min until the CPT was completely dissolved in THF.  LA (124 
mg, 0.86 mmol) was dissolved in a vial containing THF (940 μL) and the resulting 
solution was added to the mixture of CPT/(BDI-3)ZnN(TMS)2 ([LA]0 = 0.69 M).  FT-IR 
was used to follow the conversion of the LA in the polymerization solution by monitoring 
the intensity of the lactone band at 1772 cm-1.  After the LA was completely consumed, 
the polymerization was quenched with ice-cold methanol (10 mL).  The precipitate (CPT-
PLA) was collected by centrifugation and then dried under vacuum.  The resulting CPT-
PLA conjugate was denoted as CPT-LAn where n is the monomer/initiator (LA/CPT) 
molar ratio.  
 
2.2.2 Reaction of CPT with Succinic Anhydride (SA) Mediated by Zn or Mg Catalysts.    
In a glove box, (BDI-3)ZnN(TMS)2 (6.2 mg, 0.01 mmol) was dissolved in 
anhydrous THF (200 μL). The solution was added to a clean vial containing CPT (3.5 mg, 
0.01 mmol) and THF (300 μL) and stirred for 15 min until the CPT was completely 
dissolved.  SA (1.1 mg, 0.011 mmol) in THF (600 μL) was added and the vial was tightly 
 
 19 
sealed.  It was then immediately taken out of the glove box and stirred for 4h at 40oC.  
The reaction was quenched with ice-cold methanol (1 mL).  An aliquot of this solution 
was analyzed by HPLC equipped with an analytical C18 column (Luna C18(2), 250 × 4.6 
mm, 5 μ, Phenomenex, Torrance, CA).  The mobile phase for the HPLC analysis was a 
solvent mixture containing equal volume of acetonitrile and water (0.1% TFA).  All 
HPLC spectra were recorded and analyzed by a UV detector at 370 nm. The areas of the 
HPLC peaks of CPT and the CPT-SA were integrated and used for the quantification of 
their concentrations as compared to corresponding standard curves. An aliquot of the 
reaction mixture was also used for the MS analysis.  
The CPT-SA used for NMR analysis was collected by preparative thin layer 
chromatography (prep-TLC, silica gel with a fluorescent indicator (254 nm), 1.5 mm 
thickness, Aldrich) and developed by ethyl acetate/methanol (v/v = 10/1).  The Rf values 
of CPT and CPT-SA were 0.7 and 0.1, respectively.  The silica gel was removed from the 
glass plate and the CPT-SA was extracted with methanol (2 × 30 mL).  The methanol 
solution was then removed under vacuum; the resulting CPT-SA was analyzed by 1H-
NMR.  1H-NMR (CD3OD, 500 MHz): δ 8.63 (s, 1H, 7-H),  8.21 (d, J = 8.5 Hz, 1H, 12-
H),  8.07 (d, J = 8.0 Hz, 1H, 9-H), 7.87 (td, Jt = 8.5 Hz, Jd = 1.5 Hz, 1H, 11-H), 7.71 (td, 
Jt = 8.0 Hz, Jd = 1.0 Hz, 1H, 10-H), 7.43 (s, 1H, 14-H), 5.57, 5.44 (AB, JAB = 17.0 Hz, 2H, 
17-H), 5.35 (s, 1H, 5-H), 2.81 (t, J = 7.5 Hz, 2H, -CH2-COOH), 2.55 (t, J = 7.5 Hz, 2H, -
CH2-CH2-COOH), 2.24 (m, 2H, 18-H), 0.99 (t, J = 8.0 Hz, 19-H).  MS (LR-ESI, positive 
mode): calcualted for C24H20N2O7 [M + H]+ m/z 449.1; found m/z 449.1. MS (HR-ESI, 
positive mode): calcualted for C24H20N2O7 [M + H]+ m/z 449.1349; found m/z 449.1355. 
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2.2.3 General Procedure for the Formation and Characterization CPT-PLA 
Nanoconjugates (NCs)   
 A DMF solution containing the CPT-LA10 conjugate (100 μL, 5 mg/mL) was 
added dropwise to nanopure water (4 mL).  The resulting CPT-LA10 NCs were collected 
by ultrafiltration (15 min, 3000 × g, Ultracel membrane with 10,000 NMWL, Millipore, 
Billerica, MA) and were characterized by DLS and SEM for particle sizes and by HPLC 
for drug loading and release kinetics.  
 
2.2.4 Hydrolysis of CPT-LA10 NCs    
The CPT-LA10 NC in water (1 mL, 1 mg/mL) was treated with a NaOH solution 
(1M, 1 mL) for 12 h.  The solution was then tuned to pH 2 by phosphoric acid addition, 
which resulted in a yellow solution.  The solvent was removed by rotary evaporation. The 
resulting residue was then dissolved in acetonitrile/water (0.1% TFA) (v/v = 1/1) and 
injected into a semi-prep HPLC column (Jupitor Proteo 90 A, 250 × 21.20 mm, 10 μ, 
Phenomenex, Torrance, CA). The fraction that had the identical elution time as the 
authentic CPT was collected.  After the solvent was removed by vacuum, the resulting 
yellow oily residue was dissolved in phosphoric acid/methanol at a volume ratio of 1:1. 
The solution was tuned to pH 3-4 by 0.1 M NaOH and then extracted with chloroform (5 
× 100 mL).  The organic phase was combined and dried with MgSO4.  After the MgSO4 
was removed by filtration and the solvent was removed under vacuum, the resulting pale 
yellow solid was analyzed by 1H-NMR. The 1H-NMR spectrum of the CPT released from 
CPT-PLA NCs was identical to that of the authentic CPT (see Figure 2.6) [1]. 
 
2.2.5 Release Kinetics of the CPT-LAn NCs and the CPT/PLA Nanoparticle (NP) 
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 CPT/PLA NPs were prepared through nanoprecipitation of CPT and PLA (MW = 
1.5 × 104 g/mol) by following the procedures reported in literature [2]. The CPT-LA10 
NCs were prepared with CPT-LA10 conjugate by following the standard nanoprecipitation 
procedure described above. The NCs (or NPs) were collected and washed three times 
with nanopure water by ultrafiltration (Ultracel membrane 10,000 NMWL, Millipore, 
Billerica, MA). The NCs (or NPs) collected from the ultrafiltration device were dispersed 
in 1× PBS solution (1 mg/mL) and incubated at 37oC.  At selected time intervals, an 
aliquot of NCs (or NPs) (≈ 1 mL) was taken out of the incubator and centrifuged at 
10,000 rpm for 10 min. The supernatant (500 μL) was carefully transferred to an 
Eppendorf tube using micropipette without disturbing the precipitates (NCs or NPs). The 
solution was tuned to pH 2 by phosphoric acid (85%) and the resulting solution was 
directly injected into HPLC equipped with an analytical pentafluorophenyl RP-column 
(Curosil-PFP, 250 × 4.6 mm, 5 μ, Phenomenex, Torrance, CA). A mixture of acetonitrile 
and water (containing 0.1% TFA) at a volume ratio of 1:1 was used as the mobile phase.  
The flow rate was set at 1 mL/min.  The area of the HPLC peak of the released CPT was 
intergraded for the quantification of CPT as compared to the standard curve for this drug. 
   
2.2.6 Determination of the Cytotoxicity of CPT-LAn NCs   
PC-3 cells were placed in a 96-well plate for 24 h (10,000 cells per well). Cells 
were washed with 100 μL of pre-warmed PBS. Freshly prepared CPT-LA10, CPT-LA25 
and CPT-LA50 NCs (prepared in 1× PBS, 100 μL) were added to the cells.   CPT was 
used as a positive control.  Untreated cells were used as a negative control.  PLA NPs 
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without CPT being conjugated or encapsulated were prepared via the nanoprecipitation of 
the PLA with a MW of 14 kDa [2-3] and were subsequently used as a negative control in 
the MTT study.  The PLA-NPs were applied to PC-3 cells at a concentration up to 0.5 
μg/mL.  The cells were incubated for 72 h in a 5% CO2 incubator at 37oC.  The standard 
MTT assay protocols were followed thereafter [4]. 
 
 
3. Results and Discussion 
3.1 Synthesis of CPT-PLA nanoconjugates 
3.1.1 (BDI)MN(TMS)2/CPT (M=Zn, Mg)-Mediated Polymerization of Lactide 
We first tested the feasibility of forming CPT-metal complex.  (BDI-
1)MgN(TMS)2, was dissolved in THF.  A colorless solution was obtained.  We then 
added this solution to a vial containing CPT powder (1 equivalent relative to (BDI-
1)MgN(TMS)2). After the mixture was stirred for 20 min, it was noted that CPT was 
completely dissolved and the solution color gradually became orange.  In the absence of 
(BDI-1)MgN(TMS)2, however, CPT remained insoluble in THF and the solution stayed 
colorless.  The sharp contrast of the solubility of CPT in the presence versus in the 
absence of (BDI-1)MgN(TMS)2 as well as the color change after CPT was mixed with 
(BDI-1)MgN(TMS)2 suggest possibly a coordination reaction between CPT and the 
(BDI-1)MgN(TMS)2.  (BDI-1)Mg-CPT alkoxide through the C20-OH of CPT is 
presumably the complex formed in situ via the coordination of (BDI-1)MgN(TMS)2 and 
CPT (Figure 2.1).   
We next examined if the mixture of (BDI-1)MgN(TMS)2/CPT could initiate LA 
polymerization. After LA (100 equiv.) in THF was added dropwise to the (BDI-
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1)MgN(TMS)2/CPT mixture,  the polymerization proceeded rapidly and completed 
within 10 h with 100% LA conversion; the monomer conversion was followed by 
monitoring the intensity of the lactone band of LA at 1772 cm-1 on a FT-IR.  One 
interesting observation was that the orange color of the polymerization solution gradually 
faded away during the course of polymerization, which indicated the segregation of the 
(BDI-1)Mg from CPT.  This observation was in good agreement with the proposed 
reaction mechanism as shown in Figure 2.1a.  After 100% LA conversion was achieved, 
the polymerization solution was analyzed by HPLC, which showed that CPT was 
completely incorporated to PLA with no detectable free CPT in the polymerization 
solution (data not shown). This observation was similar to what we observed in 
paclitaxel- and doxorubicin-initiated LA polymerization, both of which gave 100% drug 
incorporation efficiency in corresponding drug-initiated polymerization [5].  The Mn of the 
resulting CPT-PLA conjugate was 1.13 × 104 g/mol, which was in good agreement with 
the expected Mn (1.47 × 104 g/mol) (entry 1, Table 2.1). The molecular weight 
distribution (MWD) of the CPT-PLA conjugate, however, was relatively broad (Mw/Mn = 
1.31) due in part to the chain transfer during polymerization [6].  In our previous studies of 
paclitaxel and doxorubicin initiated LA polymerization, only the primary or the 
secondary hydroxyl groups of these drugs could efficiently initiate the polymerizations of 
LA [5].  The present study demonstrated for the first time that the C20-OH of CPT, a 
tertiary hydroxyl group, could also be activated by (BDI-1)MgN(TMS)2 to initiate LA 
polymerization.  
In order to achieve better controlled polymerization, we next tested (BDI-
1)ZnN(TMS)2, a Zn analogue of (BDI-1)MgN(TMS)2.  As reported by Coates and 
coworkers, Zn catalysts in general outperform Mg catalysts for LA polymerization [6].    
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After (BDI-1)ZnN(TMS)2 and CPT were mixed and stirred for 20 min, a light yellow 
solution was obtained.  This (BDI-1)ZnN(TMS)2/CPT  complex mediated LA 
polymerization at a M/I ratio of 100 and gave CPT-PLA conjugate with a very narrow 
MWD (Mw/Mn = 1.07, entry 2, Table 2.1).  However, the CPT incorporation efficiency 
was only 61% based on the HPLC analysis, indicating the poor efficiency of forming Zn-
CPT complex during the initiation step.  The actual M/I ratio in this reaction was 163 
(calculated based on the LA/CPT ratio of 100:0.61).  It was therefore not surprising that 
the obtained Mn (2.83 × 104 g/mol) was substantially higher than the Mn calculated based 
on the LA/CPT ratio of 100:1 (expected Mn = 1.47 × 104 g/mol, entry 2, Table 2.1).  The 
poor efficiency for the coordination of CPT with (BDI-1)ZnN(TMS)2 was due in part to 
the relatively low activity of Zn as compared to Mg as well as the steric bulk of BDI-1 
ligand surrounding the coordination site (Figure 2.1b).  We next studied whether 
enhanced incorporation efficiency of CPT could be achieved by using a Zn catalyst with 
a BDI ligand with reduced steric bulk and/or altered electronic property. 
It has been reported that subtle change of BDI ligands can significantly affect the 
activity of (BDI)ZnN(TMS)2 and its capability of controlling the polymerizations of 
cyclic esters or carbonates [7].  Specifically, the 2, 6-substituents of the aryl groups (at the 
R1 and R2 positions) and the substitute at the R3 position were found to have profound 
effects on the activities of the catalysts (Figure 2.1b) [8].  We synthesized a series of zinc 
catalysts containing BDI ligands with variable 2, 6-aryl substituents and R3 group (Figure 
2.1b) and then used these catalysts in CPT-initiated LA polymerizations.  We first 
checked the effect of the steric bulk of BDI on the LA polymerization.  BDI-2 is an 
analogue of BDI-1 whose isopropyl (iPr) groups at both R1 and R2 position were replaced 
by ethyl (Et) groups; while BDI-3 is an analogue of BDI-1 whose iPr groups were 
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replaced by Et groups only at both R1 position.   Both ligands were synthesized and used 
to prepare the corresponding (BDI)ZnN(TMS)2 catalysts.  As expected, the steric bulk of 
the BDI at its R1 and R2 positions had profound effect on the capability of the Zn catalysts 
to form coordination complexes with CPT during the initiation step.  As compared to the 
61% of incorporation efficiency observed with the use of (BDI-1)ZnN(TMS)2,  100% 
incorporation efficiencies were observed in both (BDI-2)ZnN(TMS)2/CPT and (BDI-
3)ZnN(TMS)2/CPT mediated polymerizations.  The corresponding Mn’s (2.01 × 104 
g/mol and 1.73 × 104 g/mol, entries 3 and 4, Table 2.1) were much closer to the expected 
Mn than that of the PLA-CPT obtained from the (BDI-1)ZnN(TMS)2/CPT mediated LA 
polymerization (entry 2, Table 2.1).  Narrow MWDs (Mw/Mn < 1.2) were obtained for the 
CPT-PLA conjugates derived from (BDI-2)ZnN(TMS)2/CPT and (BDI-
3)ZnN(TMS)2/CPT mediated polymerizations (entries 3 and 4, Table 2.1).  BDI-4, an 
analogue of BDI-3 with a cyano group at the R3 position (Figure 2.1b), was also prepared 
and studied.  However, CPT remained insoluble in THF containing 1 equiv. (BDI-
4)ZnN(TMS)2, indicating the poor efficiency of forming (BDI-4)ZnN(TMS)2/CPT 
coordination complex at room temperature.  Thus, it was not surprising that the mixture 
of CPT and (BDI-4)ZnN(TMS)2 could not initiate LA polymerization at room 
temperature (entry 5, Table 2.1).    When this mixture of CPT and (BDI-4)ZnN(TMS)2 
was incubated at 40oC for 20-30 min, CPT was completely dissolved, suggesting the 
formation of (BDI-4)ZnN(TMS)2/CPT coordination complex requires higher temperature. 
The CPT-PLA conjugate derived from (BDI-4)ZnN(TMS)2/CPT-mediated LA 
polymerization had a high loading efficiency (98%) and a Mn very close to the expected 
molecular weight (entry 6, Table 2.1),  but its MWD (Mw/Mn = 1.32, Table 2.1) was 
broader than the CPT-PLA conjugate derived from the (BDI-3)ZnN(TMS)2/CPT-
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mediated polymerizations.  Based on these preliminary studies, (BDI-3)ZnN(TMS)2 was 
found to be the overall best catalyst with respect to control over CPT incorporation and 
polymerization.  (BDI-3)ZnN(TMS)2 was therefore selected for further investigation for 
its capability of controlling polymerization of LA at various LA/CPT ratios.   
Excellently controlled polymerizations were observed over a broad range of 
LA/CPT ratios from 75 to 400 when the LA polymerizations were mediated by (BDI-
3)ZnN(TMS)2/CPT  (Table 2.2).  Quantitative CPT incorporation efficiencies and very 
narrow MWDs (Mw/Mn = 1.02-1.18) were observed in all experiments performed.  The 
obtained MWs of the CPT-PLA conjugates were in excellent agreement with the 
expected MWs (Table 2.2), which followed a linear correlation with the LA/CPT ratios 
(Figure 2.2a).  Monomodal GPC MW distribution curves were observed in all CPT-PLA 
conjugates prepared with various LA/CPT ratios (Figure 2.2b).  The well-controlled 
polymerization mediated by (BDI-3)ZnN(TMS)2 likely proceeded through the 
conventional insertion-coordination mechanism (Scheme 2.2a). 
 
Scheme 2.1  Equilibrium of CPT Lactone and Carboxylate Forms 
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Scheme 2.2 Suggested Insertion−Coordination Mechanism of (BDI)Zn-OR Mediated Ring 
Opening of (a) LA and (b) SA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1  (a) Schematic illustration of (BDI-3)ZnN(TMS)2/CPT mediated ring-opening 
polymerization of LA to make CPT-PLA conjugates followed by nanoprecipitation of the 
resulting CPT-PLA conjugates for the preparation of CPT-PLA nanoconjugates; (b) The structure 
of (BDI-m)ZnN(TMS)2 (m = 1-4). 
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Figure 2.2  (a) (BDI-3)ZnN(TMS)2/CPT mediated ring-opening polymerization of LA at various 
LA/CPT ratios; (b) Overlay of the GPC trace of CPT-LA75, CPT-LA200 and CPT-LA400 prepared 
by (BDI-3)ZnN(TMS)2/CPT mediated LA polymerizations. 
 
 
Table 2.1  CPT/(BDI)MN(TMS)2 Mediated LA Polymerization (M = Zn or Mg).a 
entry catalyst temp. IE (%)b CV (%)c M n (×10
4g/mol)
MWD 
(M w/M n)
1 (BDI-1)MgN(TMS)2 r.t. >99 >99 1.13 1.31
2 (BDI-1)ZnN(TMS)2 r.t. 61 >99 2.83 1.07
3 (BDI-2)ZnN(TMS)2 r.t. >99 >99 2.01 1.20
4 (BDI-3)ZnN(TMS)2 r.t. >99 >99 1.73 1.18
5 (BDI-4)ZnN(TMS)2 r.t. 0 0 ND N.D
6 (BDI-4)ZnN(TMS)2 40 oC >98 >98 1.12 1.32  
aAll reactions were performed at a LA/CPT/catalyst ratio of 100:1:1.01 in anhydrous THF for 12 
h ([LA]0= 0.69 M). The expected Mn of CPT-PLA conjugate = 1.47 ×104 g/mol. Abbreviation: 
LA = lactide; CPT = camptothecin; temp. = temperature; IE = incorporation efficiency; CV = 
conversion of LA; ND = not determined.  bDetermined by the HPLC measurement of the 
unreacted CPT in the polymerization solution. cDetermined by monitoring the IR band of the LA 
lactone at 1772 cm-1.   
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Table 2.2  CPT/(BDI-3)ZnN(TMS)2 Mediated LA Polymerization at Various LA/CPT Ratios.a 
entry [LA]/[CPT] IE (%)b CV (%)c
M n Cal  
(×103g/mol)
M n  
(×103g/mol)
MWD 
(M w/M n)
1 75 >99 >99 11.1 10.4 1.02
2 100 >99 >99 14.7 17.3 1.18
3 200 >99 >99 29.1 26.6 1.13
4 300 >99 >99 43.5 40.1 1.11
5 400 >99 >99 57.9 48.0 1.16  
aAll reactions were performed in anhydrous THF for 12 h at room temperature ([LA]0= 0.69 M). 
Abbreviation: LA = lactide; CPT = camptothecin; IE = incorporation efficiency; CV = conversion 
of LA; bDetermined by the HPLC measurement of the unreacted CPT in the polymerization 
solution. cDetermined by monitoring IR band of LA lactone at 1772 cm-1.   
 
 
3.1.2 Control of Initiation by (BDI)ZnN(TMS)2 Catalysts 
As mentioned earlier, the lactone ring of CPT should be preserved in order to 
maintain the antitumor activity of CPT.  However, it is known that the lactone ring of 
CPT is unstable and subject to ring opening in the presence of a nucleophile.  We next 
studied how the initiation could be specifically controlled at the C20-OH of CPT with 
negligible CPT lactone ring opening during (BDI)ZnN(TMS)2/CPT initiated LA 
polymerizations.   
In the initiation step, LA first reacts with (BDI)Zn-CPT alkoxide and then is 
inserted between the CPT and Zn to generate (BDI)Zn-lactide-CPT alkoxide, the new 
chain-propagating end group (Scheme 2.2a).   CPT does not involve the subsequent chain 
propagation.  Apparently, the most critical step determining whether the lactone ring of 
CPT is opened or remains closed is the initiation step.  As LA is subject to rapid 
polymerization and the resulting CPT-PLA conjugate is difficult to be precisely 
characterized, we used succinic anhydride (SA) as the model monomer to study 
 
 30 
(BDI)ZnN(TMS)2/CPT-mediated initiation.  Such a reaction led to the formation of CPT-
succinic acid (CPT-SA), a small molecule instead of a polymer, whose structure can be 
easily determined by routine characterization methods.      
When just CPT and SA were mixed without addition of other reagents, no 
reaction occurred (entry 1, Table 2.3). Triethylamine (TEA), a non-nucleophilic base, has 
been used previously to facilitate the ring opening of SA by an alcohol [9]. When TEA 
was added to the mixture of CPT and SA, the reaction was very slow and generated CPT-
SA with a yield of 10.6% after the reaction mixture was incubated at 40oC for 12 h (peak 
z, Figure 2.3a-i; entry 2, Table 2.3). A substantial amount of CPT in its carboxylate form 
was also detected (peak x, Figure 2.3a-i), indicating that the lactone ring of CPT was 
unstable in the presence of TEA.  In a control study, when naphthalene ethanol, an 
alcohol with a primary -OH group that is supposed be more reactive for nucleophilic 
reaction than the tertiary C20-OH of CPT, was used for the conjugation with SA in the 
presence of TEA, the yield of naphthalene-SA was 86.8% (data not shown).     
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC), in conjunction with 4-
(dimethylamino)-pyridine (DMAP), has been used previously for the conjugation of CPT 
with SA [10].  When the reaction of CPT and SA was performed in the presence of EDC 
and DMAP at 40oC for 12 h, the yield of CPT-SA was only 12.8% (entry 3, Table 2.3), 
which was in good agreement with the previously reported result [10] and further 
confirmed the low activity of the tertiary C20-OH group of CPT. 
We next studied the ring opening of SA by CPT in the presence of Mg or Zn 
catalysts. (BDI-1)MgN(TMS)2-mediated conjugation of CPT and SA resulted in CPT-SA 
conjugates (Scheme 2.2b) with 59.5% yield when the reaction was carried out at 40oC for 
4 h ( entry 4, Table 2.3).  CPT in carboxylate form was also detected (peak x, Figure 
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2.3a-ii), indicating the CPT lactone ring was opened in the presence of (BDI-
1)MgN(TMS)2 and that it may function not only as a ROP catalyst but also as a strong 
base.  The mechanism of ring opening remains elusive.  When such a reaction was 
mediated by (BDI-1)ZnN(TMS)2, a weaker base and a less reactive ROP catalyst 
compared to its Mg analogue, CPT-SA in 18.8% yield was obtained (entry 5, Table 2.3).  
Formation of small amount of CPT in its carboxylate form was also detected (peak x, 
Figure 2.3a-iii).  
As shown in the polymerization study mentioned above (Table 2.1), the chelating 
BDI ligands have a significant impact on the activities of the BDI-metal complexes for 
LA polymerization. We tested (BDI-3)ZnN(TMS)2, which was previously identified to be 
the best catalyst for CPT initiated LA polymerization, in this CPT/SA conjugation 
reaction.  CPT-SA in 89.1% yield was obtained when the reaction of CPT and SA was 
carried out at 40oC for 4 h in the presence of (BDI-3)ZnN(TMS)2 (entry 6, Table 2.3).  
The substantially increased yield of CPT-SA in this experiment indicated that (BDI-
3)ZnN(TMS)2 activated the tertiary C20-OH group of CPT very effectively to allow for 
facile nucleophilic ring opening of SA.  Very interestingly, CPT-SA was the only product 
formed; no carboxylate form of CPT was detected (Figure 2.4a-iv). Excellently 
controlled ring opening of SA by CPT with no detectable CPT carboxylate was also 
observed with the use of (BDI-4)ZnN(TMS)2 (Figure 2.3a-v), although the yield of the 
CPT-SA (71.7%, entry 7, Table 2.3) was not as high as that derived from the (BDI-
3)ZnN(TMS)2-mediated reaction(entry 6, Table 2.3).   
The CPT-SA (peak z, Figure 2.3a-iv) was collected by preparative thin layer 
chromatography and analyzed by MS (Figure 2.3c) and 1H NMR (Figure 2.3d-e).  The 
high resolution MS analysis showed that the CPT-SA has a [M + H]+ m/z= 449.1355, 
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which was in excellent agreement with the expected [M + H]+ m/z= 449.1349.  To 
determine whether the SA ring was opened by the C17-OH (formed after the opening of 
the lactone ring of CPT) or by the C20-OH (Figure 2.3b), we compared the 1H-NMR 
spectra of CPT-SA and CPT (Figure 2.3e).  If the C17-OH mediated the ring opening of 
SA, the chemical shift of the C17-H of CPT-SA should change to some extent.  However, 
as shown in Figure 3e, the chemical shift of the C17-H of CPT-SA was nearly identical to 
that of the authentic CPT (with a change of less than 0.03 ppm, Figure 2.3e), indicating 
that the lactone ring of CPT is well preserved in CPT-SA.  In fact, the only major change 
of the chemical shifts among all the protons of CPT was the C18-H, which was shifted 
downfield from 1.97 ppm for CPT to 2.23 ppm for CPT-SA (Figure 2.3e). The only 
possible explanation is that the SA ring was opened by the C20-OH by CPT (Figure 2.3b).  
The high yield of CPT-SA obtained in this experiment indicated that (BDI-3)ZnN(TMS)2 
was capable of efficiently activating the C20-OH of CPT to facilitate the ring-opening 
reaction with SA.  The CPT/SA ring-opening conjugation mediated by BDI-Zn catalyst 
appeared to be a versatile method for converting the C20-hydroxyl group of CPT to a 
carboxylic acid end group with a degradable ester linker, which can be further used for 
conjugation to various drug delivery vehicles through the conventional carboxylate-
amine coupling chemistry.  
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Table 2.3 Ring Opening of Succinic Anhydride (SA) by CPT in the Presence of TEA, 
EDC/DMAP or (BDI)MN(TMS)2 (M = Mg or Zn).a     
 
entry temp. (oC) catalyst solvent time (h) yield (%)c
1 r.t / THF 24 0
2 40 TEA THF 12 10.6
3 40 EDC/DMAPb pyridine 12 12.8
4 40 (BDI-1)MgN(TMS)2 THF 4 59.5
5 40 (BDI-1)ZnN(TMS)2 THF 4 18.8
6 40 (BDI-3)ZnN(TMS)2 THF 4 89.1
7 40 (BDI-4)ZnN(TMS)2 THF 4 71.7  
aAll reactions were performed at a SA/CPT/catalyst ratio of 1.1:1:1 ([SA]0= 0.01 M). 
Abbreviation: SA = succinic anhydride; CPT = camptothecin; TEA = triethylamine; temp. = 
temperature; EDC = N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide; DMAP = 4-
dimethylaminopyridine; b[EDC]/[DMAP]=4/1. cDetermined by the HPLC measurement of the 
CPT-succinic ester (CPT-SA) generated in the reaction solution. 
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Figure 2.3  (a) HPLC analysis of the reaction of SA and CPT in the presence of (i) TEA, (ii) 
(BDI-1)MgNTMS2, (iii) (BDI-1)ZnNTMS2, (iv) (BDI-3)ZnNTMS2 or (v) (BDI-4)ZnNTMS2; (b) 
Structure and H-assignment of CPT-SA. (c) ESI-MS of CPT-SA (positive mode). [M+H]+: m/z 
449.1. High resolution ESI-MS for [M+H]+ obtained: m/z 449.1355; calculated: m/z 449.1349; (d) 
1H NMR of CPT-SA (CD3OD, 500 MHz). (e) The chemical shift values of CPT and CPT-SA 
derived from the corresponding 1H-NMR spectra 
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3.1.3 Controlled Formation of CPT-PLA Nanoconjugates and Their in vitro Evaluation  
CPT-PLA conjugated nanoparticles, termed nanoconjugates (NCs) in this study to 
differentiate them from the NPs prepared by co-precipitating drugs and polymers, were 
readily prepared through the nanoprecipitation of CPT-PLA conjugates (Figure 2.1a) 
after the metal and the BDI ligand were removed by solvent extraction.  NCs less than 
100 nm in size with narrow, monomodal particle distributions were readily obtained 
(Table 2.4 and Figure 2.4).  The narrow size distributions of NCs were in sharp contrast 
to the multimodal particle distributions frequently observed in the NPs prepared by the 
co-precipitation of polymers and drugs [2-3]. It is not clear why NCs derived from the 
nanoprecipitation of PLA-CPT conjugates have such narrow size distributions (Figure 
2.4a).  As the multimodal particle distributions in conventional NPs were attributed in 
part to the self-aggregation of the non-encapsulated drugs [2], the unimolecular structure 
of polymer-drug conjugates with reduced heterogeneities (low polymer polydispersities, 
controlled site of conjugation on CPT and PLA, absence of free CPT) may contribute to 
the formation of NCs with low particle polydispersity. 
Because both monomer conversion and drug incorporation were quantitative 
(Table 2.4), the drug loadings of CPT-PLA NCs can be pre-determined by adjusting 
LA/CPT feeding ratios.   At a low M/I ratio of 10, the drug loading of CPT-PLA NC can 
be as high as 19.5 % (CPT-LA10, Table 2.4).  To our knowledge, this CPT-PLA NC has 
by far one of the highest loadings of CPT ever reported.  Even at this high drug loading, 
sustained release of CPT from CPT-LA10 NC was observed through the hydrolysis of the 
ester linker that connects the CPT and the PLA (Figure 2.5a).  No burst release of CPT 
was observed in the CPT-LA10 NC (Figure 2.5a).  This observation was in sharp contrast 
to the burst release of PLA/CPT NP that was prepared by the co-precipitation of CPT and 
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PLA.  In the latter system, the release of CPT depends entirely on diffusion of the drug 
from polymer matrices; as much as 97.1% of the encapsulated CPT was released from 
CPT/PLA NP when the NP was incubated in PBS for 24 h at 37oC (Figure 2.5a).  The 
released CPT (in PBS) has an HPLC elusion time identical to the authentic CPT (Figure 
2.6a) and was confirmed to have the identical molecular structure as the authentic CPT 
after it was isolated and characterized by 1H NMR (Figure 2.6b). 
The in vitro toxicities of CPT-PLA NCs were determined by MTT assays in PC-3 
cells (Figure 2.5b). The IC50’s of CPT-LA10, CPT-LA25 and CPT-LA50 NCs with similar 
sizes (50-100 nm) were 389, 730, and 908 nM, respectively.  The MTT studies revealed 
that the toxicity of the CPT-PLA NC, which was directly related to the release kinetics of 
CPT, could be tuned by the CPT loading in the NCs (Figure 2.5b).  In general, NCs with 
higher drug loadings released drug more rapidly [5] and therefore showed higher toxicities 
(Figure 2.5b).  This observation was presumably due to the fact that the NCs derived 
from the nanoprecipitation of the higher loading (lower MW) CPT-PLA conjugates have 
more loosely packed structures, as compared to the NCs derived from the lower loading 
(higher MW) CPT-PLA conjugates.  Therefore, the ester linkers between CPT and PLA 
in the NCs with higher drug loadings were more accessible to the aqueous phase and 
were subject to faster hydrolysis.   PLA NPs without CPT were used as a negative control 
and were found to show negligible toxicity to the PC-3 cells. The cell viability was 0.956 
± 0.003 when the PC-3 cells were incubated with the PLA NPs at a concentration of 0.5 
μg/mL for 72 h at 37oC.      
Conventional polymeric NPs prepared via co-precipitation of polymers and drugs 
have several formulation challenges that remain to be addressed [11].  NPs typically 
exhibit a “burst” drug release in aqueous solution; as much as 80-90% of the 
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encapsulated drugs are rapidly released during the first few to tens of hours [12].  The rapid 
dose dumping may cause severe systemic toxicities [13].  In addition, drug loadings in 
conventional NPs can be very low, typically in a range of 1-5% in most NPs studied [12, 
14].  Drug loading of a delivery vehicle has been a critical measure of its utility in clinical 
settings [15]. At lower drug loadings, a larger amount of delivery vehicles are needed.  
Due to the limited body weight and blood volume of animals, the administered volumes 
are usually fixed. For instance, the volume of a solution intravenously administered to 
mice with 20- to 30-g body weights should be controlled to below 100 µL [16].  
Intravenous administration of NPs with 1 wt% drug loading in a 100 µL solution at a 
dose of 50 mg/kg to a nude mouse with 20-g body weight requires the formulation of a 
concentrated, 1 g/mL NP solution, which is too viscous to formulate and inject 
intravenously.  The third major challenge presented by NPs prepared via the 
encapsulation approach is the lack of a general strategy to achieve quantitative drug 
encapsulation.  Depending on the amount of drug used, the hydrophobicity and 
hydrophilicity of the drug and the compatibility of the drug and polymer, the 
encapsulation efficiencies vary drastically over a range of 10 to 90% [12, 17]. Non-
encapsulated drugs may self-aggregate [12] and can be very difficult to remove from the 
NPs.  These formulation challenges significantly impact the process ability and clinical 
translation of NP delivery vehicles prepared by drug/polymer co-precipitations.   
PLA/CPT NPs prepared by the co-precipitation method have been previously 
reported to give low drug loading (0.1-1.5%), low loading efficiency (2.8-38.3%) and 
poorly controlled release kinetics [18]. Depending on the formulation method, 20-90% of 
the encapsulated CPT was released within 1 h after the NP was exposed to the PBS 
solution.  The ring-opening polymerization method that we developed allows for the 
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incorporation of CPT to PLA with a tunable drug loading as high as 20 % and 100% 
loading efficiency (Table 2.4).   The unique conjugation technique allows for formation 
of CPT-containing PLA NCs with superbly controlled formulation parameters, which 
makes PLA-CPT NCs potentially useful agents for sustained treatment of cancer in vivo.   
 
 
 
Table 2.4  Preparation and Characterization of CPT-PLA NCs.a 
NC [LA]/[CPT] LD (%) CV (%) IE (%) NC sizes ± SD (nm) PD ± SD
CPT-LA100 100 2.36 >99 >99 80.6 ± 0.8 0.083 ± 0.016
CPT-LA50 50 4.61 >99 >99 70.7 ± 0.7 0.096 ± 0.007
CPT-LA25 25 8.82 >99 >99 76.6 ± 0.9 0.092 ± 0.006
CPT-LA10 10 19.48 >99 >99 72.5 ± 0.7 0.056 ± 0.015  
a Abbreviations:  NC = nanoconjugates; LD = CPT loading in wt%; CV = conversion of LA; IE = 
incorporation efficiency; PD = polydispersity of NCs; STD = standard deviation. 
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Figure 2.4  (a) Analysis of the particle size and size distribution of CPT-LA25 NC by DLS. (b) 
Scanning electron microscope (SEM) image of CPT-LA25 NC. Scale bar = 1.0 μm 
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Figure 2.5  (a) Release of CPT from the CPT-LA10 NC (■) and the CPT/PLA NP prepared by 
encapsulation (▲, CPT/PLA = 5/95 (wt/wt)); (b) MTT assay to evaluate the cytotoxicity of CPT-
LA10, CPT-LA25, CPT-LA50 NCs and CPT in PC-3 cell (37oC, 72 h).  
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Figure 2.6.  (a) Overlay of the HPLC spectrum of (a) authentic CPT and (b) CPT released from 
CPT-LA25 NC (incubated in PBS for 2 days at 37oC. (b) 1H NMR spectrum (DMSO-d6) of the 
CPT released from CPT-LA25 and collected on a preparative RP HPLC, and compared with the 
1H NMR spectrum of the authentic CPT. 
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4. Conclusions 
Preparation of PLA-drug conjugates with controlled drug loading and release 
profiles have been previously reported using conventional coupling chemistry [19]. In this 
study we report a unique conjugation method that allows for CPT conjugation to PLA via 
CPT-initiated ROP of LA.  This method allows for facile incorporation of CPT to PLA 
and forms PLA-CPT conjugates with low polydispersities, pre-determined drug loadings 
(as high as 20%) and 100% loading efficiencies. By controlling the metal and the 
chelating ligands of the catalysts, the initiation of LA polymerization can be specifically 
controlled at the C20-OH of CPT with negligible lactone ring opening in CPT.  CPT 
conjugated to PLA should maintain its lactone form (the therapeutically active form).  
The BDI-metal chelating complexes do not have deleterious effects on CPT and can be 
easily removed by solvent extraction.  Because both Zn and Mg ions are biocompatible 
(as key elements in our dietary mineral supplements), there should not be significant 
safety concerns regarding the use of these two metal catalysts for the ROP and 
formulation of NCs for potential clinical applications.  Multi-gram scale of PLA-CPT 
conjugates can be readily prepared within hours using this one-pot polymerization 
approach.  Because CPT molecules are covalently conjugated to PLA, the post-reaction 
formulation process (nanoprecipitation, purification, sterilization, lyophilization, shipping 
and handling, transporting, etc.) can be much more readily handled with a minimum 
change of sample property, in contrast to drug/polymer NPs prepared via encapsulation 
methods that struggle to prevent drug release during the formulation process.  Given that 
the lack of a controlled formulation for nanoparticulate drug delivery vehicles presents 
bottlenecks to their clinical translation, this unique, ROP-mediated conjugation 
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methodology may contribute to the development of clinically applicable, CPT and CPT-
analogue based nanomedicines. 
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CHAPTER 3  
NANOCONJUGATES: INCORPORATING PACLITAXEL 
 
1. Introduction 
Paclitaxel (Ptxl) is a potent chemotherapeutic agent.  However, clinical 
application of Ptxl is often accompanied with severe, undesirable side-effects.[1]  To 
reduce the side-effects of Ptxl, various nanoparticulate delivery vehicles have been 
developed and investigated in the past 2-3 decades.[2]  Of various nanoparticles (NPs) 
being studied, polymeric nanoencapsulates (NEs), NPs prepared by co-precipitating 
hydrophobic polymers and drugs, hold particular promise because of their ease of 
formulation and potential control of drug release through the degradation of polymers.[3]  
However, current NEs typically have low drug loadings, uncontrolled encapsulation 
efficiencies, and significant drug burst release effects when used in vivo.[4] These 
formulation challenges significantly limit their potential clinical applications.  In this 
chapter, I report the use of living polymerization to address these formulation challenges 
and facilitate controlled preparation of Ptxl-polylactide (PLA) conjugated NPs with pre-
defined drug loadings, nearly quantitative loading efficiencies and controlled release 
kinetics without burst release effects. In addition, the application of different lactone and 
carbonate monomers for nanoconjugates synthesis are also discussed due to the emerging 
problems in the synthesis process.  
 
2. Materials and Methods 
2.1 General 
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D,L-Lactide (LA) was purchased from TCI America (Portland, OR, USA).  It was 
recrystallized three times in toluene and stored at −30oC in a glove box.  The BDI ligands 
and the corresponding metal catalysts (BDI)MN(TMS)2 (M = Mg, Zn) were prepared by 
following the published procedure[5] and stored at −30oC in a glove box. All anhydrous 
solvents were purified through alumina columns and kept anhydrous by molecular sieves. 
Paclitaxel (Ptxl) and docetaxel (Dtxl) were purchased from the LC Laboratories (Woburn, 
MA, USA), and used as received.  All other chemicals were purchased from Sigma-
Aldrich (St Louis, MO, USA) and used as received unless otherwise noted.  The 
molecular weights of PLA or drug-PLA were determined on a gel permeation 
chromatography (GPC) equipped with an isocratic pump (Model 1100, Agilent 
Technology, Santa Clara, CA, USA), a DAWN HELEOS 18-angel laser light scattering 
detector (MALLS) and an Optilab rEX refractive index detector (Wyatt Technology, 
Santa Barbara, CA, USA). The wavelength of HELEOS detector was set at 658 nm.  Size 
exclusion columns used for the separation of PLA or drug-PLA conjugates were series 
connected on the GPC (Phenogel columns 100 Å, 500 Å, 103 Å and 104 Å, 5 µm, 300 × 
7.8 mm, Phenomenex, Torrance, CA, USA).  THF (HPLC grade) was used as mobile 
phase for GPC. The low resolution electrospray ionization mass spectrometry (LR-ESI-
MS) experiments were conducted on a Waters Quattro II mass spectrometer. HPLC 
analysis was performed on a System Gold system (Beckman Coulter, Fullerton, CA, 
USA) equipped with a 126P solvent module,  a System Gold 128 UV detector and an 
analytical pentafluorophenyl column (Curosil-PFP, 250 × 4.6 mm, 5 μ, Phenomenex, 
Torrance, CA, USA).  The UV wavelengths for Ptxl, Dtxl and CPT were set at 227, 237 
and 350 nm, respectively.  NMR analyses were conducted on a Varian U500, VXR500 or 
UI500NB (500 MHz). The sizes and polydispersities of NCs were determined on a 
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ZetaPALS dynamic light-scattering (DLS) detector (15 mW laser, incident beam = 676 
nm, Brookhaven Instruments, Holtsville, NY, USA).   The SEM analysis of nanoparticles 
is performed on a Hitachi-S4700 high resolution scanning electron microscopy.  PC-3 
cells (ATCC, Manassas, VA, USA) used for MTT assays were cultured in Ham’s F12K 
medium containing 10% FBS (Fetal Bovine Serum), 1000 units/mL aqueous Penicillin G 
and 100 μg/mL streptomycin.  
 
 
2.2 Synthesis and characterization of Ptxl-PLA nanoconjugates 
2.2.1 General procedure for the preparation of Ptxl-LA100 and Ptxl-LA100 NCs 
In a glove box, Ptxl (8.5 mg, 0.01 mmol) was dissolved in anhydrous THF (2 mL).  
(BDI)MgN(TMS)2[5] (6.2 mg, 0.01 mmol) was added and allowed to react with Ptxl for 
15-20 min.  LA (144.0 mg, 1.0 mmol) in THF (1 mL) was added dropwise to the mixture 
of Ptxl and (BDI)MgN(TMS)2 under vigorous stirring. The polymerization was 
monitored using FT-IR by following the lactone band at 1772 cm-1 or using 1H-NMR by 
checking the methine (-CH-) peak of LA around 5.2-5.0 ppm.  After the polymerization 
was complete, an aliquot of the polymerization solution was analyzed using HPLC to 
quantify the unreacted Ptxl in order to determine the incorporation efficiency of Ptxl in 
Ptxl-PLA.  One drop of water was added to the polymerization solution to hydrolyze the 
Mg-Ptxl oxide. The resulting Ptxl-LA100 was precipitated with ethyl ether (10 mL), 
washed with ether and toluene to remove BDI ligand, dried under vacuum and 
characterized by GPC.  Complete removal of BDI from Ptxl-PLA was verified by TLC. 
The Ptxl-LA100 conjugate in DMF (100 μL, 10 mg/mL) (or in other water-
miscible solvent such as THF, acetone, etc.) was dropwise added to nanopure water (2 
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mL).  The resulting NCs were collected by ultrafiltration (15 min, 3000 × g, Ultracel 
membrane with 10,000 NMWL, Millipore, Billerica, MA, USA) and characterized by 
DLS or SEM. 
 
2.2.2 Formation and characterization of Ptxl-LA25/PLGA-mPEG core-shell 
nanostructure    
The Ptxl-LA25 conjugate (5 mg/mL in DMF, 100 μL) was dropwise added to 2 
mL nanopure water to give the Ptxl-LA25 NCs.   PLGA-mPEG[3b] (MW of the PLGA 
block = 13kDa, MW of the mPEG block = 5 kDa, 5 mg/mL in DMF, 100 μL) or mPEG 
(MW of PEG = 5 kDa, 5 mg/mL in DMF, 100 μL) was dropwise added to Ptxl-LA25 NC.   
The particle sizes were analyzed by DLS.  PBS (245 μL, 10×) was added slowly 
to the mixture.  The size of Ptxl-LA25 NC coated with PLGA-mPEG was monitored for 
30 mins by DLS or by SEM. The resulting NCs were purified by ultrafiltration; their in 
vitro toxicities were then evaluated using MTT assay in PC-3 cells (24 hr incubation at 
37oC). To determine the release kinetics of Ptxl-PLA, a PBS solution of NCs was equally 
divided into several portions and then incubated at 37oC. At scheduled time, the release 
study was terminated. DMF solution was added to dissolve all precipitation. All the 
samples were then dried, re-dissolved in DCM and reacted with Bu4NBH4 for 1.5 hours.  
A drop of acetic acid was added into the solution.  The solution was stirred for 20 min 
before the solvent was evaporated. The residual solid was reconstituted in acetonitrile for 
RP HPLC analysis (Curosil, 250 × 4.6mm, 5μ; Phenomenex, Torrance, CA, USA).  The 
release kinetics of Ptxl from Ptxl-LA25 was determined by quantifying PDB.  
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2.2.3 Reductive degradation of Ptxl and Ptxl-PLA using Bu4NBH4  
The reductive degradation of Ptxl at its 13-position was achieved by following the 
literature reported procedure.[6]   Ptxl (5 mg, 5.8 mmol) in anhydrous dichloromethane (1 
mL) was allowed to react with Bu4NBH4 (2.5 mg, 10 mmol) for one and a half hours in a 
glove box.  Acetic acid (≈100 μL) was added to the reaction mixture to terminate the 
reaction. The reaction solution was stirred for 20 mins followed by complete removal of 
the solvent.  The residual solid was re-dissolved in acetonitrile. An aliquot of such 
solution was analyzed on a HPLC equipped with a Curosil RP column (250 × 4.6mm, 5μ; 
Phenomenex, Torrance, CA, USA).  The desired fractions were collected and analyzed by 
for LR-ESI-MS. The Ptxl-PLA conjugate was reductively degraded and analyzed 
similarly.   
 
2.2.4 Synthesis of Ptxl-SA 
In the glove box, 8.5 mg Ptxl was pre-weighed in a clean vial. 6.5 mg (BDI-
1)ZnN(TMS)2 was dissolved in 200 μL THF and mixed with Ptxl. 300 μL THF was 
added and the resulted solution was kept stirring over 15 min until all of Ptxl powder was 
well dissolved in solutions. 1.1 mg SA in 600 μL THF was further added into the solution. 
([SA]=0.01M) The reaction vial was tightly sealed and immediately moved out from box 
and heated at 40 oC. The reaction was kept for 4 hours and quenched by 1 ml ice-cold 
methanol. The resulted solution was immediately injected into HPLC for analysis. HPLC 
condition: analytical Luna C18(2) column (250 × 4.6 mm, 5 μ, Phenomenex, CA, USA) ; 
flow rate: 1ml/min; mobile phase: acetonitrile / water with 0.1% TFA from 50/50 to 
80/20 in 40 min. All spectrums were recorded and analyzed at 227 nm. Ptxl-SA and Dtxl-
SA mixture were analyzed by low resolution electrospray ionization mass spectrometry 
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(LR-ESI-MS) experiments, which were conducted on a Waters Quattro II mass 
spectrometer. 
Pure Ptxl-2’-SA and Dtxl-2’-SA for NMR analysis were separated by preparative 
thin layer chromatography (prep TLC silica gel matrix with UV254, 1500 μm thickness, 
Sigma Aldrich), developed by Silica gels containing Ptxl-SA part were scratched out 
from the glass plate. Ptxl-2’-SA was extracted from gel by methanol solution (30 ml, 2X). 
The resulted methanol solution was evaporated and dried by vacuum line for NMR 
analysis. 
1H-NMR (500 MHz, CDCl3); δ = 8.13 (d, J = 7.28 Hz, 2H), 7.77 (d, J = 7.36 Hz, 
2H), 7.61-7.36 (m, 15H), 7.26-7.24 (m, 6H), 7.03 (d, J = 9.16 Hz, 1H), 6.25 (s, 1H), 6.22 
(d, J = 8.9 Hz, 1H), 5.97, 5.95 (dd, J = 2.84 Hz, 2.76 Hz, 1H), 5.67 (d, J =7.08 Hz, 1H), 
5.56 (d, 1H), 5.47 (d, J = 2.96 Hz, 1H), 4.96 (d, J = 9.36 Hz, 1H ), 4.85-4.79 ( m, 3H), 
4.65(d, J =11.9 Hz, 1H), 4.41 (s, 1H), 4.31 -4.27 (m, 2H), 4.19 (d, J = 8.44 Hz, 1H), 3.99 
(t, J = 9.20 Hz, 1H), 3.81-3.73 (m,3H), 3.64 (t, J = 9.20 Hz, 1H), 3.31(s, 3H), 2.72-2.51 
(m, 6H), 2.42 (s, 3H), 2.40-2.30 (m, 1H), 2.21 (s, 3H), 1.89 (s, 3H), 1.66 (s, 6H), 1.64 (s, 
3H), 1.23 (s, 3H), 1.20 (s, 3H),  1.11 (s, 3H)  
13C-NMR (125 MHz, CDCl3); δ = 203.8, 171.5, 171.2, 171.1, 169.8, 167.9, 167.3, 
167.0, 142.6, 138.4,137.2,  136.9, 133.7, 133.6, 132.8, 132.0, 130.2, 129.2, 129.1, 129.0, 
128.7, 128.5, 128.3, 127.7, 127.6, 127.2, 126.6,126.0, 101.4, 97.5, 84.4, 82.1, 81.0, 79.0, 
76.4,  75.6, 75.1, 74.3, 73.1,72.1, 71.9, 58.5, 52.8, 49.1, 45.6, 43.2,35.6, 33.9, 29.7, 29.0, 
28.9, 26.8,  25.6, 24.9, 22.7, 22.1, 20.8, 14.8,  9.6  
 
 
2.3 Synthesis of nanoconjugates composed with various monomers  
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2.3.1 General procedure for synthesis of Ptxl-BLn polymer mediated by (BDI-
4)ZnN(TMS)2  
In the glove box, 8.6mg Ptxl (0.010 mmol, 1 equiv) was weighed in a small vial. 
6.9 mg (BDI-4)ZnN(TMS)2 (1.02 equiv) was dissolved in 300 μL THF and added to Ptxl, 
immediately forming cloudy solution. The mixture stirred over 20 min until solution 
became clear. 164 μL BBL (172 mg, 2.0 mmol, 200 equiv) in 300 μL toluene was added 
into the mixture. The vial was tightly sealed, moved out from the glove box, and heated 
at 50 degree for 10 hours. The reaction was monitored by FTIR, by observing 1829 cm-1 
peak (lactone bond in BBL) shifting to 1740 cm-1 (ester bond in poly(3-hydroxybutyrate) 
(PHB)). The reaction solution was quenched by 2 ml ice-cold methanol. The conversion 
of BL was calculated by comparing the relative magnitude peaks corresponding to 
hydrogen of BBL (δ: 3.74 ppm) and PHB (δ: 5.26-5.20ppm). The resulted solution was 
dried by vacuum line, reconstituted in HPLC grade of THF at 20 mg/ml for GPC analysis.  
1H-NMR (500 MHz, CDCl3) δ: 5.27-5.20 (m, 1H, -CH-CH3-), 2.63-2.48, 2.47-
2.42 (m, 2H, -CH(CH3)-CH2-) 1.25 (m, 3H, -CH3) 
13C-NMR (125 MHz, CDCl3); δ: 169.1(-C(=O)O-), 67.6(-CH-), 40.7(-CH2-), 
19.7(-CH3)  
 
2.3.2 Kinetic study of Ptxl-BL200 polymer mediated by (BDI-4)ZnN(TMS)2 
In the glove box, 8.6mg Ptxl (0.010 mmol, 1 equiv) was weighed in a small vial. 
6.9 mg (BDI-4)ZnN(TMS)2  (1.02 equiv) was dissolved in 300 μL THF and added to Ptxl, 
immediately forming cloudy solution. The mixture stirred over 20 min until solution 
became clear. The solution was further stirred for 10 min and dried in the glove box. 164 
μL BBL (172 mg, 2.0 mmol, 200 equiv) in 1000 μL toluene-d8 was added into the 
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mixture. The solution was immediately divided into 5 equal volume fractions in 5 vials. 
All vials were tightly sealed, moved out from the glove box, and heated at 50 degree. At 
certain time, 100 μL reaction solution was immediately injected into NMR tube with 600 
μL toluene-d8 under nitrogen atmosphere. The tube was immediately analyzed by NMR. 
The conversion of BL was calculated by comparing the relative magnitude peaks 
corresponding to hydrogen of BBL (δ: 3.74 ppm) and PHB (δ: 5.26-5.20ppm). The 
results were plotted over the time. 
 
2.3.3 General procedure for synthesis of Ptxl-CLn polymer mediated by (BDI-
1)ZnN(TMS)2  
In the glove box, 8.6mg Ptxl (0.010 mmol, 1 equiv) was weighed in a small vial. 
6.6 mg (BDI-1)ZnN(TMS)2 (1.02 equiv) was dissolved in 300 μL THF and added to Ptxl. 
The mixture stirred over 20 min and 221 μL ε-caprolactone (CL, 228mg, 2.0 mmol, 200 
equiv) was added into the mixture. The polymerization was monitored by FTIR, by 
observing 1736 cm-1 peak (lactone bond in CL) shifting to 1726 cm-1 (ester bond in poly 
(ε-caprolactone) (PCL)). The reaction solution was quenched by 5 ml ice-cold methanol. 
The conversion of CL was calculated by comparing the relative magnitude peaks 
corresponding to the hydrogens of -C(=O)OCH2- signals of PCL (δ: 4.04 ppm) and CL (δ: 
4.19 ppm). The resulted solution was dried by vacuum line, reconstituted in HPLC grade 
of THF at 20 mg/ml for GPC analysis.  
1H-NMR (500 MHz, CDCl3) δ: 4.04(t, 2H, -C(=O)OCH2-), 2.29 (t, 2H, -
CH2C(=O)O-), 1.64 (m, 4H, CH2CH2CH2), 1.38 ppm (m, 2H, CH2CH2CH2).  
13C-NMR (125 MHz, CDCl3); δ: 173.7, 64.3, 34.3, 28.5, 25.7, 24.8 ppm  
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2.3.4 General procedure for synthesis of Ptxl-VLn polymer mediated by (BDI-
1)ZnN(TMS)2  
In the glove box, 8.6mg Ptxl (0.010 mmol, 1 equiv) was weighed in a small vial. 
6.6 mg (BDI-1)ZnN(TMS)2  (1.02 equiv) was dissolved in 300 μL THF and added to Ptxl. 
The mixture stirred over 20 min and 92.6 μL δ-valerolactone (VL, 100 mg, 1.0 mmol, 
100 equiv) in 100 μL THF was added into the mixture. The polymerization was 
monitored by FTIR, by observing 1739 cm-1 peak (lactone bond in VL) shifting to 1728 
cm-1 (ester bond in poly (δ -valerolactone) (PVL)). The reaction solution was quenched 
by 5 ml ice-cold methanol. The conversion of CL was calculated by comparing the 
relative magnitude peaks corresponding to the hydrogens of -C(=O)OCH2- signals of 
PVL (δ:  4.08 ppm) and VL (δ: 4.30 ppm). The resulted solution was dried by vacuum 
line, reconstituted in HPLC grade of THF at 20 mg/ml for GPC analysis.  
1H-NMR (500 MHz, CDCl3) δ: 4.08(t, 2H, -C(=O)OCH2-), 2.34 (t, 2H, -
CH2C(=O)O-), 1.70 ppm (m, 4H, CH2CH2).  
13C-NMR (125 MHz, CDCl3); δ: 173.5, 64.1, 33.9, 28.3, 21.6 ppm.  
 
2.3.5 General procedure for synthesis of Ptxl-TMCn polymer mediated by (BDI-
1)ZnN(TMS)2 
In the glove box, 8.6mg Ptxl (0.010 mmol, 1 equiv) was weighed in a small vial. 
6.6 mg (BDI-1)ZnN(TMS)2  (1.02 equiv) was dissolved in 300 μL THF and added to Ptxl. 
The mixture stirred over 20 min and 102 mg TMC (1.0 mmol, 100 equiv) in 300 μL 
toluene was added into the mixture. The vial was tightly sealed, moved out from the 
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glove box, and heated at 50 degree for 5 hours. The reaction solution was quenched by 5 
ml ice-cold methanol. The conversion of TMC was calculated by comparing the relative 
magnitude peaks corresponding to the hydrogens of -CH2OC(=O)- of PTMC (δ: 4.23 
ppm) and TMC (δ: 4.42 ppm). The resulted solution was dried by vacuum line, 
reconstituted in HPLC grade of THF at 20 mg/ml for GPC analysis.  
 
 
3. Results and Discussion 
3.1 Synthesis of Ptxl-PLA nanoconjugates 
3.1.1 (BDI)MN(TMS)2/Ptxl (M=Zn, Mg)-Mediated Polymerization of Lactide 
Since Ptxl has multiple hydroxyl groups, we postulated that Ptxl may be 
incorporated to polyesters through metal-Ptxl alkoxide mediated polymerization of LA 
(Figure 3.1).  Drug loadings can thus be precisely controlled by adjusting LA to Ptxl 
ratios. The incorporation efficiency of Ptxl to the resulting PLA should be 100% as the 
formation of metal-OR is usually quantitative.  After polymerization, Ptxl molecules are 
covalently linked to the terminals of PLA through a hydrolysable ester linker and are 
subject to sustained release upon hydrolysis. Followed by nanoprecipitation (Figure 3.1), 
polymeric NPs containing covalently linked Ptxl should be readily obtained.   
We utilized (BDI)MgN(TMS)2, an active catalyst developed by Coates and 
coworkers for the polymerization of LA.[5] After Ptxl was mixed with 1 eq. 
(BDI)MgN(TMS)2, the in situ formed (BDI)Mg-Ptxl complex (structure uncharacterized; 
tentatively illustrated as a monomeric Mg-Ptxl alkoxide) initiated and completed the 
polymerization of LA within hours at room temperature with nearly quantitative 
incorporation of Ptxl to the resulting PLA (entries 1-4, Table 3.1). The incorporated Ptxl 
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was released to its original form and other degradation species after the Ptxl-PLA was 
treated with 1 M NaOH (Figure 3.2), which demonstrated that Ptxl was linked to PLA 
through a ester bond.  Nanoprecipitation of the Ptxl-PLA conjugates resulted in sub-100 
nm NPs (Table 3.1).  To differentiate from NEs, these NPs derived from 
nanoprecipitation of Ptxl-PLA conjugates are called nanoconjugates (NCs) with PLA 
being denoted as LAn where n is the LA/Ptxl ratio. 
Ptxl has three hydroxyl groups at its C-2’, C-1 and C-7 positions, respectively 
(Figure 3.1). All these three hydroxyl groups can potentially initiate LA polymerizations, 
resulting in Ptxl-PLA conjugates with 1 to 3 PLA chains attached to Ptxl.  To reduce the 
heterogeneity of Ptxl-PLA, we explored if the initiation can be controlled at a specific 
hydroxyl group of Ptxl to make a Ptxl-PLA conjugate containing a single PLA chain (as 
illustrated in Figure 3.1).  
The three hydroxyl groups of Ptxl differ in steric hindrance in the order of 2’-OH 
< 7-OH < 1-OH. The tertiary 1-OH is least accessible and typically inactive.[7] The 7-OH, 
however, could potentially compete with 2’-OH,[8]   the most accessible and active 
hydroxyl group of Ptxl, for coordination with metal catalyst. We postulated that a metal 
catalyst with a bulky chelating ligand may differentiate the 2’-OH from the 7-OH, and 
thus preferentially or even specifically form Ptxl-metal complex through the 2’-OH for 
site-specific LA polymerization.    
Magri et al[6] reported that tetrabutylammonium borohydride (Bu4NBH4) could 
selectively and quantitatively reduce the 13-ester bond of Ptxl into Baccatin III (BAC) 
and (1S,2R)-N-1-(1-phenyl-2,3-dihydroxypropyl)benzamide (PDB) (Figure 3.3).  We 
attempted to use this reduction reaction to disassemble Ptxl-LA5 derived from metal/Ptxl 
mediated polymerization and then to analyze whether PLA is attached to these fragments 
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(Figure 3.3 and 3.4). It was anticipated that Mg(N(TMS)2)2, a catalyst without chelating 
ligand, would initiate polymerization non-preferentially at both the 2’-OH and the 7-OH.  
As expected, both PDB-PLA and BAC-PLA were obtained after the resulting Ptxl-LA5 
was treated with Bu4NBH4 (iv, Figure 3.3b).  When (BDI)MgN(TMS)2 rather than 
Mg(N(TMS)2)2 was used, the amount of BAC-PLA derived was significantly reduced (v, 
3.3b),  indicating polymerization of LA was preferentially initiated at the 2’-OH of Ptxl 
by Mg catalysts with a proper chelating ligand.   
Although (BDI)MgN(TMS)2 gave significantly improved site-specific control in 
the metal/Ptxl initiated polymerization, the resulting Ptxl-PLAs typically have fairly 
broad molecular weight distribution (MWD) (e.g., Ptxl-LA200 Mw/Mn = 1.47).  This 
observation is attributed to fast propagation relative to initiation for the polymerization 
initiated by Mg catalysts.[5] To reduce the propagation rate and transesterification side 
reactions, we tested (BDI)ZnN(TMS)2, a zinc analogue of (BDI)MgN(TMS)2 that gives 
more controlled LA polymerization.[5] As expected, Ptxl-PLAs with projected MWs and 
narrow MWDs were readily prepared via LA polymerization mediated by the in situ 
formed (BDI)Zn-Ptxl. For instance, Ptxl-LA200 with a Mn of 28,100 Da (expected 29,700 
Da) and a MWD of 1.02 were obtained in the (BDI)ZnN-Ptxl mediated LA 
polymerization (200 eq.).  HPLC analysis of the Ptxl-LA5 prepared with 
(BDI)ZnN(TMS)2 and then treated with Bu4NBH4 showed that initiation and 
polymerization were exclusively at the 2’-OH of Ptxl (vi, Figure 3.3b).   Various studies 
suggests that the polymerization process does not lead to deleterious effect on Ptxl 
(Figure 3.5)  
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Figure 3.1 Preparation of PEGylated Ptxl-PLA NCs via Ptxl-initiated LA polymerization in 
the presence of (BDI)ZnN(TMS)2, followed by nanoprecipitation and non-covalent surface 
modification with PLGA-mPEG (or for further modification with aptamer).   
 
 
 
Table 3.1  Formation of drug-PLA nanoconjugates with high loadings, high incorporation 
efficiencies, small particle sizes and low particle distributions[a]  
 
 
 
 
 
 
 
 
 
 
[a] Abbreviations: M/I = monomer/initiator ratio, NC = nanoconjugates, LA Conv. = lactide 
conversion, Incorp. Eff. = incorporation efficiency, SD = standard deviation, PDI = polydispersity 
derived from particles sizing using dynamic light scattering technique, Ptxl = paclitaxel, Dtxl = 
docetaxel, CPT = camptothecin. [b] NCs are named as drug-LAM/I ratio. [c] Determined by                    
Entry NC[b] M/I 
Loading 
(wt%) 
LA Conv. 
(%)[c] 
Incorp. 
Eff. (%)[d] 
NC Size 
±SD (nm) PDI 
1 Ptxl-LA100 100 5.6 >99 >99 95.1 ± 2.7 0.04 ± 0.01 
2 Ptxl-LA50 50 10.6 >99 >99 80.6 ± 0.2 0.05 ± 0.01 
3 Ptxl-LA25 25 19.2 >99 97 55.6 ± 0.5 0.04 ± 0.01 
4 Ptxl-LA15 15 28.3 >99 95 85.5 ± 1.4 0.09 ± 0.03 
5 Dtxl-LA10 10 35.9 >99 95 77.9 ± 1.5 0.06 ± 0.02 
6 CPT-LA10 10 19.5 >99 96 72.5 ± 0.7 0.06 ± 0.02 
nanoprecipitation Aptamer
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(Table 3.1 continued) analyzing the unreacted lactide using FT-IR (1771 cm-1) or using 1H-NMR; 
[d] Based on Reverse phase-HPLC analysis of unincorporated drug.  
 
 
 
 
 
 
 
 
 
 
Figure 3.2 HPLC spectrum of (a) free Ptxl and (b) the solution of Ptxl / (BDI)ZnN(TMS)2-
mediated LA polymerization at a LA/Ptxl ratio of 100.  An aliquot (30-50 μL) of polymerization 
solution was injected into HPLC equipped with analytical RP-HPLC column (Curosil-PFP, 4.6 × 
250 mm, 5μ, Phenomenex, Torrance, CA). Mobile phase was acetonitrile/water with 0.1% TFA 
(50/50 (v/v)); the flow rate was set at 1.0 mL/min.  
 
 
Table 3.2  Ptxl-LAn  polymerization mediated by (BDI-1)ZnN(TMS)2 
Entry [M]/[I] Conv. (%)b Mcal(kg/mol) Mn (kg/mol)
c PDI (Mw/Mn)
c
1 50 >99% 8.1 7.8 1.04
2 75 >99% 11.7 9.6 1.09
3 100 >99% 15.3 12.7 1.03
4 200 >99% 29.7 28.1 1.02
5 300 >99% 44.1 35.2 1.03
 
a All reactions were performed in anhydrous THF with [LA]= 0.69 M at room 
temperature for 12 hours. Abbreviation: LA: lactide; Ptxl: paclitaxel; Conv. %:         
10 20
Retention Time (min)
Ptxl-LA100
Free Ptxl
b
a
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(Table 3.2 continued) conversion of LA %; Mcal: calculated molecular weight; Mn: 
number average molecular weight; PDI: polydispersity index. b The conversion of LA 
was measured by FT-IR, monitoring the disappearance of LA peak at 1772 cm -1.  c 
Determined by gel permeation chromatography (GPC).   
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Figure 3.3  (a) Bu4NBH4 induced site-specific degradation of Ptxl for the formation of PDB and 
Baccatin (BAC). (b) Reductive degradation of 13-ester of Ptxl-PLA; HPLC analysis of (i) Ptxl, 
(ii) Ptxl treated with Bu4NBH4, (iii) Ptxl-LA5 (iv) Ptxl-LA5 prepared using Mg(N(TMS)2)2 
followed by treatment with Bu4NBH4, (v-viii) same as (iv) except that various                      
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(Figure 3.3 continued) (BDI-m)ZnN(TMS)2 were used. *The PDB and partial BAC detected in v-
viii were from the free Ptxl that was not completely consumed during the polymerization at a very 
low M/I (M/I = 5).  Separation of Ptxl was not attempted.  Comparing BAC and PDB pattern in vi 
and ii, it is clear that the BAC in vi was partially from degradation of unreacted Ptxl and partially 
from the reduction of Ptxl-PLA with the PLA being attached to the 2’-OH of Ptxl.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.4.  Characterization of PDB-PLA and BAC-PLA using ESI-MS.  (a) ESI-MS (negative 
mode) analysis of Ptxl-PLA prepared by Ptxl/(BDI)ZnN(TMS)2  (1/1 molar ratio) mediated LA (5 
eq.) polymerization followed by treatment with Bu4NBH4 (b) ESI-MS (negative mode) analysis 
(a) 
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(Figure 3.4 continued) of the Ptxl-PLA degradation fragments collected from prep-HPLC with 
elution time between PDB and BAC (see Fig 9). Ptxl-PLA was prepared through Mg(N(TMS)2)2 
mediated LA polymerization (Mg/Ptxl/LA = 1/1/5) and then treated with Bu4NBH4  before HPLC 
separation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.  HPLC analysis of (a) Ptxl mixing with (BDI)ZnN(TMS)2  and (b) Ptxl. The samples 
were analyzed by RP-HPLC equipped with Curosil column (250 × 4.6mm, 5μ, Phenomenex, 
Torrance, CA, USA) at 227 nm. The HPLC analysis clearly showed that metal catalyst had no 
deleterious effect on Ptxl.  Ptxl molecule remains intact during initiation and therefore should 
maintain its original form in Ptxl-PLA NCs, the final product. 
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Figure 3.6    GPC analysis of Ptxl-LA200, Ptxl-LA100 and Ptxl-LA50.  
 
 
3.1.2 Controlled Formation of Ptxl-PLA Nanoconjugates and Their in vitro Evaluation  
NEs prepared from nanoprecipitation are usually polydisperse with multimodal 
distributions. [3b, 4c] Interestingly, NCs with monomodal particle distributions and low 
polydispersities (entries 1-4, Table 3.1), exemplified by the Ptxl-LA25 NC (Figure 3.8a), 
were consistently obtained through the nanoprecipitation of Ptxl-PLA conjugates.   As 
the multimodal distribution of NEs is due in part to the aggregation of the non-
encapsulated free drug,[4c] the monomodal distribution observed with NCs is likely 
related to the unimolecular strucutres of Ptxl-PLA conjugates. 
 
 
 Ptxl-LA50
Ptxl-LA100
Ptxl-LA200
20                       25                      30          35 
Retention Time (min)
[LA]/[Ptxl] M cal (x10
3g/mol) M n (x10
3g/mol) MWD
50 8.1 7.8 1.04
100 15.3 12.7 1.03
200 29.7 28.1 1.02
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Both the solvent and the concentration of polymer have dramatic effects on the 
sizes of NPs prepared by nanoprecipitation.   At fixed concentration of Ptxl-PLA 
conjugate, the sizes of NCs prepared by precipitating a DMF solution of Ptxl-PLA 
conjugate are typically in a range of 60-100 nm, 20-30 nm smaller than those prepared 
with acetone or THF as solvent.[4c]  When the nanoprecipitation was carried out using 
DMF as solvent at a DMF/water ratio of 1/20 (v/v),  the size of Ptxl-LA200 NCs showed a 
linear coorelation with the concentration of Ptxl-LA200 conjugate and can be precisely 
tuned from 60 nm to 100 nm by changing the concentration of Ptxl-LA200. 
Drug burst release is a long-standing formulation challenge of NEs, which causes 
undesirable side-effect and reduced therapeutic efficacy.[4d]  Conventional NEs typically 
“burst” release 60-90% of their payloads within a few to tens of hours because the release 
of drug is controlled solely by diffusion.[9]  Since the Ptxl release kinetics of Ptxl-PLA 
NCs is determined not only by diffusion but also by the hydrolysis of the Ptxl-PLA ester 
linker, the release kinetics of Ptxl from NCs are more controllable with significantly 
reduced burst release effect (Figure 3.8b).  Ptxl released from Ptxl-LA50 (10.6 wt%) and 
Ptxl-LA25 (19.2 wt%) were 7.0% and 8.7% at Day 1, and 43% and 70.4% at Day 6, 
respectively.  In comparison, 89% of Ptxl was released within 24 hrs from Ptxl/PLA NE 
(Figure 3.8b).  The release of Ptxl from Ptxl-LA50 NC was slower than that from Ptxl-
LA25 NC, presumably because of the higher MW of Ptxl-LA50 and more compact particle 
aggregation.   
The in vitro toxicities of NCs are correlated to the amount of Ptxl released; they 
show strong correlation with drug loadings (Figure 3.8c). The IC50s of Ptxl-LA15, Ptxl-
LA25 and Ptxl-LA50 NCs with similar sizes (~ 100 nm), determined by MTT assays in PC-
3 cells, are 111, 370 and 855 nM, respectively.  The Ptxl-LA15 NC has nearly identical 
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IC50 as free Ptxl (87 nM); while the IC50 of the Ptxl-LA50 NC is an order of magnitude 
higher.  As a result, the toxicity of NCs can be tuned in a wide range simply by 
controlling NC drug loading.    
Surface modification of NPs with poly(ethylene glycol) (PEG) is widely used for 
prolonged systemic circulation and reduced aggregation of NPs in blood.[10] To reduce 
the efforts of removing unreacted reagents and by-products, we attempted to use non-
covalent approach to PEGylate NC surface instead of covalently conjugating PEG to 
NCs.[2d, 3b]  We used poly(glycolide-co-lactide)-b-methoxylated PEG (PLGA-mPEG), an 
amphiphilic copolymer that has a 13 kDa PLGA and a 5 kDa segment,[11] to PEGylate 
NCs.  It is expected that the PLGA block forms strong interaction with NCs through 
hydrophobic interaction to create a stable PEG shell (Figure 3.1). Similar approach has 
been used previously in NP surface PEGylation.[12]  Sequential addition of 0.4 to 2 
equivalent (in mass) PLGA-mPEG to Ptxl-LA200 resulted in a linear increase in particle 
size from 54.5 nm to 100.3 nm.    
Ptxl-LAn NCs have negative surface zeta-potential, and thus remain non-
aggregated in water due to surface charge repulsion.  However, aggregation of NCs 
occurred immediately after they were added to PBS, presumably due to salt-induced 
screen of the repulsive force.[13]  The PLGA-mPEG modified Ptxl-LA200 NCs showed 
significantly enhanced stability in PBS as compared to the un-treated NCs or NCs treated 
with mPEG (Figure 3.8d), indicating the importance of the hydrophobic PLGA segment 
to the non-covalent interaction between PLGA-mPEG and NCs.  
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Figure 3.7  HPLC analysis of (i) Free Ptxl, (ii) Ptxl-LA100 and (iii) released Ptxl from Ptxl-LA100 
after Ptxl-LA100 was treated with 1N NaOH for 60 min and extracted with octanol. HPLC 
condition: RP-HPLC column (Curosil-PFP, 4.6 × 250 mm, 5μ, Phenomenex, Torrance, CA). 
Mobile phase was acetonitrile/water with 0.1% TFA (v/v = 50/50).  The flow rate was 1.0 
mL/min.  
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Figure 3.8  Characterization and properties of Ptxl-PLA NCs (a) Ptxl-LA25 (paclitaxel-PLA NC 
prepared at a LA/Ptxl ratio of 25) analyzed by scanning electron microscopy (SEM) and dynamic 
light scattering (DLS, inset). Scale bar = 150 nm. (b) Release kinetics of Ptxl from Ptxl-PLA NCs 
and Ptxl/PLA NE (prepared by nanoprecipitating a mixture of Ptxl and PLA (Ptxl/PLA (wt/wt) = 
1/12) at 37oC in 1× PBS. (c) Toxicity evaluation of Ptxl-LA50 NC, Ptxl-LA25 NC, Ptxl-LA10 NC 
and Ptxl using MTT assay in PC-3 cells after 24 hr incubation. *Significance at 95% confidence 
interval. (d) Stability of Ptxl-LA200 NC in PBS at 37oC before and after being treated with PLGA-
mPEG5k or mPEG5k 
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3.2 Nanoconjugates synthesized from other cyclic lactones 
For VL and CL, the polymerization proceeded similar to LA. At room 
temperature, monomer conversion was quantitative and Ptxl were successfully 
incorporated in the polymer. PVL had a little broad distribution than PCL polymerization. 
Molecular weights were both obtained in control manner, by changing the monomer/Ptxl 
concentration ratio. Table 3.3 also showed Dtxl could be incorporated in polymer similar 
to Ptxl.  
It was reported that BDI-Zn complex could be used for the six-membered 
carbonate ring opening polymerization, through the insertion-coordination mechanism 
similar as LA. A pioneer study was conducted using (BDI-1)ZnN(TMS)2 and BnOH to 
polymerize TMC in bulk. Previously study showed (BDI-1)ZnN(TMS)2  had low activity 
towards TMC; while the (BDI-1)ZnN(TMS)2  and BnOH complex after mixing in 20 min 
showed ultraproductive activity to polymerize TMC in living manner. We confirmed that 
during 6 hours, TMC was all consumed and formed polymer in toluene solution at 50 
degree. No free Ptxl was detected after the polymerization. It suggested that all Ptxl 
participate in the PTMC. 
PHB is an aliphatic polyester produced by many living organism e.g. bacteria in 
isotactic stereochemistry. It is biodegradable and biocompatiable and recently has been 
commerically engineered to make copolymer with 3-hydrocylvalerate, which have 
similar properties as polypropylene. Ring opening of BBL are always extremely slow and 
in uncontrollable manner with few exceptions such as BDI-Zn series catalyst. In this 
study we used racemeric BBL to form atactic PHB. Ptxl system was incorporated in PHB 
by similar method like LA we mentioned before. We decided to use (BDI-1)Zn and 
(BDI-4)ZnN(TMS)2  as the catalyst, since site specific activation by these two catalyst 
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has been demonstrated. BBL is known to have strong lactone band at 1829 cm-1 in FTIR 
spectrum, and after polymerization, the ester band at 1740 cm-1. FTIR was used to 
monitor the reaction process. We first tested the ROP reaction of BBL initiated by Ptxl 
with these two catalysts respectively at room temperature in THF solution. After 10 hours 
reaction, the conversions of BBL for both catalysts were less than 50%, which slower 
than other cyclic ester polymerization. We raised the reaction temperature to 50 oC in 
order to accelerate the polymerization kinetic rates. Solvent effect for BBL 
polymerization was also taken in consideration. Coates previously reported BBL 
polymerizations of BBL in benzene and toluene were faster than in THF and DCM. We 
then conducted polymerization in toluene at 50 oC with the ratio of [BBL]/[Ptxl]=100/1. 
In 10 hours, conversion of BBL was 98% for (BDI-1)ZnN(TMS)2  and 97% for (BDI-
4)Zn, which is nearly quantitative. Ptxl were both successfully incorporated into polymer 
over 98% efficiency, measured by HPLC. The molecular weight of BBL was accessed by 
GPC. It was found PHB catalyzed by (BDI-1)ZnN(TMS)2  (Table 3.3 entry 11) had broad 
molecular weight distribution (PDI=3.80) and Mn was dramatically smaller than expected 
(Mn=5.4 kg/mol, Mcal=9.5 kg/mol). PHB catalyzed by (BDI-4)ZnN(TMS)2  (Table 3.3 
entry 12) had Mn=10.7 kg/mol with PDI=1.10, suggesting the polymerization reaction 
proceeded in control manner. The reduction of molecular weight and broaden of 
distribution was previously reported for many system, including Al aloxide and BDI-Zn 
series catalyst for BBL polymerization. Coates also noted (BDI-1)ZnN(TMS)2  catalyst 
potentially would reduce molecular weight over long time. To investigate whether 
polymerization conducted with (BDI-4)ZnN(TMS)2 was in controlled living manner, we 
conducted kinetic study for [BBL]/[Ptxl]=200/1 by NMR. kapp was 0.315 h-1 (Figure 3.9c). 
The linear kinetic plot suggested that the polymerization was living polymerization. It 
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was likely (BDI-1)ZnN(TMS)2 have fast kinetic rates than (BDI-4)ZnN(TMS)2. After 
polymerization completed the side reaction would happen immediately, resulting in broad 
distribution in 10 hours (Figure 3.9a).  
It was reported that during the reduction of PHB by metal aloxide catalyst, the 
cleaved chain end would form crotonic structure (Scheme 3.1). The polymer will be 
shortened and show wide distribution. We also investigated the NMR spectrum to see the 
side reaction happening or not.  We confirmed that in 10 hours polymerization, no side 
reaction was observed. Overall, in 10 hours, the polymerization of PHB with (BDI-
4)ZnN(TMS)2 was still living polymerization to successfully provide polymer with 
controllable molecular weight and narrow distribution.  
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Table 3.3 Polymerization of various cyclic lactone/carbonate initiated by Ptxl (or Dtxl) and BDI-
Zn catalyst 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aPolymerization procedures see experimental sections. For all monomers initial concentrations: 
[CL]=3.84M; [BL]=2.62M; [VL]=2.03M; [TMC]=1.67M. Abbreviation: Temp: temperature. r.t.: 
room temperature. Conv. %: conversion % of monomer. Mcal: theoretical calculation of molecular 
weight. Mn: number average molecular weight; Mw: weight average molecular weight.  PDI: 
polydispersity index.  bEntry 1-10 were performed in THF solution at room temperature. Entry 
11-18 were performed in toluene. All reactions had over 98% Ptxl (or Dtxl) incorporation 
efficiency, determined by HPLC. c Conversion was measured by NMR. dDetermined by gel 
permeation chromatography (GPC).  
 
Entryb  initiator monomer [M]/[I] catalyst Time (h) Temp. (oC) Conv. (%) c Mcal (kg/mol) Mn (kg/mol) 
d PDI (Mw/Mn) 
d
1 Ptxl CL 200 (BDI-1)Zn 10 r.t. >99 23.7 20.3 1.07
2 Ptxl CL 200 (BDI-2)Zn 10 r.t. >99 23.7 16.4 1.11
3 Ptxl CL 200 (BDI-3)Zn 10 r.t. >99 23.7 21.9 1.06
4 Ptxl CL 200 (BDI-4)Zn 10 r.t. >99 23.7 26.2 1.07
5 Ptxl CL 300 (BDI-1)Zn 10 r.t. >99 35.1 25.5 1.15
6 Dtxl CL 100 (BDI-1)Zn 10 r.t. >99 12.2 11.2 1.05
7 Dtxl CL 300 (BDI-1)Zn 10 r.t. >99 35.0 38.4 1.13
8 Ptxl VL 100 (BDI-1)Zn 12 r.t. >99 10.8 15.1 1.17
9 Ptxl VL 200 (BDI-1)Zn 12 r.t. >99 20.8 23.1 1.18
10 Ptxl VL 300 (BDI-1)Zn 12 r.t. >99 30.8 31.2 1.18
11 Ptxl BL 100 (BDI-1)Zn 10 50 98 9.5 5.4 3.80
12 Ptxl BL 100 (BDI-4)Zn 10 50 97 9.5 10.7 1.10
13 Ptxl BL 200 (BDI-4)Zn 10 50 97 18.1 18.7 1.12
14 Ptxl BL 300 (BDI-4)Zn 10 50 98 26.7 25.4 1.06
15 Ptxl TMC 100 (BDI-1)Zn 6 50 >99 11.1 14.7 1.10
16 Ptxl TMC 100 (BDI-4)Zn 6 50 >99 11.1 18.1 1.10
17 Ptxl TMC 200 (BDI-1)Zn 6 50 >99 21.3 27.6 1.21
18 Ptxl TMC 300 (BDI-1)Zn 6 50 >99 31.5 49.2 1.21
O
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Figure 3.9  (a) PHB was prepared according to the feeding ratio: [BBL]/[Ptxl]/[(BDI-
1)Zn]=100/1/1. GPC overlay of polymer curves measured by refractive index detector (red) and 
light scattering detector (black). (b) PHB was prepared according to various [BBL]/[Ptxl] feeding 
ratio and catalyzed by (BDI-4)Zn at 50 degree in toluene over 10 hours. (c) kinetic study of BBL 
in toluene-d8. [BBL]/[Ptxl]/[(BDI-4)Zn]=200/1/1. [BBL]=1.72M. (d) 1H-NMR spectrum of 8 
hour of kinetic study (c) of PHB and BBL mixture in toluene-d8. No crotonic peak around 7-5 
ppm was found in the spectrum 
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Scheme 3.1  Polymerization of BBL and side reaction of molecular weight reduction and broaden 
of distribution 
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Figure 3.10  GPC curve of Ptxl-CL200, Ptxl-VL200, and Ptxl-TMC200. All polymers were catalyzed 
by (BDI-1)ZnN(TMS)2 
 
 
 
 74 
4. Conclusions 
Nanotechnology is making a significant impact on cancer drug delivery.  In 
conjunction with the development of lipid based drug delivery, the advancement of 
modern polyester chemistry make it possible for the preparation of a large variety of 
synthetic PLA/PLGA materials with structures tailored to accommodate the specific 
needs of systemic drug delivery.  It is anticipated that synergistic integration of the efforts 
of chemists, materials scientists, chemical and biomedical engineers and physicians will 
facilitate the design and development of polymeric nanomedicine at an unprecedented 
pace, and eventually allow for cancer therapy in a time-, tissue-, or even patient-specific 
manner. We developed a new formulation method for preparing polymeric 
nanoconjugates using drug-initiated, controlled, living polymerization of cyclic esters.  
This unprecedented strategy is alternative to the coupling chemistry-mediated polyester-
drug conjugation,[14] and allows preparation of polymer-drug nanoconjugates with very 
high drug loadings, nearly quantitative loading efficiencies, controlled release profiles 
without burst release effects, and narrow particle distributions.  It usually takes only a 
few hours to prepare gram- or larger-scale, salt-stable NCs.  The drug release profiles can 
potentially be further modified by using different cyclic esters other than LA.  This 
formulation method can potentially be broadly used for the nano-formulation of 
numerous hydroxyl-containing therapeutic agents to achieve excellent control over drug 
loading and release. The catalyst structure-activity relationship still significantly imposed 
on the regioselectivity and yield of final conjugates, as shown in previous chapter. Some 
regioselective O-acylation study in this chapter is eventually expanded and further 
discussed in Chapter 6. Last but not least, because of the scalable preparation of the Ptxl-
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PLA conjugates, they are the model polymer for formulation and preclinical in vivo study, 
which are reported in chapter 5.  
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CHAPTER 4  
NANOCONJUGATES: INCORPORATING DOXORUBICIN 
 
1. Introduction 
In this chapter, I report the use of doxorubicin (Doxo), a therapeutic agent that 
contains multiple types of conjugation-amenable groups (three hydroxyl groups, one 
amine group and one ketone group), as an initiator for the ROP of LA.   
In general, the coupling of the terminal carboxylate of PLA with Doxo, a 
molecule bearing both amine and hydroxyl groups, predominately formed Doxo-PLA 
conjugates through the 3’-NH2 of Doxo by creating an amide bond.[1,2] Such Doxo-PLA 
conjugates, however, cannot release Doxo in its original form by hydrolysis.  Instead, 
Doxo-3’-lactamide, a prodrug of Doxo, is formed.  In poly(ethylene glycol)-b-
poly(aspartic acid) (PEG-b-PAsp) copolymer micelles in which Doxo was conjugated via 
its 3’-NH2 to the pendant carboxylate groups of the PAsp block, Doxo may not be readily 
released from PEG-b-PAsp(Doxo) micelles to exhibit therapeutic effectiveness. 
In order for Doxo to be released in its original form, the hydroxyl groups of Doxo 
should be used for conjugation with the terminal carboxylate group of PLA to form an 
ester linker between Doxo and PLA. To facilitate such a reaction, protection and 
deprotection of the Doxo amine group before and after the conjugation, respectively, are 
thereby required.  Although these protection and deprotection chemistries are possible, 
the manipulation of such chemistries on a multifunctional, unstable drug is difficult and 
may result in degradation of Doxo.  Due to these challenges, efforts have been devoted 
mainly to the conjugation between the 13-ketone group of Doxo and hydrazine groups of 
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polymeric carriers by forming an acid-labile hydrazone bond.[3-6] Some promising 
preclinical results of polymer-Doxo delivery vehicles with hydrazone linkers have been 
reported.[7,8] However, clinical studies of immunoconjugates with Doxo connected to 
monoclonal antibodies with hydrazone linkers gave unsatisfactory antitumor effects, 
which led to the termination of the clinical development of such immunoconjugates.[9]  
Acylation of Doxo with its hydroxyl groups was achieved through a Subtilisin Carlsberg 
(a serine endopeptidase)-mediated reaction with vinyl butyrate.[10] Nevertheless, it is 
unlikely that this method can be used for the conjugation of Doxo to polymers.  Diatos S. 
A. Laboratories recently reported the synthesis of Vectocell peptide-Doxo conjugates in 
which Doxo was linked to a peptide with an ester bond through its 14-OH group.[11] 
However, the synthesis was not achieved through the coupling of Doxo and the peptide.  
Multistep reactions starting from daunorubicin, rather than doxorubicin, were involved in 
the synthesis of the final product.   To our knowledge, there has been no report of 
effective acylation of Doxo via its hydroxyl groups for the formulation of polymer-Doxo 
conjugates. 
In numerous previous studies involving the use of metal catalysts for LA 
polymerization, ring openings of LA proceeded predominately by metal-alkoxides (M-
ORs) rather than by metal-amides (M-NHRs). Although there are only limited reports 
that describe the differences in the polymerization activities between these two classes of 
initiators, M-OR complexes typically have higher activities for LA ring opening to form 
ester bonds than their amine analogues in a similar ring-opening reaction to form amide 
bonds.  For instance, Coates and co-workers reported that (BDI)ZnOCH(CH3)2 initiated 
and completed a LA polymerization within 20 min at a monomer/initiator (M/I) ratio of 
200, while a similar polymerization mediated by (BDI)ZnN(TMS)2 required 10 h to 
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complete.  Based on this finding, we studied whether it was possible to use Zn catalysts 
for controlling Doxo conjugation to PLA preferentially with the hydroxyl groups of 
Doxo. Our approach allows for one-pot synthesis of Doxo-PLA conjugate and 
concurrently addresses all three of the heterogeneities observed in polymer-drug 
conjugates.  This study demonstrated, for the first time, that Doxo can be incorporated 
into PLA in a regio- and chemoselective manner via a well-controlled polymerization 
process. Quantitative incorporation of Doxo and controlled polymerization 
(polydispersity (PDI) of Doxo-PLA as low as 1.02) were achieved simultaneously.  Doxo 
was conjugated to the terminus of PLA through its 14-hydroxyl group specifically, 
without the need to protect its 3’-amine or 4’- and 9-hydroxyl groups. The 
nanoprecipitation of Doxo-PLA conjugates allowed for the formation of Doxo-PLA 
conjugate NPs, which are also called nanoconjugates (NCs) to differentiate them from 
NPs prepared by co-precipitating drugs and polymers, with narrow particle size 
distributions and controlled release kinetics.  We demonstrated that this unique, 
polymerization-mediated drug conjugation method can be applied to the formulation of 
PLA NCs with a variety of hydroxyl-containing molecules. 
 
 
2. Materials and Methods 
2.1 General 
D,L-Lactide (LA) was purchased from TCI America (Portland, OR), recrystallized 
three times in toluene and stored at -30oC in a glove box prior to use.  The BDI ligands 
and the corresponding metal catalysts ((BDI)MN(TMS)2, M = Mg, Zn) were prepared by 
following the published procedures and stored at -30oC in a glove box prior to use.  All 
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anhydrous solvents were purified by being passing through dry alumina columns and 
were kept anhydrous by using molecular sieves.  Doxo·HCl was purchased from Bosche 
Scientific (New Brunswick, NJ) and used as received.  Removal of HCl of Doxo·HCl 
was achieved by following the procedure reported in the literature.  Docetaxel (Dtxl) was 
purchased from LC Laboratories (Woburn, MA) and used as received.  Cy5 was 
synthesized according to the published procedure. All other chemicals were purchased 
from Sigma-Aldrich (St Louis, MO) and used as received, unless otherwise specified.  
The MWs of PLA and Doxo-PLA were determined by a size-exclusion chromatography 
instrument (SEC) equipped with an isocratic pump (Model 1100, Agilent Technology, 
Santa Clara, CA), a DAWN HELEOS 18-angle laser light scattering detector (Wyatt 
Technology, Santa Barbara, CA) and an Optilab rEX refractive index detector (Wyatt 
Technology, Santa Barbara, CA). The wavelength of the HELEOS detector was set at 
658 nm.  The size exclusion columns used for the separation of PLA and Doxo-PLA 
conjugates were serially connected to a SEC (Phenogel columns 100 Å, 500 Å, 103 Å and 
104 Å, 5 µm, 300 × 7.8 mm, Phenomenex, Torrance, CA) equipped with a 126P solvent 
module and  a System Gold 128 UV detector (Beckman Coulter, Fullerton, CA).  THF 
(HPLC grade) was used as the mobile phase of SEC with a 1-mL/min flow rate. The low 
resolution electrospray ionization mass spectrometry (LR-ESI-MS) experiments were 
performed on a Waters Quattro II Mass Spectrometer.  The high resolution electrospray 
ionization mass spectrometry (HR-ESI MS) experiments were performed on a Micromass 
Q-TOF Ultima system. Matrix assisted laser desorption/ionization-time of flight mass 
spectrometry (MALDI-TOF MS) spectra were collected on an Applied Biosystems 
Voyager-DETM STR system.  HPLC analyses were performed on a System Gold system 
(Beckman Coulter, Fullerton, CA) equipped with a 126P solvent module, a System Gold 
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128 UV detector and an analytical pentafluorophenyl column (Curosil-PFP, 250 × 4.6 
mm, 5 μ, Phenomenex, Torrance, CA) or an analytical C18 column (Luna C18, 250 × 4.6 
mm, 5 μ, Phenomenex, Torrance, CA).  The UV wavelength for detecting Pyr-OH or Pyr-
NH2 was set at 300 nm.  The UV wavelength for detecting Doxo was set at 450 nm or 
500 nm, depending on the signal-to-noise ratio in corresponding studies.  The NMR 
experiments were conducted on a Varian U500, a VXR500 or a UI500NB (500 MHz) 
NMR spectrometer.  The sizes and particle polydispersities of the PLA-drug (dye) NCs 
were determined on a ZetaPlus Dynamic Light Scattering (DLS) detector (15-mW laser, 
incident beam = 676 nm, Brookhaven Instruments, Holtsville, NY).  The PC-3 cells 
(ATCC, Manassas, VA) used in the MTT assay were cultured in Ham’s F12K medium 
containing 10% fetal bovine serum, 1000 units/mL aqueous penicillin G and 100 μg/mL 
streptomycin.   
 
 
2.2 Synthesis and characterization of Doxo-PLA nanoconjugates 
2.2.1. 1-Pyrenemethylamine/(BDI)ZnN(TMS)2 and 1-pyrenemethanol / (BDI)ZnN(TMS)2 
-mediated LA polymerization     
In a glove box, 1-pyrenemethylamine (Pyr-NH2) (2.3 mg, 10 mmol) was 
dissolved in chloroform (0.5 mL).  The solution was mixed with a THF solution (0.5 mL) 
of (BDI)ZnN(TMS)2 (6.3 mg, 0.01 mmol).  A THF solution (400 µL) of LA (36 mg, 0.25 
mmol) was added to a vigorously stirred mixture of Pyr-NH2 and (BDI)ZnN(TMS)2.  The 
mixture was stirred for 3 h at room temperature.  An aliquot of the reaction mixture (100 
L) was taken out of the glove box for HPLC analysis.  Pyr-OH (2.1 mg, 0.009 mmol) in 
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300 µL of chloroform was added to the polymerization solution.  The reaction solution 
was stirred for an additional 3 h and analyzed by HPLC. 
 
2.2.2 Preparation of Doxo-LA100 NCs    
In a glove box, Doxo (5.5 mg, 0.01 mmol) was dissolved in anhydrous THF (1 
mL).  (BDI)ZnN(TMS)2 (18.3 mg, 0.03 mmol) was added to the Doxo solution.  The 
mixture was stirred for 15-20 min at room temperature.  LA (144 mg, 1.0 mmol) in DMF 
(1 mL) was added dropwise to a vigorously stirred mixture of Doxo and 
(BDI)ZnN(TMS)2.  The polymerization was monitored by following the lactone band at 
1772 cm-1 using FTIR or by checking the methine (-CH-) peak of LA using 1H NMR.  
After the polymerization was complete (usually within 12 h), an aliquot of the 
polymerization solution was injected to HPLC to quantify the unreacted Doxo, in order to 
determine the incorporation efficiency of Doxo to the Doxo-PLA conjugate.  One drop of 
water was added to the polymerization solution to hydrolyze the Zn-Doxo alkoxide and 
thus terminate the polymerization.  The resulting Doxo-LA100 was precipitated with ethyl 
ether (10 mL), washed with ether and methanol/acetic acid (v/v = 100/1, 10mL) to 
remove BDI ligand and metal catalyst and dried under vacuum.  Complete removal of 
BDI was confirmed by NMR, HPLC and TLC.  After the organic solvent was evaporated, 
the residue was dissolved in HPLC-grade THF (10 mg/mL) and analyzed by SEC to 
determine the MWs and polydispersities.  Doxo-PLA conjugates prepared at various M/I 
ratios were also analyzed by a SEC equipped with a UV detector.   
 
2.2.3 Doxo/(BDI)ZnN(TMS)2-mediated ring opening of succinic anhydride   
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In a glove box, Doxo·HCl (2.0 mg, 0.0035 mmol) was mixed with 
(BDI)ZnN(TMS)2 (2.4 mg, 0.0042 mmol, 1.2 eq.) ((BDI’)ZnN(TMS)2 1.2 equiv., 
Zn(N(TMS)2)2, 1.2 equiv. or (BDI)MgN(TMS)2 1.2 equiv.) in THF (200 µL) for 30 min, 
followed by removal of the solvent under vacuum.  Freshly crystallized succinic 
anhydride   (SA) (0.41 mg, 0.0042 mmol, 1.2 equiv.) in THF (42 µL) was added dropwise 
to the mixture of Doxo·HCl and (BDI)ZnN(TMS)2.  The reaction mixture was diluted 
with 200 µL of THF and stirred for an additional 60-90 min.  The solvent was removed 
under vacuum. The residue was then dissolved using a mixture of acetic acid and 
methanol (v/v = 1/1, 300 μL).  An aliquot of this solution was used for ESI-MS analysis.  
 
2.2.4 Formation, characterization and evaluation of Doxo-LA100 nanoconjugate    
A Doxo-LA100 conjugate in DMF (100 µL, 10 mg/mL) was added dropwise to 
nanopure water (2 mL).  The resulting Doxo-LA100 NC was collected by ultrafiltration 
(15 min, 3000 × g, Ultracel membrane with 10,000 NMWL, Millipore, Billerica, MA) 
and was used for the characterization of particle size by DLS, drug loading by HPLC and 
release kinetics by HPLC.  
 
2.2.5 Determination of release kinetics    
The Doxo/PLA NPs were prepared through nanoprecipitation of PLA (1.5 × 104 
g/mol) and Doxo by following the procedure reported in the literature.46  Doxo-LA10 and 
Doxo-LA50 NCs were prepared by following the standard nanoprecipitation procedure 
described above using Doxo-LA10 and Doxo-LA50 conjugates, respectively.  The NPs and 
NCs were collected and washed three times with water by ultrafiltration, using a 10,000 
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MWCO Amicon Ultra membrane (Ultracel YM-10, Millipore Inc., Billerica, MA), in 
order to completely remove DMF.  The NCs (or NPs) collected from the ultrafiltration 
device were dispersed in 5 mL 1× PBS solution; the PBS solution containing NCs (or 
NPs) was then divided into equal portions, added to five separate eppendorf tubes (1 mL 
per tube) and incubated at 37oC.  At selected time intervals, the corresponding eppendorf 
tubes were taken out of the incubator and centrifuged at 4,000 rpm for 5 min.  The 
supernatant (500 μL) was carefully transferred, using a micropipette, to a separate 
eppendorf tube without disturbing the precipitated NCs (or NPs).  The supernatant was 
injected into HPLC to quantify the released Doxo from PLA/Doxo NP, Doxo-LA10 NC 
and Doxo-LA50 NC. An analytical RP-HPLC column (Luna C18, 250 × 4.6 mm, 5 μ, 
Phenomenex, Torrance, CA) was used for the quantification of the released Doxo.  The 
area of the released Doxo peak was integrated and compared to a standard curve.  To 
confirm that Doxo was released in its original form from Doxo-PLA NCs, we collected 
the fraction that had an elution time identical to that of the authentic Doxo on HPLC and 
analyzed it with high resolution ESI-MS.  The MS (HR-ESI) was calculated for 
C27H30NO11 [M + H]+ to be m/z 544.1819, and we found m/z 544.1827.    
 
 
2.2.6 Determination of the cytotoxicity of Doxo-PLA NCs   
PC-3 cells were plated in a 96-well plate for 24 h (10,000 cells per well) before 
the addition of NCs. The cells were washed with pre-warmed PBS. Freshly prepared 
Doxo-LA10, Doxo-LA25 and Doxo-LA50 NCs (prepared in 1× PBS, 100 L) were added 　
to the cells. The cells were incubated for 72 h in a 5% CO2 incubator at 37oC. Doxo was 
used as a positive control.  Untreated cells were used as a negative control.  After 
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incubation for 72 h, the medium was removed from the cells.  Standard MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay protocols were followed 
thereafter. 
 
3. Results and Discussion  
3.1 Synthesis and characterization of Doxo-PLA nanoconjugates 
3.1.1  Metal-amide- and metal-alkoxide-initiated LA polymerization 
To evaluate metal-amide- and metal-alkoxide-initiated LA polymerization, we 
utilized 1-pyrenemethanol (Pyr-OH) and 1-pyrenemethylamine (Pyr-NH2) as the 
corresponding model hydroxyl and amine initiators. Pyrene is UV-active and thus can be 
easily characterized by a UV detector equipped with a HPLC.  (BDI)ZnN(TMS)2, the 
Coates catalyst mentioned above, was chosen for our initial study.   Instead of preparing 
and isolating (BDI)ZnOPyr and (BDI)ZnNHPyr, we tested whether these complexes 
could be formed in situ and subsequently initiate LA polymerization.  In the LA 
polymerization initiated by an equal molar mixture of Pyr-OH and (BDI)ZnN(TMS)2, 
100% consumption of LA was observed.  Pyr-OH was not detectable in the 
polymerization solution after the reaction was complete.  In contrast, a similar LA 
polymerization initiated by an equal molar mixture of Pyr-NH2 and (BDI)ZnN(TMS)2 
produced no reaction; Pyr-NH2 remained intact in the reaction solution (ii, Figure 4.1).  
To further verify the observed chemoselectivity, we used an equal molar mixture of Pyr-
NH2 and Pyr-OH with 1 equiv. (BDI)ZnN(TMS)2 to initiate a LA polymerization.  The 
polymerization was initiated exclusively by Pyr-OH, whereas Pyr-NH2 remained intact in 
the polymerization solution (i, Figure 4.1). This study demonstrated that the 
(BDI)ZnN(TMS)2 catalyst had remarkable chemoselectivity and could specifically 
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coordinate with hydroxyl groups to initiate LA polymerization, regardless the presence or 
absence of amine groups (Figure 4.1).  It also should be noted that Pyr-NH3+, the 
protonated form of Pyr-NH2, behaved similarly to Pyr-NH2 in this polymerization (data 
not shown).  Pyr-OH can be quantitatively recovered from the Pyr-PLA conjugate, the 
product of the Pyr-OH/(BDI)ZnN(TMS)2-mediated LA polymerization, by treating Pyr-
PLA with NaOH (0.1-1 M) overnight (data not shown).   This study suggests that Pyr-OH 
molecules were linked to PLA termini through ester linkers that were subject to base-
induced rapid hydrolysis (Figure 4.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Reverse-Phase (RP) HPLC analysis of (i) the mixture of Pyr-NH2/Pyr-OH (1:1 molar 
ratio), (BDI)ZnN(TMS)2 (1 equiv.) and LA (25 equiv.); (ii) the mixture of Pyr-NH2,             
Reactant
Product
25               50 (min)  
i
ii
iii
iv
Pyr-OH
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(Figure 4.1 continued) (BDI)ZnN(TMS)2 (1 equiv.) and LA (25 equiv.); (iii) Pyr-OH; (iv) Pyr-
NH2. Note: The ill-defined peak of Pyr-PLA in (i) is largely due to the use of the reverse-phase 
HPLC column that is not suitable for the separation of Pyr-PLA.  Substantially improved elution 
peak was obtained when SEC columns were used for the analysis of Doxo-PLA conjugates. 
 
 
3.1.2 Chemoselective conjugation of Doxo to PLA   
We first studied whether the metal catalyst would decompose Doxo during the 
initiation step and evaluated the coordination of (BDI)ZnN(TMS)2 and Doxo without 
adding LA monomers.  From the HPLC and MS analyses, it was evident that Doxo 
remained in its original form in the presence of the metal catalyst (Figure 4.2).  It was 
thus very unlikely that Doxo would be deleteriously affected during 
Doxo/(BDI)ZnN(TMS)2-mediated LA polymerization.   
We next used Doxo as the initiator in (BDI)ZnN(TMS)2-mediated LA 
polymerization.  When 100 equiv. LA was added to a mixture of (BDI)ZnN(TMS)2 and 
Doxo, the polymerization was complete within 12 h, with 100% Doxo incorporation 
efficiency (Figure 4.3a-ii) and 100% LA conversion.  After Doxo-LA100, the Doxo-PLA 
conjugate prepared with a LA/Doxo ratio of 100, was treated with 0.1 M NaOH, 88-92% 
of Doxo was recovered in its original form (Figure 4.3a-iii).  Doxo is known to be 
unstable in NaOH; therefore, it is not surprising that Doxo cannot be recovered 
quantitatively.  This study suggests that Doxo molecules were likely linked to PLA 
through its hydroxyl group(s) by forming ester linker(s) with PLA and were subject to 
base-induced rapid hydrolysis. To demonstrate that Doxo was conjugated to PLA, we 
prepared Doxo-LA10 using Doxo/(BDI)ZnN(TMS)2-mediated LA polymerization at a 
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LA/Doxo ratio of 10 and analyzed its end group using MALDI-TOF MS.  The MS 
analysis clearly showed that Doxo was covalently conjugated to PLA (Figure 4.4). 
To evaluate whether Doxo can be released from Doxo-PLA in physiological 
conditions in its original form, we incubated Doxo-LA10 in PBS solution at 30oC for 10 
days and then analyzed the solution using HPLC.  As shown in Figure 4.3b-ii, a peak 
with an elution time identical to that of the original Doxo was observed, along with other 
peaks that were presumed to represent the Doxo-PLA oligomers. The fragment with the 
same elution time as Doxo was isolated and confirmed to be Doxo by high resolution 
ESI-MS (Figure 4.3b-iii) and UV spectrometry (Figure 4.5). 
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Figure 4.2 HPLC analysis of (a) Doxo treated with (BDI)ZnN(TMS)2 and (b) Doxo treated 
without (BDI)ZnN(TMS)2. ESI-MS analysis of Doxo treated (c) with (BDI)ZnN(TMS)2  and (d) 
without (BDI)ZnN(TMS)2.  For (c) Doxo treated with (BDI)ZnN(TMS)2,  MS (HR-ESI): calcd. 
for C27H30NO11 [M + H]+ m/z 544.1819, found m/z 544.1832.    For (d) the Doxo control (Doxo 
treated without (BDI)ZnN(TMS)2), MS (HR-ESI): calcd. for C27H30NO11 [M + H]+ m/z 544.1819, 
found m/z 544.1829. 
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Figure 4.3 (a) RP-HPLC analysis of (i) Doxo, (ii) the polymerization solution of 
Doxo/(BDI)ZnN(TMS)2 (1/3 molar ratio) mediated LA polymerization (LA/Doxo = 100), and 
(iii) Doxo-LA100 treated with 1 N NaOH overnight followed by Doxo extraction with chloroform. 
HPLC analysis was mediated by an analytical pentafluorophenyl column (Curosil-PFP, 250 × 4.6 
mm, 5 μ, Phenomenex, Torrance, CA) with acetonitrile/water (0.1% TFA) (50/50) at a flow rate 
of 1 mL/min. Note: the ill-defined peak of Doxo-LA100 in ii is largely due to the use of the 
reverse-phase HPLC column that is not suitable for the separation of Doxo-LA100.  Substantially 
improved elution peak of Doxo-LA100 was obtained when SEC columns were used for the 
analysis of this polymer-drug conjugate. (b) RP-HPLC analysis of (i) free Doxo incubated at 
37oC in 1× PBS for 72 h and (ii) Doxo-LA10 incubated in 1× PBS at 37oC for 10 days. (iii) High 
resolution ESI (HR-ESI) MS analysis of the fraction in (Figure 4.3b-ii) that has the identical 
elution time as the authentic Doxo and was isolated using RP-HPLC.  HPLC analysis and Doxo 
separation were mediated by an analytical RP-HPLC column (Luna C18, 250 × 4.6 mm, 5 μ, 
Phenomenex, Torrance, CA) with acetonitrile/water (0.1% TFA) (50/50) at a flow rate of 1 
mL/min.    MS (HR-ESI): calcd. C27H30NO11 [M + H]+ m/z 544.1819, found m/z 544.1827.    
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Figure 4.4 MALDI-TOF MS analysis of Doxo-LA10.  The obtained m/z is identical to the 
calculated m/z of Doxo-LAn (543.52 + 144.13 × n).  Mw = 2.0×103 g/mol, Mn = 1.7×103 g/mol, 
PDI = 1.17 (determined by MALDI-TOF MS) 
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Figure 4.5  HPLC analysis of the authentic Doxo (red trace) and the Doxo released from Doxo-
LA10 after incubation in 1× PBS at 37oC for 10 days (black trace). The spectra were recorded on a 
System Gold 128 UV detector between 200 and 600 nm (Beckman Coulter, Fullerton, CA).  
 
 
3.1.3 Effects of metals and ligands on regioselective conjugation of Doxo to PLA 
Doxo has three hydroxyl groups at its C4’, C9 and C14 positions.   Theoretically, 
LA polymerization can be initiated by any or all of these hydroxyl groups of Doxo.  In 
the latter case, a lack of control over regioselective initiation will result in Doxo-PLA 
conjugates with heterogeneous structures.  We next studied whether the initiation could 
be specifically controlled at one of the three hydroxyl groups of Doxo.  Previous studies 
have indicated that the C14-OH of Doxo is  most sterically accessible.73 Due to the steric 
bulk of BDI, the catalyst likely forms an alkoxide complex with Doxo preferentially with 
its C14-OH, rather than with the more sterically hindered C4’- or the most sterically 
hindered C9-OH, to facilitate regioselective initiation and polymerization.   
UV Wavelength  (nm)
200                 300                 400                  500 600
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To evaluate the initiation regioselectivity, we mixed Doxo/(BDI)ZnN(TMS)2 with 
succinic anhydride (SA) to mimic the initiation step of the Doxo/(BDI)ZnN(TMS)2-
mediated LA polymerization and characterized the reaction mixture by MS (Figure 4.6) 
and NMR (Figure 4.7).  As expected, Doxo-14-succinic ester (Doxo-SE) was the 
predominate product (Figure 4.6a and Figure 4.7).  The chemical signal of the C14-H 
(peak g, Figure 4.7b and 4.7c) was shifted downfield by 0.69 ppm (from 4.59 ppm to 5.28 
ppm), while the peaks corresponding to the C4’-H and C3’-H remained nearly unchanged 
(peak i and e, respectively, Figure 4.7b and 4.7c).  It was thus evident that the SA ring 
was opened by the C14-OH of Doxo rather than by the C4’-OH or C3’-NH2 of Doxo.  
C9-OH is the most sterically hindered and is thus unlikely to initiate polymerization. 
When (BDI)ZnN(TMS)2 was replaced by (BDI’)ZnN(TMS)2, a catalyst with a structure 
similar to (BDI)ZnN(TMS)2 but having a less bulky diimine ligand (Figure 4.6b), the 
formation of Doxo-4’, 14-bissuccinic ester (Doxo-2SE) was identified in conjunction 
with Doxo-SE (Figure 4.6b). When (BDI)ZnN(TMS)2 was replaced by Zn(N(TMS)2)2, a 
Zn catalyst without ligands, the initiation regioselectivity completely disappeared.  Doxo-
4’, 14-bissuccinic ester (Doxo-2SE) and Doxo-4’, 9, 14-trisuccinic ester (Doxo-3SE) 
were the predominant products (Figure 4.6c).  Interestingly, the metal activity also had a 
profound effect on regioselectivity.  When (BDI)MgN(TMS)2 (which is more active than 
its Zn analogue) was used in a similar reaction, the formation of Doxo-2SE was also 
identified in conjunction with Doxo-SE (Figure 4.6d).  Thus, by rationally designing 
ROP metal catalysts, Doxo-PLA conjugates with highly controlled regio- and 
chemoselectivity are achievable within one step without the need to protect the C3’-NH2 
and other competing hydroxyl groups of Doxo.   
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Figure 4.6 MS analysis of the mixture of (a) Doxo, 1 eq. (BDI)ZnN(TMS)2 and 3 equiv. SA, (b) 
Doxo, 1 equiv. (BDI’)ZnN(TMS)2 and 3 equiv. SA, (c) Doxo, 1 eq. Zn(N(TMS)2)2 and 3 equiv. 
SA, and (d) Doxo, 1 eq. (BDI)MgN(TMS)2 and 3 eq. SA. Peak assignment: (a) Doxo-SE: (MDoxo-
SE+H) 644.3; (b) Doxo-SE: (MDoxo-SE +H) 644.3; Doxo-2SE: (MDoxo-2SE +H) 744.2; (c) Doxo-2SE: 
(i = (MDoxo-2SE +H) 744.3, ii = (MDoxo-2SE+NH4) 759.7; Doxo-3SE: (i = (MDoxo-3SE +H) 842.3, ii = 
(MDoxo-3SE +Na) 863.3); (d) Doxo-SE: (MDoxo-SE+H) 644.3; Doxo-2SE: (MDoxo-2SE +H) 744.3.  
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(Figure 4.7, continue on page 96) 
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(Figure 4.7 continued) 
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Figure 4.7 (a) Schematic illustration of the anticipated ring opening of succinic anhydride (SA) 
by the C14-OH of Doxo when SA was treated with Doxo/(BDI)ZnN(TMS)2. (b) 1H NMR 
analysis (DMSO-d6) of Doxo and Doxo-succinic ester (Doxo-SE) to confirm the attachment of 
SE to the C14-OH of Doxo and formation of Doxo-SE. (c) 1H NMR chemical shifts of Doxo and 
Doxo-SE. (d) HPLC analysis of (i) the reaction mixture of SA (1 equiv.) and 
Doxo/(BDI)ZnN(TMS)2 (1/1.2 molar ratio) and (ii) Doxo-SE incubated in 1× PBS solution at 
37oC for 48 h.  (e) ESI-MS analysis of the compound derived from the reaction of SA with 
Doxo/(BDI)ZnN(TMS)2 (i). The high resolution ESI-MS analysis of Doxo-SE was performed on 
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a Micromass Q-TOF Ultima system.  MS (HR-ES): calcd. for C31H34NO14 [M + H]+ m/z 
644.1979; found m/z 644.1987. 
3.1.4 Metal and ligand effects on Doxo-PLA molecular weight     
We next studied Doxo-initiated LA polymerization in the presence of these metal 
catalysts. Doxo/(BDI)ZnN(TMS)2-mediated LA polymerization resulted in Doxo-PLA 
with low polydispersities (Mw/Mn less than 1.2) and the expected molecular weights 
(MWs) by adjusting the LA/Doxo feeding ratios (Table 4.1 and Figure 4.8a). For 
example, Doxo/(BDI)ZnN(TMS)2-mediated LA polymerization at a M/I ratio of 200 
resulted in Doxo-LA200 with a polydispersity as low as 1.02 (Table 4.1).  The obtained Mn 
of Doxo-LA200 (3.38 × 104 g/mol) was close to the expected Mn (2.93 × 104 g/mol).  A 
similar Doxo/(BDI)MgN(TMS)2-mediated polymerization also produced Doxo-LA200 
with well-controlled MW (Mn = 3.12 × 104 g/mol).  Nonetheless, a much higher 
polydispersity (Mw/Mn = 1.50) was observed, which was attributed presumably to the 
poorly controlled regioselectivity during initiation (Figure 4.8d), slow initiation relative 
to chain propagation and potential trans-esterification side reactions.  In general, Zn-
alkoxides undergo slightly slower but better controlled polymerization reactions, as 
compared with their Mg analogues (Figure 4.8a-b).61,75 (BDI’)ZnN(TMS)2, the Zn 
catalyst with a less bulky diimine ligand, also resulted in Doxo-LA200 with relatively high 
polydispersity (Table 4.1).  These observations were in good agreement with the 
observed initiation regioselectivity of the corresponding Doxo/catalyst complexes for the 
ring openings of SA (Figure 4.6).   
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Figure 4.8.  (a) SEC (equipped with a UV detector) analysis of Doxo-LAn (n = LA/Doxo (M/I) 
prepared through Doxo/(BDI)ZnN(TMS)2  mediated LA polymerizations at LA/Doxo ratios of  
10, 25, 50, 75, 100 and 200, respectively; Note: Polymerizations at LA/Doxo ratio of 25, 50, 75, 
100 and 200 resulted in corresponding Doxo-PLAs with monomodal SEC distribution patterns. 
Polymerization at a LA/Doxo ratio of 10, however, resulted in Doxo-LA10 with a multimodal 
SEC distribution pattern, which indicated that polymerization at such a low M/I ratio may not be 
as well controlled as similar polymerizations at higher M/I ratios. (b) SEC (equipped with a UV 
detector) analysis of the Doxo-LA100 prepared through Doxo/(BDI)ZnN(TMS)2, 
Doxo/(BDI)MgN(TMS)2, and Doxo/Zn(N(TMS)2)2 mediated LA polymerizations at a LA/Doxo 
ratio of 100.   
 
 
 
 
 
 
LA/Doxo
200 100 75 50 25 10
20 30 40 (min) 20 30 40 (min)
(BDI)MgN(TMS)2
(BDI)ZnN(TMS)2
Zn(N(TMS)2)2
a b
 
 99 
 
Table 4.1 Polymerization of LA initiated by the complex of Doxo with (BDI)ZnN(TMS)2, 
(BDI’)ZnN(TMS)2, or (BDI)MgN(TMS)2  
Catalyst LA/Doxo (M/I)
Expexted M n (x 
103 g/mol)
Obtained M n 
(x 103 g/mol)
Obtained M w 
(x 103 g/mol)
M w/M n
10a 2.0 1.7 2.0 1.17
25 4.1 ND ND ND
50b 7.7 6.3 7.4 1.18
75b 11.3 12.7 13.6 1.07
100b 14.9 18.3 19.8 1.08
200b 29.3 33.8 34.5 1.02
(BDI')ZnN(TMS)2
200b 29.3 25.4 33.8 1.33
(BDI)MgN(TMS)2
200b 29.3 31.2 46.8 1.50
 
NN
Mg
NSi Si
(BDI)Zn(TMS)2
 
 
a MW determined by MALDI-TOF MS (see Figure 4.4).  bMW determined by SEC (See Figure 
4.8a). Note: The MW of Doxo-LA25 was too high to be analyzed by MALDI-TOF MS and too 
low to be determined by SEC equipped with a multi-angle static light scattering detector.  
However, the SEC distribution pattern of Doxo-LA25 collected on a UV detector was monomodal 
and very similar as those of Doxo-LA50-200.  Therefore, it is very likely that the Doxo-LA25 also 
had the expected Mn and low polydispersity. ND = Not Determined.   
 
 
3.1.5 Doxo-PLA conjugated nanoparticle 
Due to the excellent control over the Doxo-PLA structure and composition, NPs 
derived from these materials have well-controlled formulation parameters, which could 
potentially impact their in vivo performance and clinical translation. Doxo-PLA 
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conjugated nanoparticles, termed nanoconjugates (NCs) in this paper to differentiate 
them from NPs prepared from the co-precipitation of drugs and polymers, were readily 
prepared through the nanoprecipitation of Doxo-PLA conjugates (Table 4.1e). NCs less 
than 100 nm in size with narrow, monomodal particle distributions were readily obtained 
(Table 4.2 and Figure 4.9), similar to the results that we reported previously for 
paclitaxel-PLA NCs.65 The narrow size distributions of the NCs were in sharp contrast to 
the multimodal particle distributions frequently observed in conventional NPs prepared 
by co-precipitating polymers and drugs. It is not clear why NCs derived from 
nanoprecipitation have such narrow size distributions. The multimodal particle 
distributions in conventional NPs have been attributed in part to the self-aggregation of 
non-encapsulated drugs, and thus, the unimolecular structure of polymer-drug conjugates 
with reduced heterogeneities (low polymer polydispersities, the controlled site of 
conjugation on both polymer and Doxo and the absence of free Doxo) may contribute in 
part to the formation of NCs with low particle polydispersities (Table 4.2).  
The surface compositions of Doxo-PLA NCs are unclear.  Because the 
daunosamine sugar moiety of Doxo is hydrophilic, it is likely that Doxo molecules reside 
on or close to the surface of Doxo-PLA NCs and are subject to rapid release after the 
ester linkers between Doxo and PLA are hydrolyzed.  The size of Doxo-PLA NCs can be 
fine-tuned within a range of 50-150 nm by adjusting the Doxo-PLA concentration in 
water-miscible organic solvents or by varying the types of water-miscible solvents 
present during nanoprecipitation.  For instance, NCs prepared using DMF as solvent are 
typically 20-30 nm smaller than those prepared using THF or acetone as solvent, 
following the same trend that we observed previously in our study of 
docetaxel/poly(lactide-co-glycolide) nanoprecipitation. We will report a comprehensive 
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study of NC formulation, in particular for the control of NC sizes and formulation of NCs 
in solid form, in a separate paper. 
Because both the monomer conversion and drug incorporation were nearly 
quantitative (Table 4.2), Doxo loadings in Doxo-PLA NCs could thus be predetermined 
by adjusting the LA/Doxo feeding ratios.   At a low M/I ratio of 10, the drug loading was 
as high as 27.4% (Doxo-LA10, Table 4.2).  To our knowledge, this is by far the highest 
loading ever reported in Doxo-containing polymeric NPs.  Even at this high drug loading, 
sustained release of Doxo from Doxo-LA10 NC was observed through the hydrolysis of 
the ester linker connecting the Doxo and the PLA (Figure 4.10a).  No burst release of 
Doxo was observed in Doxo-LA10.  This observation was in sharp contrast to the burst 
release of PLA/Doxo NP prepared by co-precipitation (Figure 4.10a), in which Doxo 
release depended entirely on diffusion and over 90% was released within 3 hours. The 
HPLC elution time and the MS spectrum of the Doxo released in PBS were identical to 
those of authentic Doxo, similar to the results we observed in the separate study 
mentioned above (Figure 4.2b).  The MTT studies revealed that the toxicity of Doxo-PLA 
NC, which is directly related to the release kinetics of Doxo, could be tuned by adjusting 
the Doxo loading in the NCs (Figure 4.10b).  In general, NCs with higher Doxo loadings 
released Doxo more rapidly (Figure 4.10a) and, therefore, showed higher toxicities 
(Figure 4.10b).  This observation is presumably due to the fact that the NCs derived from 
the nanoprecipitation of higher loading (lower MW) Doxo-PLA conjugates have more 
loosely packed structures, as compared to NCs derived from the lower loading (higher 
MW) Doxo-PLA conjugates.  Therefore, the ester linkers between Doxo and PLA in NCs 
with higher drug loadings were more accessible to the aqueous phase and were subject to 
faster hydrolysis.   
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Doxo has amine and multiple hydroxyl groups; it is therefore highly water soluble 
in its protonated form (10 mg/mL).  Due to its high hydrophilicity, the encapsulation of 
Doxo in hydrophobic polymer can be very difficult.  For instance, Yoo et al. reported a 
Doxo loading of 0.51% and a loading efficiency of 23% for micelles formed by co-
precipitating Doxo and poly(DL-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-
PEG).[2] Doxo loadings of 0.6-8.7% and loading efficiencies of 11.4-43.6% were also 
reported by Hubbell and co-workers in their studies of encapsulating non-protonated 
Doxo (which has increased hydrophobicity) into polymeric NPs using inverse emulsion 
polymerization.[12] The unencapsulated Doxo has to be removed from the NPs by column 
separation.  Burst releases of Doxo were reported in both systems.  
The Doxo-initiated ring-opening polymerization method that we have developed 
allows for the controlled incorporation of Doxo to PLA with drug loadings as high as 
30% and up to 100% loading efficiency (Table 4.2).  The Doxo-PLA NCs derived from 
this Doxo-initiated ROP technique followed by nanoprecipitation exhibit controlled 
release kinetics without any burst release effects and a precisely controlled Doxo-PLA 
structure.  This unique formulation technique allows for the formation of Doxo-
containing PLA NCs with well-controlled formulation parameters. 
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Table 4.2  Doxo/(BDI)ZnN(TMS)2 Initiated LA Polymerization followed by nanoprecipitation to 
form NCa  
 
M/I LD(%) CV(%) IE(%) NCb
NC size ± 
SD (nm) PD ± SD
100 3.6 >99 >99 Doxo-LA100 79.1 ± 0.7 0.08 ± 0.01
50 7.1 >99 >99 Doxo-LA50 101.6 ± 0.7 0.07 ± 0.01
25 13.1 >99 98 Doxo-LA25 90.8 ± 0.9 0.09 ± 0.01
10c 27.4 >99 94 Doxo-LA10 125.2 ± 2.3 0.11 ± 0.01  
 
aAbbreviations:  M/I = LA/Doxo ratio; LD = Doxo loading in wt%; CV = conversion of LA; IE = 
incorporation efficiency of Doxo; SD = standard deviation; PD = polydispersity of NC. bNCs are 
denoted by Doxo-LAM/I ratio. cPrepared with (BDI)MgN(TMS)2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9    Analysis of Doxo-LA100 NC using dynamic light scattering. Doxo-LA100 was 
prepared using (BDI)ZnN(TMS)2 by following the standard procedure as described in the 
experimental section. 
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Figure 4.10   (a) Release of Doxo from Doxo-LA50 NC, Doxo-LA10 NC and Doxo/PLA NP  
((Doxo/PLA (wt/wt = 1/13), ~7.1 wt% theoretical drug loading) prepared by co-precipitation of 
Doxo and PLA (MW = 15,000 g/mol) at 37oC in 1× PBS. Doxo-LA10 and Doxo-LA50 were 
prepared using (BDI)ZnN(TMS)2 by following the standard procedure as described in the 
experimental section.  (b) MTT assay for the analysis of cytotoxicity of Doxo-PLA NCs in PC-3 
cells.  
 
3.2 Nanoconjugates incorporating other drugs 
To demonstrate that this technique can be broadly applied to the formation of NCs 
with agents that contain hydroxyl groups, we tested the capabilities of Cyanine 5 (Cy5), 
camptothecin (CPT), docetaxel (Dtxl) and cyclopamine (Cpa) to initiate LA 
polymerization in the presence of Zn or Mg catalysts.  All of the therapeutic (Dtxl, CPT, 
Cpa) and dye (Cy5) molecules tested, when mixed with (BDI)ZnN(TMS)2, initiated LA 
polymerization similar to that observed with Doxo, with nearly quantitative incorporation 
efficiencies and 100% LA conversions (Table 4.3).  NCs with adjustable loadings 
(achieved by controlling the LA/drug (or dye) ratio) and low polydispersities were readily 
Doxo-LA50 NC (7.1%)
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obtained (Table 4.3).  Surprisingly, oligopeptides can even be used as initiators in Zn-
catalyst-mediated LA polymerization. LA polymerization.  Goserelin (Gos), a luteinizing 
hormone-releasing hormone agonist,[13]  initiated the successful ROP of LA in DMF.  The 
resulting Gos-PLA conjugates and corresponding NCs could be prepared with extremely 
high drug loadings (>50%) at low LA/Gos ratios and very low polydispersities (Table 3).  
Gos was recovered quantitatively through base treatment of Gos-PLA conjugates. 
 
Table 4.3  Dtxl-LAn  polymerization mediated by (BDI-1)ZnN(TMS)2 
Entry [M]/[I] Conv. (%)b Mcal(kg/mol) Mn (kg/mol)
c PDI (Mw/Mn)
c
1 75 >99% 11.6 8.9 1.05
2 100 >99% 15.2 13.6 1.04
3 200 >99% 29.6 25.2 1.03
4 300 >99% 44.0 47.1 1.04
5 400 >99% 58.4 55.3 1.13
 
 
a All reactions were performed in anhydrous THF with [LA]= 0.69 M at room temperature for 12 
hours. Abbreviation: LA: lactide; Dtxl: Docetaxel; Conv. %: conversion of LA %; Mcal: 
calculated molecular weight; Mn: number average molecular weight; PDI: polydispersity index  b 
The conversion of LA was measured by FT-IR, monitoring the disappearance of LA peak at 1772 
cm-1.  c Determined by gel permeation chromatography (GPC).  
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Table 4.4  Formulation of NCs with Hydroxyl-Containing Therapeutic and Dye Molecules 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aAbbreviations: M/I = monomer/initiator ratio, NC = nanoconjugates, LA Conv. = lactide 
conversion, Incorp. Eff. = incorporation efficiency, SD = standard deviation, PDI = 
polydispersity, Dtxl = docetaxel, Cpa = cyclopamine, Cy5 = cyanine 5, CPT = camptothecin, Gos 
= goserelin. bNCs are named as drug(or dye)-LAn where n is the ratio of [LA] to [agent] 
cDetermined by analyzing unreacted lactide using FTIR (1772 cm-1); dBased on RP-HPLC 
analysis of free molecules. We use incorporation efficiency instead of encapsulation efficiency 
because drug molecules are conjugated to, not encapsulated in PLA. eDetermined by dynamic 
light scattering. 
 
Substrate M/I NCsb
Loadin
g (%)
LA Conv. 
(%)c
Incorp. 
Eff. (%)d
NC size ± 
SD (nm)e PDI ± Sd
e
Dtxl 25 Dtxl-LA25 18.3 >99 >99 64.5 ± 0.7 0.05 ± 0.02
Dtxl 10 Dtxl-LA10 35.9 >99 97 77.9 ± 1.5 0.06 ± 0.02
Cpa 100 Cpa-LA100 2.8 >99 >99 89.9 ± 1.8 0.04 ± 0.01
Cpa 50 Cpa-LA50 5.4 >99 >99 78.0 ± 2.7 0.12 ± 0.01
Cy5 100 Cy5-LA100 3.4 >99 98 95.1 ± 0.6 0.04 ± 0.02
Cy5 25 Cy5-LA25 12.3 >99 95 76.3 ± 3.8 0.06 ± 0.01
CPT 100 CPT-LA100 2.4 >99 >99 68.3 ± 0.8 0.08 ± 0.02
CPT 25 CPT-LA25 8.8 >99 96 76.6 ± 0.9 0.09 ± 0.01
Gos 100 Gos-LA100 8.1 >99 90 97.6 ± 2.3 0.05 ± 0.02
Gos 10 Gos-LA10 46.8 >99 81 120.6 ± 2.7 0.01 ± 0.01
N
N
O
O
OH O
Camptothecin (Cpt)
topoisomerase I inhibitor
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4. Conclusions 
Preparations of Doxo-polymer conjugates with controlled loadings and release 
profiles have been previously reported using conventional coupling chemistry.17,54,55,62,86 
In this paper, we report a unique conjugation method accomplished via Doxo-initiated 
ROPs. This ROP-mediated Doxo conjugation method allows for facile regio- and 
chemoselective incorporation of Doxo into PLA and allows for the formation of PLA-
Doxo conjugates with low polydispersity, pre-determined drug loadings (up to ≈30%) 
and quantitative loading efficiencies. The BDI-metal chelating complexes do not have 
deleterious effects on Doxo and can be easily removed by solvent extraction.  Because 
both Zn and Mg ions are biocompatible (as key elements in our dietary mineral 
supplements), there should not be significant safety concerns regarding the use of these 
two metal catalysts for the ROP and formulation of NCs for potential clinical 
applications.  The multi-gram scale of PLA conjugates can be readily prepared within 
hours using this one-pot polymerization approach.  Because drug molecules are 
covalently conjugated to PLA, the post-reaction formulation process (precipitation, 
removal of catalysts, nanoprecipitation, sterilization, lyophilization, shipping and 
handling, etc.) can be much more readily handled with a minimum change of sample 
property, as compared to drug/polymer NPs prepared via encapsulation methods. This 
polymerization-mediated conjugation method may be utilized for the formulation of 
polymer-drug conjugates, not only for drug delivery but also for other controlled release 
applications (scaffolds, coatings of stents, etc).  Other cyclic esters (e.g., ε-caprolactone 
and β-valerolactone) are likely to replace LA and find use as monomers in such drug-
initiated polymerizations. The Doxo/(BDI)ZnN(TMS)2-initiated polymerization of these 
cyclic esters at room temperature has recently been achieved in our laboratory, which will 
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provide further tunability of the release profiles and other physicochemical properties. 
Given that the lack of a controlled formulation for nanoparticulate drug delivery vehicles 
is one of the bottlenecks to their clinical development, this unique, ROP-mediated 
conjugation methodology may contribute to the development of clinically applicable 
nanomedicines. 
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CHAPTER 5 
NANOCONJUGATES: FORMULATION AND PRELIMINARY IN VIVO STUDY 
 
1. Introduction 
Polymeric nanoparticles (NPs) are attractive drug delivery vehicles [1]. They have 
been employed for the delivery of many types of chemotherapeutic agents for cancer 
treatment [2].  In these polymeric NPs, chemotherapeutic agents are either encapsulated in 
polymer matrices [3] or covalently conjugated to polymers via hydrolysable or 
enzymatically degradable linkages .  Ideally, systemically administered NPs are able to 
bypass the recognition of the reticuloendothelial system (RES) , extravasate at the leaky 
tumor vasculatures [2b], penetrate and homogeneously distribute in solid tumor tissues [4], 
get internalized by the target cancer cells , penetrate cellular and subcellular membranes , 
and then release the payload in the cytoplasma of the target cancer cells in a sustained 
manner.   
NPs that can successfully overcome all these systemic, tissue and cellular barriers 
are yet to be developed.  However, much information has been accumulated in the last 
10-20 years for the control of the physicochemical properties of NPs and for the 
correlation of these properties with the in vivo biodistribution and antitumor efficacy of 
NPs [5].  Although the ideal physicochemical properties of NPs for drug delivery 
applications have not been completely elucidated, a general consensus about important 
parameters of NPs, such as particle size, drug loading, loading efficiency, and release 
kinetics, that are critical to their in vivo applications, have been reached [2b, 2c].  The sizes 
of NPs should typically be controlled at less than 200 nm with narrow polydispersities to 
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give satisfactory in vivo biodistribution [2b]. High drug loadings, quantitative loading 
efficiencies and controlled release profiles are also desirable for the in vivo applications 
of NPs [6].  
Polylactide (PLA), a biodegradable and non-cytotoxic material, has been 
extensively used in the formulation of particles for biotechnology and drug delivery 
applications [7].  NPs are typically prepared via nanoprecipitation of PLA and drugs [7c].  
However, this conventional method tends to give NPs with various formulation 
challenges remaining to be addressed.  PLA/drug NPs typically show “burst” drug release 
profiles in aqueous solution; as much as 80-90 % of the encapsulated drug is rapidly 
released during the first few to tens of hours [8].  The rapid drug release, also called dose 
dumping, may cause severe systemic toxicities [1].  In addition, drug loadings in 
conventional NPs can be very low, typically in a range of 1-5% for most NPs studied [9]. 
The drug loading of a delivery vehicle has been a critical measure of its utility in 
clinically settings [9]. At lower drug loadings, larger amounts of delivery vehicles are 
needed.   Because of the limited body weight and blood volume of animals, the 
administration volumes are usually fixed.  For instance, the volume of a solution 
intravenously administered to mice with 20- to 30-g body weights should be controlled 
around 100 to 200 μL [10].  Intravenous administration of NPs with 1% drug loading in a 
100-μL solution at a dose of 50 mg/kg to a mouse with 20-g body weight requires the 
formulation of a concentrated, 1 g/mL NP solution. In practice, it is impossible to 
formulate such concentrated solutions and inject them intravenously.  Furthermore, there 
is also a lack of general strategy to achieve quantitative drug encapsulation in PLA/drug 
NPs.  Depending on the amount of drug being used, the hydrophobicity and 
hydrophilicity of drug, and the compatibility of drug and polymer, the encapsulation 
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efficiencies vary drastically in a range of 10 to 90% [8]. Unencapsulated drugs may self-
aggregate [7c] and can be very difficult to be removed from the NPs.  These formulation 
challenges significantly impact the processability and the clinical translation of PLA NP 
delivery vehicles for cancer therapy. 
Controlled polymerization methodologies allowing preparations of polyesters [11], 
polypeptides [12] and hydrocarbon based synthetic polymers [13] with precisely controlled 
molecular weights and narrow polydispersities have been well established. These 
materials have been extensively utilized in drug delivery.  However, controlled 
polymerization directly used in the formulation of drug delivery vehicles is rare.  Since 
we developed the new method that allows drug molecules to be incorporated into PLA 
via drug-initiated, controlled ring-opening polymerization of lactide (LA) (Figure 5.1a) [6], 
quantitative incorporation of paclitaxel (Ptxl) [6a] and other hydroxyl-containing 
therapeutic molecules [6b] can been incorporated to PLA via ester bonds facilitated by Zn-
catalysts.  When bulky chelating complexes are used, the Zn-catalyst regulates the 
initiation and polymerization via the least sterically hindered 2’-OH of Ptxl and results in 
Ptxl-PLA conjugates with precisely controlled composition and molecular weights [6a].  
At a monomer/initiator (LA/Ptxl) ratio of 10, the drug loading of Ptxl-PLA conjugates 
and the NPs derived from the conjugates can be as high as 40% with nearly 100% loading 
efficiencies [6a].  Ptxl can be released in a controlled manner with negligible burst from 
these Ptxl-PLA conjugate NPs, termed nanoconjugates (NCs) to differentiate them from 
the PLA/drug NPs prepared via encapsulation methods [6a].   
Extended from these preliminary studies that were mainly focused on controlled 
polymerization, here we report a comprehensive study of the formulation of Ptxl-PLA 
NCs as well as the development of cancer targeting NCs by conjugating a cancer-specific 
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targeting aptamer ligand to the surface of NCs.  Our study addressed various formulation 
challenges central to the clinical translation of polymeric NPs, such as control of particle 
size in salt solution, minimization of NP aggregation during lyophilization and solid 
formulation, and formulation of NPs in solid form with targeting property well preserved.  
These techniques may find widespread utility in the controlled formulation of many other 
polymeric nanomedicines for disease diagnosis, monitoring, and therapy.    
 
2. Materials and Methods 
2.1 General 
D,L-Lactide (LA) was purchased from TCI America (Portland, OR), recrystallized 
three times in toluene and stored at −30oC in a glove box prior to use.  β-Diimine (BDI) 
ligand and the corresponding metal complex (BDI)ZnN(TMS)2 were prepared by 
following the published procedures [11a] and stored at −30oC in a glove box. All 
anhydrous solvents were purified by passing the solvents through alumina columns and 
kept anhydrous by storing them with molecular sieves.  Ptxl was purchased from LC 
Laboratories (Woburn, MA) and stored at −30oC in a glove box prior to use.   All other 
chemicals were purchased from Sigma-Aldrich (St Louis, MO) and used as received 
unless otherwise noted.  The molecular weights (MWs) of PLA were determined on a gel 
permeation chromatography (GPC) equipped with an isocratic pump (Model 1100, 
Agilent Technology, Santa Clara, CA), a DAWN HELEOS 18-angle laser light scattering 
detector and an Optilab rEX refractive index detector (Wyatt Technology, Santa Barbara, 
CA).  The wavelength of the HELEOS detector was set at 658 nm.  Size exclusion 
columns (Phenogel columns 100 Å, 500 Å, 103 Å and 104 Å, 5 µm, 300 × 7.8 mm, 
Phenomenex, Torrance, CA) used for the separation of PLA or Ptxl-PLA conjugates were 
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serially connected on the GPC.  THF (HPLC grade) was used as the mobile phase of 
GPC. HPLC analysis was performed on a System Gold system (Beckman Coulter, 
Fullerton, CA) equipped with a 126P solvent module, a System Gold 128 UV detector 
and an analytical pentafluorophenyl column (Curosil-PFP, 250 × 4.6 mm, 5 μ, 
Phenomenex, Torrance, CA).  The UV wavelength for Ptxl analysis was set at 227 nm. 
The NMR studies were performed on a Varian UI500NB system (500 MHz). The sizes 
and polydispersities of PLA NCs were determined on a ZetaPALS dynamic light-
scattering (DLS) detector (15 mW laser, incident beam = 676 nm, Brookhaven 
Instruments, Holtsville, NY).  The lyophilization of NCs was carried out on a benchtop 
lyophilizer (Freezone 2.5, Fisher Scientific, Pittsburgh, PA).   
 
2.2 Preparation and characterization of Ptxl-LA100  
In a glove box, Ptxl (8.5 mg, 0.01 mmol) was dissolved in anhydrous THF (2 mL).  
(BDI)ZnN(TMS)2 (6.4 mg, 0.01 mmol) was added and allowed to react with Ptxl for 15-
20 min.  LA (144.0 mg, 1.0 mmol) in THF (1.2 mL) was added dropwise to the 
vigorously stirred mixture of Ptxl and (BDI)ZnN(TMS)2. The polymerization was 
monitored using FT-IR by following the disappearance of the lactone band of LA 
monomer at 1772 cm-1 or using 1H-NMR by checking the methine (-CH-) peak of LA 
around 5.2-5.0 ppm.  After the polymerization was complete, an aliquot of the 
polymerization solution was analyzed using HPLC to quantify the unreacted Ptxl in order 
to determine the incorporation efficiency of Ptxl in the Ptxl-PLA conjugates.  The 
resulting Ptxl-PLA conjugate prepared at a LA/Ptxl ratio of 100 (Ptxl-LA100) was 
precipitated with ethyl ether (10 mL), washed with ether and methanol to remove the BDI 
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ligand, dried under vacuum and characterized by GPC and 1H NMR.  Complete removal 
of BDI from Ptxl-PLA was verified by TLC.   
 
2.3  General procedure for the preparation of Ptxl-LA100 NCs via nanoprecipitation  
Ptxl-LA100 conjugate in DMF (50 μL, 10 mg/mL) (or in another water-miscible 
solvent such as acetone) was added dropwise to a nanopure water solution (2 mL).  The 
resulting NCs were analyzed by DLS after nanoprecipitation, collected by ultrafiltration 
(5 min, 3000 × g, Ultracel membrane with 10,000 NMWL, Millipore, Billerica, MA), 
washed with water to remove DMF (or other organic solvent), and then analyzed by SEM. 
 
2.4  Synthesis of PLA-PEG multiblock copolymer 
PLA-PEG block polymers were synthesized by following the procedures as 
described in Section 2.2 using (BDI)ZnN(TMS)2 as the catalyst and PEG as initiator.  To 
prepare PLA-PEG diblock copolymer and PLA-PEG-PLA triblock copolymer (LE5 and 
LE5L, respectively, Table 5.1), we used mPEG5k-OH and HO-PEG5k-OH as the 
corresponding initiator in the presence of (BDI)ZnN(TMS)2. 
General Procedure  In a glove box, mPEG5k-OH (50 mg, 0.01 mmol) in 
anhydrous dichloromethane (DCM, 300 μL) was mixed with a DCM solution of 
(BDI)ZnN(TMS)2 (6.5 mg, 0.01 mmol, 50 μL).  The mixture was stirred for 15 min.  A 
DCM solution of LA (144 mg, 1 mmol, 2.88 mL) was added to the vigorously stirred 
mPEG5k-OH/(BDI)ZnN(TMS)2 solution. The mixture was stirred at room temperature for 
16 h. The conversion of LA was determined by FT-IR by monitoring the lactone band at 
1772 cm-1.  The resulting copolymer LE5 was precipitated with ethyl ether (10 mL), 
washed with ether and methanol/acetic acid (100/1 (v/v), 10 mL) to remove the BDI 
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ligand, and dried under vacuum.  Complete removal of BDI was confirmed by NMR, 
HPLC and TLC.  After the organic solvent was evaporated, the resulting product (LE5) 
was dissolved in THF (10 mg/mL) and analyzed by GPC.  LE5L was prepared and 
characterized similarly as LE5.  The MWs and molecular weight distributions (MWDs) 
of both LE5 and LE5L were listed in Table 5.1. 
 
2.5 Formation and characterization of Ptxl-LA100/LE5 via sequential precipitation    
A DMF solution of Ptxl-LA100 conjugate (50 μl, 2 mg/mL) was added dropwise 
into a nanopure water solution (2 mL) to give the Ptxl-LA100 NCs.  LE5 (Mn = 1.9 × 104 
g/mol, 2 mg/mL, 100 μL) or mPEG5k (E5, 2 mg/mL, 100 μL) in DMF was added 
dropwise to the Ptxl-LA100 NCs.  A concentrated PBS solution (10×, 228 μL) was added 
to the nanoprecipitation solution to make the final salt concentration equivalent to 1× 
PBS.  The NC sizes were measured by DLS.  To determine the stability of the NCs in 
PBS solution, the particle sizes were followed for 30 min by DLS. 
 
2.6 Formation and characterization of Ptxl-LA100/LE5 NC via co-precipitation  
(CPP) 
A DMF solution of Ptxl-LA100 conjugate (12 mg/mL, 50 μL) was mixed with a 
DMF solution of LE5 (12 mg/mL, 50 μL). The mixture was then added dropwise to a 
vigorously stirred water solution (4 mL). The resulting NCs were analyzed by DLS.   
 
2.7 Formation and characterization of Ptxl-LA100/LE5L via co-precipitation  
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A DMF solution of Ptxl-LA100 (8 mg/mL, 50 μL) was mixed with LE5L in 
acetone (8 mg/mL, 50 μL).  The mixture was then added dropwise to a vigorously stirred 
water or PBS solution (4 mL).  The resulting NCs were analyzed by DLS.  The stability 
of the NCs in the PBS solution was followed for 10-30 min by DLS. 
 
2.8  Lyophilization of PLGA-mPEG NPs in the presence of lyoprotectants 
An acetone solution of PLGA-mPEG (5 mg/mL, 100 μL) was added dropwise 
into a vigorously stirred water solution (4 mL) to make the PLGA-mPEG NP.  A 
lyoprotectant was added to the vigorously stirred NC solution at the selected 
lyoprotectant/NC mass ratio (varying from 2 to 20).  The solution was then lyophilized, 
reconstituted with 2 mL water and stirred for 5 min. The sizes of the resulting NCs were 
analyzed by DLS. 
 
2.9 Lyophilization of Ptxl-LA100/LE5L NCs in the presence of albumin 
An acetone solution of Ptxl-LA100 (4 mg/mL, 50 μL) was mixed with an acetone 
solution of LE5L (4 mg/mL, 50 μL). The mixture was added dropwise to a vigorously 
stirred water solution (4 mL). The resulting NC solution was stirred for 6 h in a fume 
hood to evaporate the acetone; the resulting NC solution was then analyzed by DLS. An 
aqueous solution of bovine serum albumin (BSA) (12 mg/mL, 500 μL) was added to the 
NC solution.  The mixture was lyophilized for 16 h at −50 oC.  The resulting white 
powder was reconstituted with nanopure water (2 mL) and followed by addition of a 
concentrated PBS solution (10 ×, 222 μL). The solution was stirred for 5 min at room 
temperature. The resulting NC solution was analyzed by DLS.   
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2.10  Conjugation of aptamer to Cy5-LA50/PLA-PEG-COOH NCs   
Cy5-LA50 was prepared by following the previously reported procedure [6b]. Cy5-
LA50 / PLA-PEG-COOH NCs (w/w=1/1, 1 mL, 1 mg/mL in DNase RNase-free water) 
were incubated with an aqueous solution of 1-(3-dimethylaminopropyl)-3-
ethylcarbodimide hydrochloride (EDC) (400 mM, 200 µL) and N-hydroxysuccinimide 
(NHS) (100 mM, 200 µL) for 15 min at room temperature. The resulting NHS-activated 
NCs were reacted with 5'-NH2-modified A10 PSMA aptamer (1 µg/µL in DNase RNase-
free water, 50 μL). The resulting NC-aptamer bioconjugates were washed with ultrapure 
water (15 mL) by ultrafiltration (5 min, 1000 × g, Ultracel membrane with 10,000 
NMWL, Millipore, Billerica, MA, USA). The aptamer-modified NCs were re-suspended 
(1 mg/mL in DNase RNase-free water) and analyzed by fluorescence-activated cell 
sorting (FACS, BD FACScan™ Flow Cytometer) and fluorescence microscopy (Leica 
SP2 Laser Scanning Confocal Microscope). 
 
2.11 Analysis of cellular uptake of Cy5-LA50/PLA-PEG-COOH NC-aptamer 
bioconjugates by fluorescence microscope 
LNCaP and PC3 cells were grown in chamber slides in RPMI medium 1640 and 
F-12 medium (American Type Culture Collection), respectively, supplemented with 100 
units/ml aqueous penicillin G, 100 μg/mL streptomycin, and 10% FBS at concentrations 
to allow 70% confluence in 24 h (i.e., 40,000 cells per cm2). On the day of experiments, 
the medium was replaced with Opti-MEM medium (200 μL) containing Cy5-LA50/PLA-
PEG-COOH (w/w=1/1, 50 μg) NC or Cy5-LA50 /PLA-PEG-COOH NC-aptamer (NC-
aptamer, 50 μg, 5 wt% of aptamer).  The cells and NCs were co-incubated for 2-6 h, after 
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which the cells were washed with PBS (3 × 200 μL), fixed with 4% formaldehyde, 
counterstained with Alexa-Flour 488 Phalloidin (Invitrogen, CA, USA), mounted and 
then analyzed on a Leica SP2 Laser Scanning Confocal Microscope at 40× magnification. 
The images were collected along the z axis with a 0.8-μm interval and reconstructed 
using the provided software.  
 
2.12 Analysis of cellular uptake of Cy5-LA50/PLA-PEG-COOH NC-aptamer 
bioconjugates by FACS 
LNCaP and PC3 cells were grown in 24-well plates in RPMI medium 1640 and F-
12 medium (American Type Culture Collection), respectively, supplemented with 100 
units/ml aqueous penicillin G, 100 μg/mL streptomycin, and 10% FBS at concentrations 
to allow 70% confluence in 24 h (i.e., 40,000 cells per cm2). On the day of experiments, 
cells were washed with prewarmed PBS and incubated with prewarmed phenol-red 
reduced OptiMEM media for 30 min before the addition of the Cy5-LA50/PLA-PEG-
COOH (50 μg) NC or Cy5-LA50 /PLA-PEG-COOH NC-aptamer (50 μg, 5 wt% of 
aptamer).  The cells were incubated for 4 h at 37oC, washed with PBS (2× 500 μL per 
well) and subsequently treated with 0.25% trypsin with EDTA for 10 min. The cells were 
transferred to a 15-mL falcon centrifuge tube and centrifuged at 1200 rpm for 5 min 
followed by removal of the trypsin solution using a pipette. After the cells were washed 
with PBS (2× 500 μL/well), they were fixed with 4% formaldehyde for 10 min at room 
temperature, washed with PBS (1× 500 μL) and analyzed by FACS.    
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2.13  Preparation and formation of PLA-PEG-PAM  NPs for bone tumor targeting 
study 
A DMF solution of PLGA-mPEG/PLA-PEG-PAM conjugate (15 mL, v/v=10/1, 
10 mg/mL) was added dropwise into a nanopure water solution (300 mL) to give the NPs.  
The solution was then concentrated using the filtration tube (Ultracel membrane with 
10,000 NMWL, Millipore, Billerica, MA, USA) by centrifuge (3000 rpm) to 5 mL. The 
concentrated solution with 45 mL saline (sterilized) in the biohood and used within 6 
hours for labeling with active 99mTc and bone tumor targeting. 
 
2.14 Preparation and formation of Doxo-LA25/PLA-PEG-PAM NPs for in vivo 
toxicity study 
A DMF solution of Doxo-LA25/PLGA-mPEG/PLA-PEG-PAM conjugate (15 mL, 
v/v=10/1, 10 mg/mL) was added dropwise into a nanopure water solution (300 mL) to 
give the NPs.  The solution was then concentrated using the filtration tube (Ultracel 
membrane with 10,000 NMWL, Millipore, Billerica, MA, USA) by centrifuge (3000 rpm) 
to 5 mL for further dilution for in vivo cytotoxicity study. The analysis of tissues was 
assisted by Prof. Tim Fan (UIUC). 
 
2.15 Formation of Ptxl-LA25/PLA-mPEG NPs for Lewis Lung carcinoma (LLC) 
tumor prevention study 
Female C57BI/6 mice were anesthetized, shaved, and prepared for implantation of 
the tumor cells.  LLC cells were collected from culture, and 1,000,000 cells were then 
mixed with NPs and immediately injected subcutaneously into one flank of a mouse.  
Equivalent injections of cells with drug-free NPs, Ptxl solubilized with Cremophor EL / 
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ethanol (currently used clinically), and saline were also performed. The animals were 
monitored closely, and measurements of the tumor size for each animal were performed 
at regular intervals using calipers without knowledge of which injection each animal had 
received.    The tumor volume for each time point was calculated according to the 
formula (length) × (width) ×(height)×π/2, where the  long axis is the length,  the short 
axis is the width, and  the protrusion  from the body is the height.  When the tumor load 
reached 2000 mm3 or the animal had become moribund, the mouse was sacrificed.  
 
2.16 In vivo evaluation of Cy5-PLA NPs biodistribution 
3 female balb/c mice were injected each with 1 mg of PLA/Cy-5 NP (300 µl) via 
lateral tail vein and then sacrificed 24 hours later.  One untreated balb/c mouse was 
sacrificed and used as an autofluorescence background control. The in vivo 
biodistribution of PLA/Cy-5 NP within visceral organs including heart, lung, liver, spleen, 
and kidney was studied using a LI-COR Odyssey scanner (LI-COR Bioscience, Lincoln, 
NE).  
 
3. Results and Discussion 
3.1 Synthesis of Ptxl-LA100 nanoconjugates 
To ensure a rapid and complete polymerization of LA at room temperature using 
Ptxl as the initiator, we utilized (BDI)ZnN(TMS)2, an active catalyst developed by Coates 
and coworkers for the polymerization of LA (Figure 5.1a) [11a].  We have previously 
reported regioselective initiation of Ptxl followed by controlled polymerization of LA 
when the polymerization was mediated by (BDI)ZnN(TMS)2 [6a]. After Ptxl was mixed 
with 1 equiv. (BDI)ZnN(TMS)2, the (BDI)Zn-Ptxl alkoxide formed in situ via the 2’-OH 
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of Ptxl (Figure 5.1a) initiated and completed the polymerization of LA within hours at 
room temperature, with nearly quantitative incorporation of Ptxl to the resulting PLA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 (a) Regioselective initiation and controlled LA polymerization mediated by the 
Ptxl/(BDI)ZnN(TMS)2 complex to give Ptxl-PLA conjugate. (b) Formulation of Ptxl-PLA NCs 
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(Figure 5.1 continued) through i) nanoprecipitation of Ptxl-PLA, ii) nanoprecipitation of Ptxl-
PLA followed by coating with PLA-PEG, iii) co-precipitation of Ptxl-PLA and PLA-PEG, and iv) 
co-precipitation of Ptxl-PLA and PLA-PEG-PLA.  NPP = nanoprecipitation; CPP = co-
precipitation.  
 
3.2   Formation of Ptxl-LA100 nanoconjugates via nanoprecipitation (NPP) 
Nanoprecipitation (NPP) is an extensively used method for the preparation of NPs 
with therapeutic agents embedded in the hydrophobic polymeric matrices [7c, 14]. This 
method allows for rapid access to NPs in large quantity.  Typically, a mixture of 
hydrophobic polymer and drug is dissolved in water-miscible organic solvent (e.g., DMF 
or acetone) and then added dropwise to a vigorously stirred water solution (Vwater/Vsolvent = 
10 to 40). The instantaneous diffusion of the organic solvent into water results in 
formation of polymer/drug NPs.   
The NPP of Ptxl-LA100 resulted in sub-100 nm Ptxl-LA100 NCs with monomodal 
particle size distributions and low polydispersities (Figure 5.2).  In hundreds of NPP 
experiments that we have performed using Ptxl-PLA conjugates with various MWs, we 
rarely observed NCs with more than one particle size distribution based on the DLS 
analysis. The narrow, monomodal particle size distributions for NCs derived from NPP of 
the Ptxl-PLA conjugates have also been confirmed by SEM analysis in our previous 
study [6a], and are in sharp contrast to the multimodal particle size distribution typically 
observed with the NPs prepared by the co-precipitation (CPP) of a mixture of Ptxl and 
hydrophobic polymer (e.g., PLA or PLGA (poly(lactide-co-glycolide)) [7c]. As the 
multimodal distribution of NPs is due in part to the aggregation of the non-encapsulated 
drug molecules [7c], the monomodal particle size distribution pattern observed and very 
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low polydispersities with the Ptxl-LA100 NCs are likely related to the unimolecular 
strucutres of the Ptxl-PLA conjugates.    
 
 
 
 
 
 
 
 
 
Figure 5.2. Dynamic light scattering (DLS) analysis of Ptxl-LA100 NC in water (0.025 mg/mL). 
 
3.3. Control of Ptxl-LA100 NC size in the NPP process (Approach i, Figure 5.1b) 
Particle size is one of the most important parameters of NPs and has significant 
impact on biodistribution, clearance kinetics, and in vivo efficacy [3, 15]. With respect to 
biodistribution, the upper limit of desirable NP size is typically around 200 nm.  Particles 
with diameters of 200 nm or greater are more likely to induce an immune response and be 
taken up by the Kupffer cells than their smaller counterparts, resulting in rapid clearance 
of particles from circulation [2b].  Particles 150 nm or smaller can escape through 
fenestration of the vascular endothelium and be cleared from circulation, while particles 
smaller than 10 and 30 nm are easily cleared through the kidney or lymph nodes, 
respectively [2b]. Although it is still not entirely clear which NP size leads toward the most 
favorable biodistribution and highest therapeutic efficacy in vivo when NPs are 
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systemically administered, there is a general consensus that NPs should be controlled 
below 200 nm [2b]. Previous studies have revealed that NPs with diameters less than 200 
nm can passively accumulate in solid tumor through the enhanced permeation retention 
effect (EPR) [16], a mechanism that has been broadly utilized to improve the residence of 
NPs in tumor tissues.  However, NPs with sizes below 200 nm may still behave 
dramatically different in different size ranges in terms of their in vivo biodistribution, 
tumor targeting efficiency, tumor penetration and anticancer efficiency[4].  One goal of 
this research project is to develop NCs with various size ranges as a tool to facilitate the 
evaluation of the correlation of the biodistribution and anticancer efficacy of NCs with 
NC size. Such information can be subsequently utilized for in vivo targeted cancer 
therapy.  To achieve this goal, it is essential to develop methods that allow for facile 
formulation of NCs with precisely-controlled sizes.  For this reason, we performed a 
series of studies using Ptxl-LA100 as a model PLA-drug conjugate to assess how solvent, 
concentration of Ptxl-LA100 and surfactant would affect the sizes of NCs and how NCs 
could be prepared with no or negligible aggregation in PBS solution for an extended 
period of time to facilitate their in vivo applications. 
We first studied the effect of solvent on the NPP of Ptxl-LA100 with water as the 
non-solvent.  Previous studies by us [7c] and others [17] showed that the miscibility of the 
organic solvent with water can dramatically impact NP size in a given solvent/water 
system.  As shown in Figure 5.3, the sizes of Ptxl-LA100 NCs and the water-miscibility of 
the two organic solvents used in this study were well correlated; an increase of water 
miscibility led to a decrease in the mean NC size when all other formulation parameters 
were held constant.  Ptxl-LA100 NCs prepared with DMF as the solvent, a more water-
miscible solvent, resulted in smaller particles.  This is presumably due to more efficient 
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solvent diffusion and polymer dispersion into water in this DMF/water NPP system.  The 
Ptxl-LA100 NCs prepared with acetone, a less water-miscible solvent than DMF, were 
typically 20-30 nm larger than the NCs prepared with DMF as the solvent at the 
corresponding concentration (Figure 5.3).  Acetone can be readily removed by 
evaporation because of its low boiling point.  In contrast, DMF has to be removed by 
ultrafiltration followed by extensive washing.  Thus, NC formulation via NPP in the 
acetone/water system is much easier, which is more suitable for the large-scale 
preparation of NCs.  
We next studied the effect of the Ptxl-LA100 concentration during NPP on the size 
of NCs. When the polymer concentrations were varied during the NPP of Ptxl-LA100 at a 
fixed solvent:water ratio (Figure 5.3), we observed a linear correlation of NC size with 
the Ptxl-LA100 concentration.  The sizes of the NC increased from 90.9 nm to 195.3 nm 
as the polymer concentration in DMF increased from 1 mg/mL to 10 mg/mL. Similar 
correlation was also observed with acetone as the solvent for the NPP of Ptxl-LA100 
(Figure 5.5). In both DMF/water and acetone/water NPP systems, the polydispersities of 
the NCs at all concentrations remained very low, ranging 0.061-0.128 and 0.081-0.168 
for NCs derived from DMF/water and acetone/water system, respectively.  Because of 
the linear correlation of NC size with the concentration of Ptxl-PLA conjugate during 
NPP, NCs with any desirable sizes ranging from 80 to 250 nm can be obtained simply by 
adjusting precipitation concentration.  
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Figure 5.3  Ptxl-LA100 NC size versus the concentration of Ptxl-LA100 with the use of acetone (●) 
or DMF (■) as the solvent for nanoprecipitation. The volume ratio of organic solvent to water 
was fixed at 1/40. The dash line indicated the linear correlation of the NC size with the 
concentration of Ptxl-LA100. R2 is the linear correlation constant of corresponding system. 
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3.4.  Formation of NCs via sequential precipitation of Ptxl-LA100 and LE5 
(Approach ii, Figure 5.1b) 
NCs are designed specifically for in vivo drug delivery applications. It is desirable 
to have NCs with prolonged circulation to maximize their therapeutic efficacy.  To 
achieve protracted retention in circulation with reduced recognition by reticuloendothelial 
system, both the size and surface properties of NCs have to be well controlled [2b].  
Systemically administered NPs without proper surface modification are usually cleared 
rapidly from the circulation and localized predominately in liver and spleen [7c, 18].  
Severe liver and spleen retention greatly diminishes the accessibility of the NPs to tumor 
tissues and also causes liver and spleen damage. The clearance is due to the scavenging 
by liver Kupffer cells and spleen macrophages [2b]. NP surface properties play a critical 
role in the blood opsonization, a process involving the deposition of protein opsonins that 
are recognized by phagocytic cells, thereby accelerating the clearance of NPs from blood.  
Opsonization of NPs can be substantially reduced when NP surface features are properly 
controlled [19].  Modification of NP surfaces with PEG, termed “PEGylation”, is a well-
established approach to reduce protein binding [20].  Suppression of opsonization is thus 
achievable by PEGylation and has been utilized to enhance the circulation half-life of 
NPs from several minutes to several or tens of hours [10, 15, 21]. Since the report of long-
circulating NP [15], surface PEGylation has been extensively used to prepare in vivo 
applicable drug delivery systems [20] and other biotechnology applications [22].    
Ptxl-LAn NCs have negative surface zeta-potential and remain non-aggregated in 
water due to surface charge repulsion.  However, aggregation of NCs occurred in PBS, 
presumably due to salt-induced screening of the repulsive force (Figure 5.6a) [23].  The 
popular PEGylation strategy was thus adopted in this study to create NCs that will not 
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aggregate in salt solution.  PEGylated NCs likely also have reduced protein binding for 
their in vivo applications.    
PEG is typically covalently conjugated to the surface of NPs [7c, 14]. To minimize 
efforts involved in conjugation chemistry, we attempted a direct deposition method to 
coat NC with PEG.  PLA-mPEG5k (LE5, Table 5.1), an amphiphilic block copolymer 
with PLA block of 14 kDa and mPEG segment of 5 kDa, was synthesized via the ring 
opening polymerization of LA using a mixture of mPEG and (BDI)ZnN(TMS)2.  
Dropwise addition of LE5 to the Ptxl-LA100 NC aqueous solution resulted in rapid 
coating of Ptxl-LA100, presumably via the hydrophobic interaction of PLA segment of 
LE5 and the hydrophobic NC surface. After treatment, the size of the Ptxl-LA100 NC 
increased from 101.6 nm to 112.7 nm.  The resulting NCs remained non-aggregated for at 
least 30 min in PBS (Figure 5.6a). To demonstrate the importance of the PLA block to 
the non-covalent surface PEGylation, we added mPEG5k (E5, Table 5.1) to the NC 
solution followed by the addition of PBS. Without the hydrophobic PLA block, E5 
should not form stable interaction with NCs. As expected, Ptxl-LA100/E5 NCs formed 
large aggregates almost instantaneously after PBS was added, following a very similar 
aggregation pattern as the parental NCs in PBS (Figure 5.4a).  Furthermore, analyses of 
the Ptxl-LA100 NC by DLS before and after treatment showed that particles retained their 
monomodal distribution pattern (Figure 5.4b). The DLS experiments indicated that LE5 
favorably precipitated on the surface of Ptxl-LA100 NCs instead of self-assembling to 
form micelles.  The resulting PEG coated NCs form a core-shell nano-structure with 
hydrophobic polymer-drug conjugate being in the core and LE5 on the shell, which has 
been confirmed by various TEM studies.  
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Figure 5.4 (a) Stability of Ptxl-LA100 NCs in PBS (1×) after coated with mPEG5k (E5) or with 
PLA-mPEG5k (LE5). (b) DLS spectra of Ptxl-LA100/LE5 NC and the untreated Ptxl-LA100 NC.  
Particle sizes were determined 4 min after particles were present in PBS solution. 
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Table 5.1  PEG and PEG-PLA copolymers* 
 
 
 
 
 
* Mn = number-average molecular weight; PDI = polydispersity index. Abbreviations of 
chemicals:  mPEG5k-OH = mono-methoxy poly (ethylene glycol) with a molecular weight of 5 
kDa; PLA = polylactide; PLGA = poly(lactide-co-glycolide) (LA/GA=50/50 molar ratio).  
 
 
3.5.  Formation of NCs via co-precipitation of mixtures of Ptxl-LA100 and LE5 
(Approach iii, Figure 5.1b) 
 Formation of Ptxl-LA100/LE5 core-shell type nanostructures requires two steps to 
finish − the NPP of Ptxl-LA100 to form NC core followed by coating with LE5 to form the 
PEG shell.  Preparation of salt-stable NCs in such a step-wise manner is difficult to 
handle, especially for the preparation of NCs in large scale.  It is desirable to formulate 
salt-stable Ptxl-LAn NCs in one step.  We next tested whether we could formulate salt-
stable NCs by co-precipitating (CPP) a mixture of Ptxl-LA100 and LE5.  
 We mixed Ptxl-LA100 with LE5 at 1:1 mass ratio in DMF, a fixed ratio utilized 
throughout the studies reported in this paper, and then precipitated them in nanopure 
water (VDMF/Vwater  = 1/40).  Linear increase in particle size with the increase of polymer 
concentration was observed (Figure 5.5a), following a similar trend as the NPP of Ptxl-
LA100 previously discussed in the Figure 5.3.   The sizes of NCs gradually increased from 
61.4 nm to 121.0 nm when the concentration of Ptxl-LA100 increased from 2 mg/mL to 10 
Abbreviation Name M n (x10
3g/mol) MWD
E5 mPEG5k-OH 5.3 1.01
LE5 PLA-mPEG5k 19.3 1.09
LE5L PLA-PEG5k-PLA 34.4 1.12
PLGA-mPEG5k 18.3 1.41
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mg/mL. When acetone was used as the solvent, similar linear correlation of NC sizes 
with the concentration of Ptxl-LA100 was observed.  The sizes of NCs increased from 
79.2 to 145.9 nm when the concentration of Ptxl-LA100 increased from 2 mg/mL to 10 
mg/mL. The NCs obtained in the latter case (CPP of Ptxl-LA100/LE5 from acetone to 
water) were roughly 20-25 nm larger than the NCs prepared with DMF as solvent at 
corresponding concentration, similar to the solvent effect described in Figure 5.5.  NCs 
prepared in both DMF/water and acetone/water systems showed narrow-dispersed, 
monomodal particle size distribution, exemplified by the Ptxl-LA100/LE5 NC prepared 
via the NPP with a concentration of 6 mg/mL in acetone (Figure 5.5b).  We next 
evaluated the stability of the NCs in PBS.  After precipitating a mixed DMF solution of 
Ptxl-LA100 and LE5 (Ptxl-LA100 = 4 mg/mL) in a water solution (VDMF/Vwater  = 1/40) 
followed by the addition of PBS to the resulting NC solution, the particles remained non-
aggregated for an extended period of time based on the DLS analyses (data not shown).   
  
 
 
 
 
 
 
 
 
 
 
 
 133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 (a) Co-precipitation (CPP) of Ptxl-LA100/LE5 (wt/wt = 1/1) from DMF or acetone 
solution into water at various Ptxl-LA100 concentration. (DMF (or acetone)/water = 1/40 (v/v)). (b) 
Ptxl-LA100/LE5 NC size distribution determined by DLS. Condition: Ptxl-LA100 in DMF (50 μL, 
12 mg/mL) was mixed with a DMF solution of LE5 (50 μL, 12 mg/mL).    The mixture was 
added dropwise to a vigorously stirred water solution (4 mL). The resulting Ptxl-LA100/LE5 NCs 
was analyzed by DLS.  
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3.6.  Formation of NCs via co-precipitation of mixtures of Ptxl-LA100 and LE5L 
(Approach iv, Figure 5.1b) 
To further simplify NC formulation, we explored whether it was possible to 
formulate stable NCs directly in PBS solution.  When the mixture of Ptxl-LA100 and LE5 
was directly co-precipitated in PBS, the resulting NCs were not stable in PBS and formed 
large aggregates rapidly (Figure 5.6).  The particle size increased from 83 nm to 197 nm 
within 6 min.  Interestingly, when LE5L (Table 5.1), a ABA type triblock copolymer 
with PEG as the B clock (MW = 5 kDa) and PLA as the A block (MW = 14 kDa), was 
mixed with Ptxl-LA100 at 1:1 mass ratio in DMF and subsequently precipitated in PBS, 
the resulting Ptxl-LA100/LE5L NCs were found to be surprisingly stable in PBS and 
remained non-aggregated for an extended period of time (Figure 5.6).  To compare the 
non-solvent effect on the NC formulation, we conducted CPP of Ptxl-LA100 / LE5L at 
various concentrations in both PBS and water.  When water was used as the non-solvent, 
the size of the Ptxl-LA100/LE5L NC gradually increased from 66.8 nm to 125.5 nm as the 
concentration of the mixture increased from 2 mg/mL to 10 mg/mL.  CPP of the Ptxl-
LA100 and LE5L mixture in water or to PBS showed a linear correlation of Ptxl-LA100 
concentration with NC size (Figure 5.7), similar to the NPP of the Ptxl-LA100 in water 
reported previously (Figure 5.3). When the CPP was performed with PBS as the non-
solvent, the sizes of NCs were typically 20-40 nm larger than those derived from the NPs 
prepared with water as the non-solvent and followed a linear trend with the concentration 
of Ptxl-LA100; the sizes of NCs increased from 99.0 to 156.5 nm when the concentration 
of the of Ptxl-LA100 in the mixture increased from 2 mg/mL to 10 mg/mL (Figure 5.7).  
NCs prepared at various concentrations all stayed non-aggregated in PBS for an extended 
period of time (data not shown).  It is known that triblock LE5L and diblock LE5 self-
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assemble in different manners.  LE5 forms star-like micelles, while LE5L, because of its 
ABA type of amphiphilic structure, tends to form flower-like micelles (Figure 5.1b) [24]. 
Hydrophobic polymer chains in flower-like micelles tend to have stronger interaction 
than those in star-like micelles, which may in part contribute to the formation of Ptxl-
LA100/LE5L NCs with stably coated PEG shell and enhanced stability in the PBS solution.  
The detailed mechanism of Ptxl-LA100/LE5L and Ptxl-LA100/LE5 NC self-assembly is yet 
to be determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6    The stability of NCs in PBS solution. ■: A mixture of Ptxl-LA100 and LE5 in DMF 
(w/w = 1/1, Ptxl-LA100 = 4 mg/mL) was co-precipitated directly to 1× PBS (DMF/PBS = 1/40 
(v/v)). ●: A mixture of Ptxl-LA100 and LE5L in DMF (w/w = 1/1, Ptxl-LA100 = 4 mg/mL) was co-
precipitated directly to 1× PBS (DMF/PBS = 1/40 (v/v)). ▲: A mixture of Ptxl-LA100 and LE5L 
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(Figure 5.6 continued) in acetone (w/w = 1/1, Ptxl-LA100 = 2 mg/mL, 100 μL) was co-precipitated 
to water (4 mL). The obtained NC had a diameter of 88.9 nm with a polydispersity of 0.092. The 
resulting NC solution was mixed with an aqueous solution of BSA (500 μL, 12 mg/mL).  The 
mixture was lyophilized for 16 h at -50 oC. The resulting powder was reconstituted with 2-mL 
water and followed by addition of a concentrated PBS solution (222 μL, 10×).  The mixture was 
stirred for 5 min at room temperature and analyzed by DLS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7  Linear correlation of Ptxl-LA100/LE5L NC size with Ptxl-LA100 concentration in 
DMF when the mixture of Ptxl-LA100/LE5L was co-precipitated in water or in PBS 
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3.7.  Lyophilization and storage of Ptxl-PLA NCs  
Formulations of small-scale NPs that stay non-aggregated in PBS for in vitro or in 
vivo laboratory studies are relative easy to control.  However, in order to facilitate their 
clinical translation, NPs have to be prepared in large quantity with well controlled 
properties, which should remain unchanged during the processes of manufacturing, 
storage and transport prior to their use in clinic. In Ptxl-PLA, because Ptxl is covalently 
conjugated to PLA through an ester bond that is subject to hydrolysis upon exposure to 
water, handling of NCs in aqueous solution in the abovementioned processes is 
undesirable.  NCs have to be formulated in solid form in order for them to be used in 
clinic.     
It is known that PLA-based NPs tend to aggregate during lyophilization. As 
expected, when the Ptxl-LA100/LE5 or the Ptxl-LA100/LE5L NCs with sub-100 nm sizes 
were lyophilized, reconstituted and re-analyzed by DLS, micrometer-sized, non-
dispersible aggregates were observed.  Administration of polymeric NPs with micron size 
aggregates via tail vein injection led to instantaneous mice death based on our previous 
experience.   
There have been many studies using lyoprotectants to physically separate NP 
from aggregating during lyophilization.  Mono- or di-saccharides, such as sucrose, 
dextrose, maltose, sorbitol, glucose, are frequently used as lyoprotectants because their 
biocompatibility and low cost [25].  In our previous efforts of developing aptamer-based 
cancer targeting and therapy, we conducted preliminary studies on the lyophilization of 
PLGA-mPEG5k NPs with the use of sucrose as the lyoprotectant [7c].  Although the 
aggregation of PLGA-mPEG5k NPs was reduced during lyophilization, formation of 
substantial amount of large, non-dispersible aggregates was still observed.   Based on this 
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previous study, we screened a large number of lyoprotectants using PLGA-mPEG5k based 
NPs and compared them with sucrose for their capabilities of preventing NP aggregation 
during lyophilization (Table 5.2)  
PLGA-mPEG5k NPs were prepared via nanoprecipitation of PLGA-mPEG5k 
(Table 5.1) as previously described [7c].   Commonly used saccharide-based lyoprotectants, 
such as sucrose, sorbitol, maltose, dextrose and mannose, were able to reduce NP 
aggregation to some degree when the NPs were lyophilized along with these 
lyoprotectants (Table 5.2).  High lyoprotectant chemical/NP mass ratio (Wc/WNP, Table 
5.2) was more effective in terms of reducing NP aggregation (Table 5.2).  However, even 
at a Wc/WNP ratio as high as 10, significant NP aggregations were observed in all systems 
(Table 5.2).  DLS analyses of these NPs after lyophilization showed multimodal particle 
size distributions.  Some large, non-dispersible aggregates precipitated from the solution 
and were even visible with the naked eye.  Other sugars, such as galactose, could not 
prevent NP aggregation at all even at a lyoprotectant/NC mass ratio of 10.  We also tested 
whether amino acid (e.g., glycine) or surfactant (e.g., SDS) could be used as the 
lyoprotectant and found that they were unable to prevent NP aggregation during 
lyophilization (Table 5.2).  
Because none of the small molecules tested could effectively prevent NP 
aggregation during lyophilization, we next tested whether macromolecules could provide 
better lyoprotection during NP lyophilization.  Albumin, an abundant protein in blood, 
has attracted much interest in drug delivery recently.  Abraxane®, an albumin-paclitaxel 
NP, has been recently approved by the US Food and Drug Administration for cancer 
treatment [26].  We tested whether bovine serum albumin (BSA) could be used as a 
lyoprotectant of NPs.   At a BSA/NP mass ratio of 2, the NP size increased by 8.2 times 
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from 62 nm before lyophilization to 512 nm after lyophilization; two particle size 
distributions were observed.  When the BSA/NP mass ratio increased to 6 and 10, the 
size of the lyophilized NP became 176 nm and 114 nm, respectively, This corresponds to 
roughly 2.8- and 1.8-times the pre-lyophilized NPs.  For the first time we were able to 
completely disperse the lyophilized NPs with sub-200 nm diameters with absolutely no 
precipitates.  The reconstituted NPs showed monomodal particle size distribution as 
determined by DLS (data not shown).    
We next tested whether albumin could be used to stabilize Ptxl-LA100/LE5L NC.  
A Ptxl-LA100/LE5L NC was first prepared by co-precipitation as described previously in 
Figure 5.9.  The particles size and the polydispersity of the resulting NC were 88.9 nm 
and 0.092, respectively, as determined by DLS.  After lyophilization at a BSA/NC mass 
ratio of 15 followed by reconstitution with 1× PBS, the NC size increased slightly to 
105.9 nm (Figure 5.8) but remained non-aggregated for at least 10 min during the course 
of DLS analysis.  Monomodal particle size distribution was verified by DLS analysis 
(Figure 5.10). The polydispersity of NCs remained as low as 0.112.  This experiment has 
been repeated multiple times with consistent and highly reproducible results and no NC 
aggregation in each of the repeated experiments.  Because of the biocompatibility of 
albumin, this albumin-based lyoprotection strategy may be broadly used in solid 
formulations for drug delivery or other translational applications.   
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Figure 5.8 (a) DLS spectrum of NC obtained from the co-precipitation of an acetone solution of 
Ptxl-LA100/LE5L (w/w = 1/1, Ptxl-LA100 = 2 mg/ml, 100 μL) to water (4 mL, acetone/water = 
1/40 (v/v)). The obtained NC had a diameter of 88.9 nm with a polydispersity of 0.092. (b) The 
resulting NC solution was then mixed with an aqueous solution of BSA (500 μL, 12 mg/mL).  
The mixture was lyophilized for 16 h at -50 oC. The resulting powder was reconstituted with 2-
mL water and followed by addition of a concentrated PBS solution (222 μL, 10×).  The mixture 
was stirred for 5 min at room temperature and analyzed by DLS. The obtained NC had a diameter 
of 105.9 nm with a polydispersity of 0.112.  
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Table 5.2  Characterization of PLGA-mPEG NPs Lyophilized in the Presence of Various 
Lyoprotectant and Reconstituted by Watera   
 
 
aIn this study PLGA-mPEG5k (Mn = 19.4 × 103 g/mol) was used to study the efficiency of 
lyoprotectant.  The original PLGA-mPEG NP had a diameter of 62.7 nm, which was formulated 
through the NPP of PLGA-mPEG to water. After the NPP was complete, the corresponding 
lyoprotectant was added as the selected lyoprotectant/NP mass ratio prior to lyophilization. bSDS 
= sodium dodecyl sulfate; BSA = bovine serum albumin. cWc/WNP = the mass ratio of 
lyoprotectant chemicals vs. NP. dPDI = polydispersity; STD = standard deviation. eDistrib. Num. 
= the number of particle size distribution. N.D. = not determined. fSL/SO = the ratio of the 
lyophilized NP size to pre-lyophilized NP size.  gAggr. = visible large aggregates; Y = aggregates 
observed; N = no aggregates observed.  
 
 
 
3.8.  Ptxl-PLA NCs for prostate cancer targeting 
Aptamers are either single-stranded DNA or RNA that specifically bind to a target 
ligand or ligands.  They were selected from a library of nucleic acids with random 
sequences via a combinatorial process called Systematic Evolution of Ligands by 
Lyoprotectant b WC/WNP
 c Size in nm (STD) d PDI (STD) d Distrib. Num. e SL/SO
 f Aggr. g
Sucrose 2 245.2 (2.1) 0.227 (0.003) 2 3.93 Y
Sucrose 10 217.5 (3.0) 0.220 (0.002) 2 3.49 Y
Sorbitol 2 >1000 >1000 N.D. N.D. Y
Sorbitol 10 764.8 (39.2) 0.299 (0.021) 2 12.28 Y
Maltose 2 >1000 >1000 N.D. N.D. Y
Maltose 10 220.4 (3.2) 0.288 (0.008) 2 3.54 Y
Dextrose 2 250.4 (9.5) 0.345 (0.0120 2 4.02 Y
Dextrose 10 79.1 (2.3) 0.075 (0.032) 2 1.26 Y
Mannose 2 >1000 >1000 N.D. N.D. Y
Mannose 10 245.2 (1.6) 0.254 (0.011) 2 3.93 Y
Galactose 10 >1000 >1000 N.D. N.D. Y
Glycine 10 >1000 >1000 N.D. N.D. Y
SDS 10 >1000 >1000 N.D. N.D. Y
BSA 2 511.8 (24.7) 0.392 (0.005) 2 8.21 Y
BSA 6 175.9 (3.3) 0.343 (0.008) 1 2.82 N
BSA 10 114.1 (1.4) 0.110 (0.002) 1 1.83 N
 
 142 
Exponential Enrichment (SELEX) [27]. When used for cancer targeting, aptamers are 
capable of binding to target antigens with extremely high affinity and specificity in a 
manner resembling antibody-mediated cancer targeting. Aptamers are typically non-
immunogenic and exhibit remarkable stability against pH, temperature and solvent. 
Synthesis of aptamers is an entirely chemical process and thus shows negligible batch-to-
batch inconsistency [28]. These unique properties of aptamers are in sharp contrast to 
antibodies that are typically unstable against temperature and pH change, are 
immunogenitic, and have significant batch-to-batch variability.    
An A10 aptamer with 2'-fluoro-modified ribose on all pyrimidines and a 3'-
inverted deoxythymidine cap has been identified via SELEX and utilized to target 
extracellucular prostate-specific membrane antigen (PSMA) [29].  It binds to the PSMA-
positive LNCaP prostate cancer cells but not PSMA-negative PC3 prostate cancer cells. 
Previous study showed that PLGA-A10 aptamer bioconjugates were capable to target 
LNCaP cells in vitro and in vivo [14, 30].  
Cy5 (a fluorescence dye with hydroxyl groups) was used to initiate LA 
polymerization to prepare Cy5-PLA and subsequently Cy5-PLA NCs for study of the in 
vitro cancer targeting. The amine-terminated A10 aptamer was conjugated to the PLA-
PEG-COOH/Cy5-PLA NCs  (particle size 132.8 nm with the polydispersity of 0.031) 
through the carboxylic acid-amine coupling reaction in the presence of EDC and NHS to 
give aptamer/PLA-PEG-COOH/Cy5-PLA NCs (aptamer-Cy5 NC) [30]. After purifying 
the aptamer-Cy5 NCs by centrifugation and washing the NPs with PBS, we found that 
the size of aptamer-Cy5 NCs increased slightly to 157.1 nm with a polydispersity of 
0.144 after conjugation of the A10 aptamer. Freshly prepared aptamer-Cy5 NCs were 
then applied to the LNCaP (PSMA+) and PC-3 (PSMA-) cells, and their binding and 
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internalization were assessed by FACS (Figure 5.11). As shown in Figure 5.11(a), the 
mean fluorescence intensity of the LNCaP cells (PSMA+) incubated with aptamer-Cy5 
NC for 4 h was 376.7 (arbitrary intensity unit on FACS Cy5 channel), as compared to 
72.4 for PS3 cell (PSMA-) and 16.4 in the untreated LNCaP cells.  The fluorescence 
intensity of the aptamer-Cy5 NC treated LNCaP cells was 5.2 times higher than that of 
PC-3 cells treated under the same condition, indicating enhanced aptamer-Cy5 NC 
binding to PSMA+ LNCaP cells and potentially improved NC internalization.  A kinetic 
study for the internalization of aptamer-Cy5 NCs into LNCaP cells was then performed 
(Figure 5.11(b)).  The LNCaP cells treated with aptamer-Cy5 NCs for 2 h revealed a 
mean fluorescence intensity of 136.2, as compared to 16.4 of the untreated cells.  When 
the LNCaP cells were treated with aptamer-Cy5 NCs for 6h, the mean fluorescence 
intensity increased to 779.8, indicating 5.7 times more NCs were internalized into the 
cells.  Those observations were confirmed by an uptake imaging study using confocal 
microscopy. As shown in Figure 5.12, the uptake of Cy5 NCs to LNCaP cells was 
significantly enhanced when NCs were coated with aptamer (A versus E; B versus F).  
Incubation of aptamer-Cy5 NCs with LNCaP cells for longer time resulted in 
substantially increased NC internalization (A versus B).  Because PC3 cells do not 
express the PSMA protein, there was essentially no difference between the aptamer-Cy5 
NC and the Cy5 NC without aptamer with respect to their capability of cell-binding and 
internalization.  Incubating PC3 cells with NCs for longer time resulted in slightly 
increased NC uptake. The binding of aptamer-Cy5 NCs to the PC3 cells was substantially 
weaker than to LNCaP cells (B versus D).  These in vitro studies demonstrated that NCs 
conjugated with aptamer targeting ligand can potentially be used for prostate cancer 
targeting. 
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We have previously demonstrated that NCs can be formulated into solid form 
when albumin is used as the lyoprotectant.  We next tested whether aptamer-Cy5 NCs 
can be made in solid form and then reconstituted to give NCs with similar sizes and 
targeting capability.    At a BSA/Aptamer-Cy5 NC mass ratio of 10, the size of the 
lyophilized and reconstituted aptmaer-Cy5 NC was 212.6 nm (with a polydispersity of 
0.386) as compared to NCs with 157.1 nm (with a polydispersity of 0.144) before 
lyophilization.  DLS analysis indicated that the lyophilized and reconstituted aptamer-
Cy5 NCs maintain monomodal size distribution (data not shown). The reconstituted 
aptamer-Cy5 NC were then applied in cell-binding studies and analyzed by FACS; their 
targeting capability was found to be well preserved during the lyophilization process.  
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Figure 5.9  Flow cytometry analysis of NP-Apt conjugates cellular uptake. (a) Untreated LNCaP 
cells (red line); PC3 cells treated with NP-Apt for 4 hours (blue line); LNCaP cells treated with 
NP-Apt for 4 hours. (b) Untreated LNCaP cells (black line); LNCaP cells treated with NP-Apt for 
2 hours (red line) and 6 hours (blue line). 
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Figure 5.10  Confocal images of LNCaP (left) and PC3 (right) cells treated with aptamer-
functionalized nanoparticles (NP-Apt, top) and nanoparticles without aptamer (NP, bottom). The 
Cy-5 incorporated NP or NP-Apt are shown in red color. The cells counterstained with Alexa-
Flour 488 Phalloidin (binding to cellular actin) are shown in green 
 
 
3.9 In vivo distribution of PLA-Cy5 NPs 
There is growing interest of developing non-invasive, whole-body animal 
fluorescent imaging techniques to assess the biodistribution of drug delivery systems or 
diagnostic agents.  To ensure effective measurement of fluorescent signal in vivo, it is 
crucial to use red or near-IR dyes.  Quantum dots, a class of inorganic nanocrystals with 
excellent fluorescent intensity and photostability, can be readily prepared to have a far-
red emission band.   However, there is a general consensus that quantum dots cannot be 
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used in human because of their severe toxicity.  Small molecule organic dyes are 
promising probes to be coupled with imaging systems for clinical applications.    
Polymeric nanoparticles (NPs) are important carriers for the delivery of 
chemotherapeutics or imaging materials because they can provide prolonged systemic 
circulation and improved tumor accumulation compared to unformulated drugs.  To 
evaluate the biodistribution of NPs, it is particularly important to formulate NPs with 
stably incorporated fluorescent ligands and controlled formulation parameters (size, 
surface properties, etc.).  Our monomodal, narrow distributed Cy5-PLA NPs with PEG 
on the surface has the potential as the candidate of whole body in vivo imaging agents. 
The unique chemistry of the Cy5-PLA NP fabrication, allows for large 
concentrations (50 mg/kg) of Cy5-PLA NP to be safely injected into living mice without 
adverse or acute biologic consequences such as immediate or sudden death following 
intravenous delivery.  To demonstrate of the potential of using Cy5-PLA NPs as a non-
invasive fluorescence imaging agent, we conducted the intravenous injection via the 
lateral tail vein of Cy5-PLA NP to 3 female balb/c mice. After the injectons, we were 
able to study the biodistribution of Cy5-PLA NP in balb/c mice through the use of a 
highly sensitive fluorescent scanner (LI-COR Odyssey scanner).  Twenty-four hours 
following intravenous injection, Cy5-PLA NP were detected at the highest concentration 
within the spleen (fluorescent intensity >20-fold greater than background tissue 
autofluorescence).  Additionally, Cy5-PLA NPs were also identified in the liver, heart, 
kidney, and lungs (Figure 5.11).   The chemical stability of fabricated Cy5-PLA NP, in 
conjunction with the high detail tissue resolution (21 microns) capacity of the LI-COR 
Odyssey scanner, allows the possibility to study the biodistribution and biologic fate of 
Cy5-PLA NP when administered to living mice.  The combined technologies of Cy5-
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PLA NP and LI-COR Odyssey scanner will be very useful for characterizing the ability 
of Cy5-PLA aptamer NP to penetrate into established PSMA-expressing tumors when 
implanted into living mice, i.e. LNCaP xenograft studies. 
Heart and Lungs
Spleen
Liver
Kidneys
Background Cy5‐PLA NP
 
Figure 5.11  In vivo biodistribution of Cy5-PLA NP following intravenous administration.  
Visceral organ biodistribution of Cy5-PLA NP following lateral tail vein injection using the LI-
COR Odyssey scanner.  Accumulation of Cy5-PLA NP within visceral organs allows for greater 
than 10-fold increase in fluorescent intensity in comparison to background autofluorescence.  
Splenic accumulation of Cy5-PLA NP is the greatest for all visceral organs examined (spleen, 
liver, kidney, lung, and heart). 
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3.10 PLA NPs for Lewis Lung carcinoma tumor prevention 
Of all major cancers, lung cancer has the lowest 5-year survival rate at 15.3%. 
Moreover, local recurrence following lobectomy for stage I lung cancer occurs in 9% of 
patients, with documented recurrence rates increased to 24% in patients with poor 
pulmonary reserve who receive more limited wedge resections. Adjuvant therapies in 
patients unable to tolerate lobectomy (e.g., radio frequency ablation, external radiation 
treatment, placement of radioactive seeds, systemic chemotherapy) result in inferior 
outcomes, and therefore, additional treatment strategies for improved local control of 
tumor growth following surgery are needed. The local delivery of antineoplastic agents to 
the resection site at the time of limited surgical therapies (i.e., wedge resections or 
ablations) is an attractive approach, as it would enhance the local efficacy of 
chemotherapy while minimizing detrimental systemic side effects that are common with 
systemic administration. Moreover, a drug delivery system capable of preventing 
recurrence at the tumor-tissue interface would potentially extend the benefit of surgical 
therapy to improve the clinical outcomes of patients previously deemed unacceptable 
candidates for lobectomy. 
Therefore, to assess the ability of paclitaxel-loaded expansile nanoparticles to 
prevent establishment of lung cancer in an in vivo model mimicking microscopic disease 
that can remain when the surgical margin is close to the tumor, we evaluated Ptxl-PLA 
NCs in a rapidly growing subcutaneous tumor model. Specifically, we assessed the 
ability of Ptxl-PLA NCs to prevent establishment of rapidly growing LLC tumors in 
C57Bl/6 female mice compared to Ptxl alone (in clinical formulation) and controls 
without any drugs. In these experiments, 1,000,000 LLC tumor cells plus Ptxl-LA25 / 
PLGA-mPEG nanoparticles containing a total dose of 5 and 50 mg/kg incorporated Ptxl 
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were injected subcutaneously into the flank of a mouse. Other groups received the 
injection of 1,000,000 LLC cells alone or LLC cells mixed with Ptxl solubilized with 1:1 
Cremophor EL/ethanol as used clinically at 5mg/kg dosage. At 25 days, large tumors 
were noted at the site where LLC cells were coinjected with media alone, or paclitaxel 
alone. In contrast, sites receiving LLC cells plus paclitaxel-loaded expansile 
nanoparticles showed a significantly reduced incidence of tumor and tumor burden. After 
30 days, rapid growing tumors were noticed at the site where LLC cells were coinjected 
with Ptxl-LA25 NCs at 5 mg/kg; whereas tumors sizes were maintained for the group 
coinjected with with Ptxl-LA25 NCs at 50 mg/kg (Figure 5.12). The observation that 
animals receiving all other treatment regimes besides the Ptxl loaded NCs (50mg/kg) 
rapidly developed large tumors suggests that NCs are an effective delivery vehicle for 
Ptxl.  
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Figure 5.12    LLC tumor prevention study for C57Bl/6 mice, by mixing LLC cells (1,000,000) 
with Ptxl-LA25/PLGA-mPEG NPs (5 and 50 mg/kg Ptxl equiv.), Ptxl in Cremophor EL / ethanol 
(5mg/kg Ptxl equiv.) in matrigels for s.c. injection. The data showed statistical significance after 
20 days. 
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3.11 In vivo toxicity evaluation of PLA-Doxo NPs with pamidronate for bone tumor 
targeting 
A treatment for osteoporosis that is gaining popularity is bisphosphonate therapy. 
Bisphosphonates are antiresorptive medications that bind to the mineral phase of bone 
and inhibit the activity of osteoclasts. Bisphosphonates have a long history with many 
applications including use as detergent additives in hard water treatment, in toothpaste to 
prevent tartar buildup, as treatment for Paget’s disease, and as a diagnostic tool for bone 
tumor treatment. In recent years, they have been mainly studied as an osteoporosis 
therapy because of their ability to inhibit bone resorption. The complex mechanism of 
action of bisphosphonates has only recently been understood, but in general, 
bisphosphonate binds to hydroxyapatite, the main mineral component of bone. When 
osteoclasts begin to resorb the bone, bisphosphonate is taken up by the cell, which then 
loses its resorptive function and undergoes apoptosis. The loss in the ability of the 
osteoclast to resorb bone following the administration of bisphosphonates causes an 
increase in bone mineral density. We hence selected pamidronate (PAM), a well-know 
bisphosphonate drug, as the targeting ligand for bone-tumor cancer chemotherapy.  PAM 
was conjugated to the PLA-PEG-COOH through conjugation reaction using EDC/NHS. 
The resulted PLA-PEG-PAM was purified by dialysis. Doxo-LA25 was mixed with 
PLGA-mPEG/PLA-PEG-PAM in DMF and nanoprecipitation to prepare NPs with 126 
nm sizes. To validate the potential of Doxo-LA25/PLA-PEG-PAM NPs for bone tumor 
therapy, we evaluate the toxicity of NPs to tissues by histological study in balb/c mice. 
After staining by hematoxylin and eosin, kidney tissue damage was found in the group 
treated with 8 mg/kg Doxo; while no kidney tissue toxicity are found in groups received 
NPs with same and twice Doxo equivalent dose (8 and 16 mg/kg) and controls. In 
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addition PLA-PEG-PAM NPs itself did not exhibit in vivo toxicity in histological tissue 
analysis (Figure 5.13). The study demonstrated that Doxo-LA25/PLA-PEG-PAM can be 
further applied for preclinical study for bone cancer therapy. The in vivo tissue toxicity 
was also confirmed by infusion PLA-PEG-PAM NPs (50mL saline solution, 3 mg/mL 
NPs) to dogs (n=5), and no severe or abnormal symptoms were observed even few days 
after injection. 
It is noted that PAM can be labeled with 99mTc for real time in vivo imaging, 
facilitating the monitor of targeting process. The potential to employ the radionuclide 
technetium-99m with its optimal decay characteristics into targeting molecules has been 
the foremost consideration in developing diagnostic radiopharmaceuticals. 99mTc-labeled 
radiopharmaceuticals are preferred over other isotopes because of the ideal nuclear 
properties of the isotope, as well as its widespread availability from commercial 
generator columns. 99mTc emits a 140 keV γ-ray with 89% abundance, which is ideal for 
imaging with commercial γ cameras. We in situ labeled PLA-PEG-PAM NPs with 
sodium 99mTcO4  in saline and the reductant SnCl2 and quickly used for in vivo bone 
tumor targeting study in dog. Bone tumors were grown in one leg of the dog and 
confirmed by X-ray. The accumulation of PLA-PEG-PAM NPs with 99mTc labeling was 
observed in γ camera images, and the amount was increased over the time even 2 hours 
after injection (Figure 5.14). Whole body biodistribution analysis of the dog showed NPs 
were not accumulated in liver and kidney over 2 hour after infusion, suggesting NPs with 
PAM can quickly target bone tumor in vivo. It is noted that intensity was also increased 
in the bladder site after 30 hours which was suspected the 99mTc reagents might be 
sheared off from NPs. 
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Figure 5.13    Histological analysis of balb/c mice tissue sections. The mice were dosed (i.v.) 
with Doxo (8 mg/kg) and PLA-PEG-PAM / Doxo-LA25 (8 and 16 mg/kg), saline and blank NPs. 
Tissue sections from the mice kidney indicated that Doxo (8mg/kg) has severe toxicity to kidney, 
while NPs with 16 mg/kg Doxo equiv. did not show any toxicity to kidney tissues. 
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(a) (b)
(c) (d)
 
Figure 5.14    In vivo imaging of PLA-PEG-PAM NPs labeled with 99mTc for bone tumor in dog: 
X ray and 99mTc radioactive γ imagings of (a) front and (b) lateral view of dog leg with one side 
implanted with tumor. The intensity (black) area of 99mTc radioactive images indicated the 
accumation of the NPs. (c) Kinetic study of NPs accumulation in bone tumor of 1 hour (up)and 2 
hours (bottom) after injection. (d) Whole body biodistribution of NPs in dog 5 min after injection 
(top view). Site number: 1: lateral saphenous vein (NPs infusion site); 2: caudal vena cava; 3: 
urinary bladder; 4: left kidney; 5: right kidney; 6: liver; 7: heart. 
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4.  Conclusions 
In summary, we developed various techniques that allow for formulation of 
polymeric nanoconjugates with controlled chemo-physical and biological properties.  We 
developed a one-step, co-precipitation method to formulate nanoconjugates that could 
stay non-aggregated in a salt solution with the use amphiphilic triblock copolymer as the 
surfactant for particle surface modification.  We also discovered that albumin can 
function as an excellent lyoprotectant and successfully achieved the solid formulation of 
nanoconjugates that could be reconstituted with absolutely no particle aggregation. By 
incorporating the albumin-based lyoprotection technique, we demonstrated for the first 
time that polymer nanoparticles containing a conjugated nucleic acid targeting ligand can 
be prepared in solid form that can be reconstituted to well-dispersed, non-aggregated 
particles and well-maintained targeting capability. These new formulation strategies and 
findings can potentially be broadly employed for the controlled preparation of numerous 
nanoparticles. Preliminary in vivo studies showed potential application for the 
nanoconjugates system as the candidate for nanomedicine. 
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CHAPTER 6 
EFFICIENT REGIOSELECTIVE O-ACYLATION OF THERAPEUTIC AGENTS 
BY β-DIIMINATE ZINC CATALYST 
 
1. Introduction 
The development of medicinal chemistry builds upon the efficient generation of 
analogs of natural products and lead drugs.[1] Based on the statistical investigation in 
1999, alcohols are the most abundant functional group in natural products (65% of 
pharmacophors groups in 78,318 structural entries).[2] Standard O-acylation is one of the 
most commonly methods for direct derivatization. Besides, ester bond for linking 
therapeutic agents with delivery vehicles or polymeric scaffolds has been a strategy 
extensively employed in drug delivery and tissue engineering.[3] Efficient acylation of the 
hydroxyl groups (O-acylation) in these hydroxyl-containing agents is expected to 
facilitate the generation of drug analogues and the application of conjugates in drug 
delivery and even bioengineering field. However, direct and precise acylation of 
therapeutic agents are typically challenging because of their complex structures and 
multifunctional nature.[4] Enzymatic synthesis in non-aqueous solution emerged as one 
promising method in this context.[5]  Yet, the specificity in the reaction and the selection 
of enzymes leads to a limited set of natural-product analogs.[6] Miller and coworkers 
recently reported an intriguing method based on the selection of oligo-peptides as 
acylation catalysts for the regioselective reaction of complex biologically active agents 
(e.g. Erythromycin A) with anhydrides.[7] Hoveyda, Snapper and coworkers devised 
amino-acid based chiral catalyst to promote enantioselective silyation of alcohols.[8] A 
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recent remark by the director of the National Institutes of Health pointed out: 'one 
interesting result of the NIH Roadmap development process came when we surveyed 
scientists to find out what the stumbling blocks for biological sciences were. The number 
one stumbling block turned out to be synthetic organic chemistry.'[9] Given the 
importance and broad utility of releasable ester linkers, it is in great demand for new 
methodologies that allow for controlled O-acylation for many important therapeutic 
agents. 
We previously reported drug-initiated ring-opening polymerization of lactide (LA) 
in the mediation of (BDI-1)ZnN(TMS)2 catalyst[10] (BDI= β-diiminate, the structures are 
shown in Scheme 6.1(a)). When (BDI-1)ZnN(TMS)2 was mixed with hydroxyl-
containing drug molecules, (BDI-1)Zn-drug alkoxides were in situ quantitatively formed.  
The activated hydroxyl group of the therapeutic agents allows for ring-opening of LA and 
gave well-controlled ROP of LA.  Interestingly, in our development of drug-polylactide 
(PLA) nanoconjugates (NCs), we demonstrated that the reaction of succinic anhydride 
(SA) with Paclitaxel (Ptxl) or Doxorubicin (Doxo) proceeded in a highly regioselective 
manner in the presence of (BDI-1)ZnN(TMS)2 and produced corresponding prodrugs 
with tethered carboxylic acid group.[10] We initially investigated whether activation of the 
hydroxyl group of therapeutic agents by (BDI)ZnN(TMS)2 can be used for O-acylation 
by reacting with acylation-amenable reagents (Scheme 6.1).  Complex therapeutic agents 
are focused in this study due to their potential significance in the development of 
medicinal chemistry and bioconjugates. Finally we further explored the one pot acylation 
strategy, easing the protocol from more commercial available carboxylic acids instead of 
anhydrides. 
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Scheme 6.1  Regioselective O-acylation reaction mediated by BDI-Zn catalyst. (a) The O-
acylation reaction scheme of SA, ClAA, MAA and PA. (b) The chemical structures of Dasa, Cpt, 
Ptxl and Rapa. 
 
(a)
(b)
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2. Materials and Methods 
2.1 General 
BDI ligands and the corresponding metal catalysts (BDI)ZnN(TMS)2 and 
(BDI)ZnEt were prepared by following the published procedure[11] and stored at −30oC in 
a glove box. All anhydrous solvents were purified through alumina columns and kept 
anhydrous by molecular sieves. Paclitaxel (Ptxl), (S)-(+)-Camptothecin (Cpt), Dasatinib 
(Dasa) and Rapamycin (Rapa) was purchased from the LC Laboratories (Woburn, MA, 
USA), and used as received. Doxorubicin HCl salt (Doxo) was purchased from Bosche 
Scientific (New Brunswick, NJ) and used as received.  All other chemicals were 
purchased from Sigma-Aldrich (St Louis, MO, USA) and used as received unless 
otherwise noted.  Triethylamine (TEA) was dried with 4 Å molecular sieves overnight, 
transferred by a cannula under nitrogen to a clean flask containing CaH2, refluxed 
overnight, distilled and collected under nitrogen, and stored in glove box with 4 Å 
molecular sieves.   Methacrylic anhydride (MAA) was dried with CaH2  for 24 hours, 
vacuum transferred onto activated  4 Å molecular sieves, and then fractionally distilled 
under reduced pressure. The entire process was repeated. The fresh purified MAA was 
stored in the glove box fridge at -30 oC degree before use. Succinic anhydride (SA) and 
chloroacetic anhydride (ClAA) were recrystallized from chloroform and stored in the 
glove box. Pent-4-ynoic anhydride (PA) was synthesized following reference. PA was 
freshly distilled twice under reduced pressure and stored in the glove box fridge at -30 oC 
degree before use. 
The low resolution electrospray ionization mass spectrometry (LR-ESI-MS) 
experiments were conducted on a Waters Quattro II mass spectrometer. The high 
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resolution electrospray ionization mass spectrometry (HR-ESI MS) experiments were 
performed on a Micromass Q-TOF Ultima system.   
HPLC analysis was performed on a System Gold system (Beckman Coulter, 
Fullerton, CA) equipped with a 126P solvent module,  a System Gold 128 UV detector 
and an analytical pentafluorophenyl column (Curosil-PFP, 250 × 4.6 mm, 5 μ, 
Phenomenex, Torrance, CA) or an analytical C18 column (Luna C18(2), 250 × 4.6 mm, 5 
μ, Phenomenex, Torrance, CA). The UV wavelengths for analysis of Ptxl, Rapa, Cpt, 
Dasa, Doxo were 227, 280, 370, 400, 450 nm, respectively.  
NMR analyses were conducted on a Varian U500, VXR500 or UI500NB (500 
MHz). The following abbreviations are used to describe spin multiplicity: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, b = broad, dd = doublet of doublets, dt = 
doublet of triplets, dq = doublet of quartets, and ddd = doublet of doublet of doublets; 
other combinations derive from those listed. Coupling constants (J) are reported in Hertz 
(Hz). Carbon-13 NMR spectra are reported as chemical shifts in ppm based on the middle 
peak of chloroform-d (77.0 ppm) and are recorded with complete heterodecoupling. 
Analytical TLC was performed with 0.25 mm silica gel 60 plates with a 254 nm 
fluorescent indicator from Merck. Plates were developed in a covered chamber and 
visualized by UV light and by treatment with anisaldehyde stain followed by heating. 
Preparative thin layer chromatography (prep TLC) was conducted with silica gel plates 
(1500 μm thickness, Sigma-Aldrich) with a 254 nm fluorescent indicator 
PC-3 cells (ATCC, Manassas, VA, USA) were cultured in Ham’s F12K medium 
containing 10% FBS (Fetal Bovine Serum), 1000 units/mL aqueous Penicillin G and 100 
μg/mL streptomycin.  
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NTera-2 cells ATCC, Manassas, VA, USA) were cultured in Dulbecco's Modified 
Eagle's Medium (ATCC, Catalogue 30-2002) containing 10% FBS (Fetal Bovine Serum), 
1000 units/mL aqueous Penicillin G and 100 μg/mL streptomycin. The medium were 
replaced every day. 
 
2.2 Synthesis of Naph derivatives 
In a glove box, (BDI-1)ZnN(TMS)2 (6.4 mg, 0.01 mmol) was dissolved in 
anhydrous THF (200 μL). This solution was added to a clean vial containing Naph (1.7 
mg, 0.01mmol).  The reaction mixture was diluted with THF (300 μL) and stirred for 15 
min.  SA (1.1 mg, 0.011 mmol) in THF (300 μL) was added to the mixture of Npah and 
(BDI-1)ZnN(TMS)2  at [SA]0 of 0.01 M. The reaction vial was tightly sealed, 
immediately moved out of glove box, and put in a 40 oC oil bath.  The reaction mixture 
was stirred for an additional of 4 h and quenched with ice-cold methanol (1 mL).  An 
aliquot of this solution was analyzed by HPLC equipped with an analytical C18 column 
(Luna C18(2), 250 × 4.6 mm, 5 μ, Phenomenex, Torrance, CA).  The mobile phase for 
the HPLC analysis was a mixed solvent of equal volume of acetonitrile and water with 
0.1% TFA.  All HPLC spectra were recorded and analyzed with a UV detector at 280 nm. 
The areas of Naph and Naph-anhydride peaks were integrated and used for their 
quantification of the yield.  
 
2.3 Synthesis of Dasa-MAA 
Dasa (4.8 mg) was mixed with (BDI-1)ZnN(TMS)2 at 1/1 equiv in a glove box. 
The mixture was stirred for 20 min. MAA was distilled freshly before using and stored in 
glove box fridge. 1.2 equiv MAA in THF (0.5 mL) was added into the mixture and 
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further stirring over 10h at room temperature. The solution was quenched by methanol, 
and dried. The solid was redispersed at 0.5 mL methanol solution.  On 1.5 mm thick TLC 
plates, the concentrated solution was applied, and developed by ethyl acetate/methanol 
(9/1). Rf~0.3.   The silica gel was scratched from plates and extracted by methanol twice 
(2x20ml). The solution was dried and used for NMR analysis.  
MS (LR-ESI, positive mode): calcualted for C26H30N7O3SCl  [M + H]+ m/z 555.1, 
found m/z 555.1. 
 
2.4 Synthesis of Cpt-SA 
In a glove box, (BDI-2)ZnN(TMS)2 (6.2 mg, 0.01 mmol) was dissolved in 
anhydrous THF (200 μL). This solution was added to a clean vial containing Cpt (3.5 mg, 
0.01mmol).  The reaction mixture was diluted with THF (300 μL) and stirred for 15 min 
until Cpt was completely dissolved.  SA (1.1 mg, 0.011 mmol) in THF (600 μL) was 
added to the mixture of Cpt and (BDI-2)ZnN(TMS)2  at [SA]0 of 0.01 M. The reaction 
vial was tightly sealed, immediately moved out of glove box, and put in a 40 oC oil bath.  
The reaction mixture was stirred for an additional of 4 h and quenched with ice-cold 
methanol (1 mL).  An aliquot of this solution was analyzed by HPLC equipped with an 
analytical C18 column (Luna C18(2), 250 × 4.6 mm, 5 μ, Phenomenex, Torrance, CA).  
The mobile phase for the HPLC analysis was a mixed solvent of equal volume of 
acetonitrile and water with 0.1% TFA.  All HPLC spectra were recorded and analyzed 
with a UV detector at 370 nm. The areas of Cpt and Cpt-SA peaks were integrated and 
used for their quantification using the corresponding standard curves. An aliquot of 
reaction mixture was used for MS analysis.  
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Pure Cpt-SA used for NMR analysis was separated by preparative thin layer 
chromatography (prep TLC, silica gel matrix with UV254, 1500 μm thickness, Aldrich) 
and developed by ethyl acetate/methanol (10/1, v/v).  The Rf values of Cpt and Cpt-SA 
were 0.7 and 0.1, respectively.  The silica gels containing Cpt-SA were collected from the 
glass plate; the Cpt-SA in the gel was extracted with methanol (2 × 30 mL).  The 
methanol solution was then removed under vacuum; the resulting Cpt-SA was analyzed 
by 1H NMR.  1H-NMR (CD3OD, 500 MHz): δ 8.63 (s, 1H, 7-H),  8.21 (d, J = 8.5 Hz, 1H, 
12-H),  8.07 (d, J = 8.0 Hz, 1H, 9-H), 7.87 (td, Jt = 8.5 Hz, Jd = 1.5 Hz, 1H, 11-H), 7.71 
(td, Jt = 8.0 Hz, Jd = 1.0 Hz, 1H, 10-H), 7.43 (s, 1H, 14-H), 5.57, 5.44 (AB, JAB = 17.0 Hz, 
2H, 17-H), 5.35 (s, 1H, 5-H), 2.81 (t, J = 7.5 Hz, 2H, -CH2-COOH), 2.55 (t, J = 7.5 Hz, 
2H, -CH2-CH2-COOH), 2.24 (m, 2H, 18-H), 0.99 (t, J = 8.0 Hz, 19-H). MS (LR-ESI, 
positive mode): calcualted for C24H20N2O7 [M + H]+ m/z 449.1; found m/z 449.1. MS 
(HR-ESI, positive mode): calcualted for C24H20N2O7 [M + H]+ m/z 449.1349; found m/z 
449.1355. 
 
2.5 Synthesis of  Cpt-MAA 
In a glove box, (BDI-2)ZnN(TMS)2 (6.2 mg, 0.01 mmol) was dissolved in 
anhydrous THF (200 μL). This solution was added to a clean vial containing Cpt (3.5 mg, 
0.01mmol).  The reaction mixture was diluted with THF (300 μL) and stirred for 15 min 
until Cpt was completely dissolved.  MAA (1.70 mg, 0.011 mmol) in THF (300 μL) was 
dropwise added to the mixture of Cpt and (BDI-2)ZnN(TMS)2  at [MAA]0 of 0.01 M. 
The reaction vial was tightly sealed, immediately moved out of glove box, and put in a 40 
oC oil bath.  The reaction mixture was stirred for an additional of 4 h and quenched with 
ice-cold methanol/acetic acid (1.1 mL, v/v=10/1).  An aliquot of this solution was 
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analyzed by HPLC equipped with an analytical C18 column (Luna C18(2), 250 × 4.6 mm, 
5 μ, Phenomenex, Torrance, CA).  The mobile phase for the HPLC analysis was a mixed 
solvent of equal volume of acetonitrile and water with 0.1% TFA.  All HPLC spectra 
were recorded and analyzed with a UV detector at 370 nm. The areas of Cpt and Cpt-
MAA peaks were integrated and used for their quantification using the corresponding 
standard curves. An aliquot of reaction mixture was used for MS analysis.  
Pure Cpt-MAA used for NMR analysis was separated by preparative thin layer 
chromatography (prep TLC, silica gel matrix with UV254, 1500 μm thickness, Aldrich) 
and developed by ethyl acetate/dichloromethane/methanol (1/9/1, v/v).  The Rf values of 
Cpt and Cpt-MAA were about 0.1 and 0.3, respectively.  The silica gels containing Cpt-
MAA were collected from the glass plate; the Cpt-MAA in the gel was extracted with 
methanol (2 × 30 mL).  The methanol solution was then removed under vacuum; the 
resulting Cpt-MAA was analyzed by 1H-NMR.  1H-NMR (CD3OD, 500 MHz): δ  8.63 (s, 
1H, 7-H),  8.21 (d, J = 8.5 Hz, 1H, 12-H),  8.07 (d, J = 8.0 Hz, 1H, 9-H), 7.87 (td, Jt = 8.5 
Hz, Jd = 1.5 Hz, 1H, 11-H), 7.71 (td, Jt = 8.0 Hz, Jd = 1.0 Hz, 1H, 10-H), 7.43 (s, 1H, 14-
H), 6.33, 5.83 (s, C(CH3)=CH2), 5.63, 5.49 (AB, JAB = 17.0 Hz, 2H, 17-H), 5.35 (s, 1H, 
5-H), 2.81 (t, J = 7.5 Hz, 2H, -CH2-COOH),  2.26 (m, 2H, 18-H), 1.98 (s, C(CH3)=CH2), 
1.04 (t, J = 8.0 Hz, 19-H). MS (LR-ESI, positive mode): calcualted for C24H20N2O5 [M + 
H]+ m/z 417.1; found m/z 417.3.  
 
2.6 Synthesis of Ptxl derivatives 
2.6.1    General synthesis procedure 
Briefly, Ptxl (8 mg, 0.0094 mmol, 1 equiv) was be mixed with (BDI-
1)ZnN(TMS)2  (6.0mg, 0.0094 mmol) and THF (0.50mL) in a glove box. The reaction 
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mixture will be stirred for 20 min. Freshly distilled MAA (1.7 mg, 0.011 mmol, 1.2 equiv) 
in THF solution (0.20 mL) will be added into Ptxl/(BDI-1)ZnN(TMS)2 and further 
stirring for certain time. The solution will be quenched by ice-cold methanol (1mL), and 
dried under vacuum. The solid will be redispersed in methanol solution (0.30mL).  All 
HPLC spectra were recorded and analyzed with a UV detector at 227 nm. The areas of 
Ptxl and Ptxl-MAA peaks were integrated and used for their quantification of the yield. 
An aliquot of reaction mixture was used for MS analysis.  
Pure Ptxl-MAA used for NMR analysis was obtained by prep TLC. The 
concentrated reaction solution will be applied on 1.5 mm thick prep-TLC plates, and 
developed by ethyl acetate/hexane (1/3). The product will be recovered by extraction 
using methanol twice (2 x 20ml). The solution will be dried under vacuum and analyzed 
by NMR. 
2.6.2 Characterization of Ptxl derivatives 
Ptxl-MAA 
1H-NMR (500MHz, CDCl3): δ = 8.13 (d, J = 7.57 Hz, 2H), 7.72 (d, J = 7.57 Hz, 2H), 
7.62 – 7.40 (m, 11H), 6.93 (d, J = 9.14 Hz, 1H), 6.29 – 6.23 (m, 2H), 6.01 (d, J = 7.14 Hz, 
1H), 5.66 (d, J = 6.80 Hz, 1H), 5.55 (d, J = 2.24 Hz, 1H), 4.96 (d, J = 8.79 Hz, 1H), 4.43 
(m, 1H), 4.30 (d, J = 8.29 Hz, 1H), 4.20 – 4.15 (m, 2H), 3.81 (d, J = 6.71 Hz, 1H), 2.56 – 
2.34 (m, 3H), 2.45 (s, 3H), 2.21 (s, 3H), 2.19 (m, 1H), 1.95 – 1.82 (m, 3H), 1.92 s, (3H), 
1,67 (s, 3H), 1.22 (s, 3H), 1.13 (s, 3H) ppm.  
MS (LR-ESI, positive mode): calcualted for C51H55NO15 [M + H]+ m/z 922.5; found m/z 
922.5. 
MS (HR-ESI, positive mode): calcualted for  
Ptxl-2’-ClAA 
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1H-NMR (500MHz, CDCl3): δ = 8.13 (d, J = 7.57 Hz, 2H), 7.72 (d, J = 7.57 Hz, 2H), 
7.62 – 7.40 (m, 11H), 6.93 (d, J = 9.14 Hz, 1H), 6.29 – 6.23 (m, 2H), 6.01 (d, J = 7.14 Hz, 
1H), 5.66 (d, J = 6.80 Hz, 1H), 5.55 (d, J = 2.24 Hz, 1H), 4.96 (d, J = 8.79 Hz, 1H), 4.43 
(m, 1H), 4.30 (d, J = 8.29 Hz, 1H), 4.20 – 4.15 (m, 2H), 3.81 (d, J = 6.71 Hz, 1H), 2.56 – 
2.34 (m, 3H), 2.45 (s, 3H), 2.21 (s, 3H), 2.19 (m, 1H), 1.95 – 1.82 (m, 3H), 1.92 s, (3H), 
1,67 (s, 3H), 1.22 (s, 3H), 1.13 (s, 3H) ppm.  
13C-NMR (125 MHz, CDCl3): δ = 203.6, 171.1, 169.7, 167.3, 167.0, 166.9, 166.3, 142.3, 
136.4, 133.6, 133.5, 132.9, 132.0, 130.1, 129.2, 129.1, 128.7, 128.6, 127.0, 126.5, 84.3, 
81.0, 79.0, 76.3, 75.4, 75.2, 75.0, 72.2, 72.0, 58.4, 52.7, 45.5, 43.1, 40.1, 35.5, 26.7, 22.6, 
22.0, 20.7, 14.7, 9.5 ppm.  
MS (LR-ESI, positive mode): calcualted for C49H53NO15Cl [M + H]+ m/z 930.3; found 
m/z 930.3. MS (HR-ESI, positive mode): calcualted for C49H53NO15Cl [M + H]+ m/z 
930.3104; found m/z 930.3094. 
Ptxl-2’-PA 
1H-NMR (500MHz, CDCl3): δ = 8.13 (d, J = 7.28 Hz, 2H), 7.77 (d, J = 7.36 Hz, 2H), 
7.61-7.36 (m, 15H), 7.26-7.24 (m, 6H), 6.96 (d, J = 9.16 Hz, 1H), 6.30 (s, 1H), 6.26 (d, J 
= 8.9 Hz, 1H), 5.98, 5.97 (dd, J = 2.84 Hz, 2.76 Hz, 1H), 5.69 (d, J =7.08 Hz, 1H), 5.55 
(d, 1H), 4.98 (d, J = 9.36 Hz, 1H ), 4.98 ( m, 3H), 4.65 (d, J =11.9 Hz, 1H), 4.32 -4.20 (m, 
2H), 3.82 (t, J = 9.20 Hz, 1H), 2.72-2.51 (m, 6H), 2.46 (s, 3H), 2.40-2.30 (m, 1H), 2.23 (s, 
3H), 1.94 (s, 3H), 1.66 (s, 6H), 1.69 (s, 3H), 1.24 (s, 3H),  1.14 (s, 3H)  
MS (LR-ESI, positive mode): calcualted for C52H56NO15 [M + H]+ m/z 934.3; found m/z 
934.3. MS (HR-ESI, positive mode): calcualted for C52H56NO15 [M + H]+ m/z 934.3650; 
found m/z 934.3638. 
Ptxl-2’-SA 
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1H-NMR (500 MHz, CDCl3); δ = 8.13 (d, J = 7.28 Hz, 2H), 7.77 (d, J = 7.36 Hz, 2H), 
7.61-7.36 (m, 15H), 7.26-7.24 (m, 6H), 7.03 (d, J = 9.16 Hz, 1H), 6.25 (s, 1H), 6.22 (d, J 
= 8.9 Hz, 1H), 5.97, 5.95 (dd, J = 2.84 Hz, 2.76 Hz, 1H), 5.67 (d, J =7.08 Hz, 1H), 5.56 
(d, 1H), 5.47 (d, J = 2.96 Hz, 1H), 4.96 (d, J = 9.36 Hz, 1H ), 4.85-4.79 ( m, 3H), 4.65(d, 
J =11.9 Hz, 1H), 4.41 (s, 1H), 4.31 -4.27 (m, 2H), 4.19 (d, J = 8.44 Hz, 1H), 3.99 (t, J = 
9.20 Hz, 1H), 3.81-3.73 (m,3H), 3.64 (t, J = 9.20 Hz, 1H), 3.31(s, 3H), 2.72-2.51 (m, 6H), 
2.42 (s, 3H), 2.40-2.30 (m, 1H), 2.21 (s, 3H), 1.89 (s, 3H), 1.66 (s, 6H), 1.64 (s, 3H), 1.23 
(s, 3H), 1.20 (s, 3H),  1.11 (s, 3H)  
13C-NMR (125 MHz, CDCl3); δ = 203.8, 171.5, 171.2, 171.1, 169.8, 167.9, 167.3, 167.0, 
142.6, 138.4,137.2,  136.9, 133.7, 133.6, 132.8, 132.0, 130.2, 129.2, 129.1, 129.0, 128.7, 
128.5, 128.3, 127.7, 127.6, 127.2, 126.6,126.0, 101.4, 97.5, 84.4, 82.1, 81.0, 79.0, 76.4,  
75.6, 75.1, 74.3, 73.1,72.1, 71.9, 58.5, 52.8, 49.1, 45.6, 43.2,35.6, 33.9, 29.7, 29.0, 28.9, 
26.8,  25.6, 24.9, 22.7, 22.1, 20.8, 14.8,  9.6 
 
 
2.7 Synthesis of Rapa derivatives 
2.7.1    General synthesis procedure 
Briefly, Rapa (9.1 mg, 0.01 mmol, 1 equiv) was be mixed with (BDI-
1)ZnN(TMS)2  (6.5 mg, 0.01 mmol) and THF (0.50mL) in a glove box. The reaction 
mixture will be stirred for 20 min. Freshly distilled MAA (1.7 mg, 0.011 mmol, 1.2 equiv) 
in THF solution (0.20 mL) will be added into Rapa/(BDI-1)ZnN(TMS)2 and further 
stirring for certain time. The solution will be quenched by ice-cold methanol (1mL), and 
dried under vacuum. The solid will be redispersed in methanol solution (0.30mL).  All 
HPLC spectra were recorded and analyzed with a UV detector at 280 nm. The areas of 
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Rapa and Rapa-MAA peaks were integrated and used for their quantification of the yield. 
An aliquot of reaction mixture was used for MS analysis.  
Pure Rapa-MAA used for NMR analysis was obtained by prep TLC. The 
concentrated reaction solution will be applied on 1.5 mm thick prep-TLC plates, and 
developed by acetone/hexane. The product will be recovered by extraction using 
methanol twice (2 x 20ml). The solution will be dried under vacuum and analyzed by 
NMR. 
2.7.2 Characterization of Ptxl derivatives (MS) 
Rapa-40-MAA 
MS (LR-ESI, positive mode): calcualted for C55H83NO14Na [M + Na]+ m/z 1004.9; found 
m/z 1004.9.  
Rapa-40-PA 
MS (LR-ESI, positive mode): calcualted for C56H83NO14Na [M + H]+ m/z 1016.5; found 
m/z 1016.5.  
MS (HR-ESI, positive mode): calcualted for C56H83NO14Na [M + Na]+ m/z 1016.5711; 
found m/z 1016.5722. 
 
2.8 Cytotoxicity of Ptxl prodrugs for PC-3 cells.   
PC-3 cells were placed in a 96-well plate for 24 h (10,000 cells per well) before 
the addition of Ptxl-2’-MAA, Ptxl-2’-ClAA, Ptxl-2’-PA and Ptxl (as positive control). On 
the day of experiments, cells were washed with 100-μL, pre-warmed PBS, followed by 
the addition of freshly prepared Ptxl prodrugs in cell medium with selected concentration.  
The cells for negative control were incubated with just 100- μL medium.  All cells were 
incubated for a total of 72 h in an incubator with 5% CO2 at 37 oC. Standard MTT (3-
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(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay protocols was 
followed thereafter. 
 
2.9 Anti-proliferation of Rapamycin prodrugs for NTera-2 cells. 
PC-3 cells were placed in a 24-well plate for 24 h (100,000 cells per well) before 
the addition of Rapa-40-MAA, and Rapa (as positive control). On the day of experiments, 
cells were washed with 300 μL, pre-warmed PBS, and followed by the addition of freshly 
prepared Rapa and Rapa-40-MAA in cell medium (300 μL) with selected concentration.  
The cells for negative control were incubated with just 300 μL medium.  All cells were 
incubated for a total of 72 h in an incubator with 5% CO2 at 37 oC. Standard MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay protocols was 
followed thereafter. 
 
 
2.10  Potential bioconjugation application exemplified by click chemistry 
2.10.1  Materials: 
Copper(I) iodine was immobilized on the solid support, Amberlyst A-21 free base 
(PS-NMe2) following the method developed by Girard etc. The loading of Cu(I)I was ~ 
1.0 mmol/g. QP-TU beads (bearing thiourea) and PS-PPh2 beads were purchased from 
Sigma-Aldrich.  
2.10.2    Experiment procedures of CuAAC methods using : 
The azide, 1-azido-1-deoxy-β-D-glucopyranoside tetraacetate ( 2.0 equiv) and 
Ptxl-2’-PA (1.0 equiv) were dissolved in dichloromethane solution (1.0 mL) and stirring 
over 3 days onto Cu(I)I immobilized Amberlyst A-21 beads (0.1 equiv.). The reaction 
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solution was separated from bead by filtration. The CuI beads were further washed by 
DCM (2.0 mL) To remove leaching copper species in the solution, 50 mg QP-TU beads 
was added into the solution as metal scavenging. After 30 minutes, the solution was 
separated from QP-TU beads by filtration. The excess azide, contaminating the desired 
triazole product, could be removed by flowing the reaction solution through a column of 
phosphine resin (PS–PPh2), thus capturing the azide onto the solid phase as an 
iminophosphorane via a Staudinger reaction. The resulted DCM solution was 
concentrated for characterization. In general, all purities were assessed as being >95%, as 
determined by LC-ESI-MS and 1H-NMR. 
 
2.11 Chemoselectivity reaction of Doxo reacted with PA 
Briefly, Doxo·HCl salt (5.7 mg, 0.01 mmol, 1 equiv) was be mixed with (BDI-
1)ZnEt  (5.1 mg, 0.01 mmol) and THF (0.50mL) in a glove box exclusive of light. The 
reaction mixture will be stirred for 30 min. Freshly distilled PA (1.7 mg, 0.01 mmol, 1.0 
equiv) in THF solution (0.20 mL) will be added into Doxo/(BDI-1)ZnEt and further 
stirring for certain time. The solution will be quenched by ice-cold methanol (1mL), and 
analyzed by HPLC.  The HPLC spectra were recorded and analyzed with a UV detector 
at 280 nm. The areas of Doxo and Doxo-PA peaks were integrated and used for their 
quantification of the yield. An aliquot of reaction mixture was used for MS analysis.  
 
2.12 DCC/(BDI)Zn one-pot acylation 
In a glove box, PhAc (27.2mg, 0.2 mmol) in DCM (0.30 mL) was mixed with 
DCC (20.6 mg, 0.1 mmol) at -20 oC. The mixture was stored in the fridge of glove box. 
After 4 hours, (BDI-1)ZnN(TMS)2 (6.5 mg, 0.01 mmol) was mixed with Ptxl (8.5 mg, 
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0.01 mmol) in DCM (0.30mL) for 20 min. DCC/PhAc solution (30 µL) was added into 
the (BDI-1)Zn/Ptxl solution. The mixture was stirring over 3-4 h and analyze by HPLC. 
QuadTU beads (Sigma-Aldrich) were added into solution to remove Zn. The solution was 
dried, and the final product was purified by prep TLC (EtOAc/ Hex= 2/1) for NMR and 
MS analysis. 
 
 
3. Results and Discussion 
3.1 O-acylation reactions of simple hydroxyl molecules 
Inspired by the O-acylation reaction of drugs with SA in previous study, we 
utilized various commercially available anhydrides in the similar reaction as the activated 
acylation reagents.  Methyacrylic anhydride (MAA), chloroacetic anhydride (ClAA) and 
iodoacetic anhydride (IAA) were extremely reactive towards the acylation reaction with 
2-naphthalene-enthanol (Naph) in the presence of (BDI-1)ZnN(TMS)2, giving 
quantitative O-acylations products (Table 6.1). The six-membered cyclic anhydrides, e.g. 
diglycolic anhydride (DGA), are poor substrates for the acylation reaction (Data not 
shown). It was noted that cyclic SA usually requires higher temperature (40 oC) to 
achieve the quantatative reaction (Table 6.1, entry 1 vs 2). Additionally, pent-4-ynoic 
anhydride (PA) was synthesized and we found (BDI-1)ZnEt cound mediate Naph/PA 
reaction more efficiently than (BDI-1)ZnN(TMS)2 (Table 6.1, entry 6). The –N(TMS)2 
group was suspicious to have side effects on the acylation reaction in the presence of 
terminal alkyne in PA.[12] However, replacing the leaving group with carboxylate ((BDI-
1)ZnOAc) cannot initiating the acylation reaction.  
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Table 6.1    The reaction of Naph with various anhydrides under the mediation of BDI-Zn 
catalyst 
 
Entry Reactant Anhydride Catalyst Temp. (oC) Time (h) Yield (%)
1 Naph SA (BDI-1)ZnN(TMS)2 25 2 73 
2 Naph SA (BDI-1)ZnN(TMS)2 40 2 >98 
3 Naph MAA (BDI-1)ZnN(TMS)2 25 4 >98 
3 Naph MAA TEA 25 4 <10 
4 Naph ClAA (BDI-1)ZnN(TMS)2 25 4 >98 
5 Naph IAA (BDI-1)ZnN(TMS)2 25 4 >98 
6 Naph PA (BDI-1)ZnEt 40 2 92 
 
 
3.2 O-acylation reactions of Dasa and Cpt 
We next tested whether this highly efficient reaction can be extended to other 
therapeutic molecules. As a prototype complex molecule for our study of acylation 
reaction, Dasatinib (a Bcl/Abl tyrosine kinase inhibitor) with primary hydroxyl group was 
chosen to subject to the reactions with MAA in the presence of (BDI-1)ZnN(TMS)2. 
Significantly rapid reaction was observed to generate Dasa-MAA with the yield of 91% 
in 2 hours (Table 6.7, entry 1), indicating the nature of high efficiency of the zinc 
alkoxide intermediates. Another intriguing drug, 20(S)-Camptothecin (Cpt), a 
topoisomerase II inhibitor, was selected to examine. Cpt has inherent less active tertiary 
hydroxyl group, and one lactone ring which should be essentially intact to maintain its 
antitumor activity. The reaction between Cpt and MAA catalyzed by (BDI-1)ZnN(TMS)2 
generated the Cpt-MAA with the intact lactone ring, yet with lower yield of 26% even at 
40 oC for 12 hours. Asymmetric ligand BDI-2 replacing BDI-1 for zinc catalyst strongly 
improved the yield of Cpt-MAA to 82% for 4 hours (Table 6.7 entry 4). These results 
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reinforced the drastic effect of chelating ligand architectures on the catalyst activities as 
reported by Coates. It is worth noting that conventional TEA or DMAP/EDC reagent 
failed to effectively convert 20-OH of Cpt to expected derivatives, due in part to the 
instability of lactone ring and low activity of 20-OH (Table 6.7 entry 2 vs 3).  
 
Table  6.2  1H-NMR chemical shifts of Cpt, Cpt-MAA and Cpt-SA in CD3OD (500MHz)  
 
  
Cpt (δ, 
ppm) 
Cpt-SA (δ, 
ppm) 
Cpt-
MAA (δ, 
ppm) 
7-H 8.64 8.63 8.64 
12-H 8.21 8.21 8.16 
9-H 8.07 8.07 8.07 
11-H 7.87 7.87 7.86 
10-H 7.72 7.71 7.7 
14-H 7.46 7.43 7.34 
17-H 5.58, 5.41 5.57, 5.44 5.63, 5.49 
5-H 5 5.35 5.35 
6 
18-H 1.97 2.23 2.26 
19-H 1.01 0.99 1.04 
SA -
CH2COOH   2.81  
SA -
OCOCH2   2.55  
MAA 5.83 
MAA 6.33 
MAA       1.98 
 
 
3.3 O-acylation reactions of Ptxl 
We then evaluated the regioselectivity using Ptxl as model drug. The site selective 
derivatization of polyols is demanding for the powerful catalyst to exhibit kinetic 
preference based on the inherent reactivity of different hydroxyl groups. We tested O-
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acylation of Ptxl with MAA (Table 6.7 entry 5).  Ptxl is a potent mitotic inhibitor and has 
three hydroxyl groups at its C-2’, C-1 and C-7 positions, respectively (Scheme 6.1 (b)). 
The three hydroxyl groups of Ptxl differ in steric hindrance in the order of 2’-OH < 7-OH 
< 1-OH. The tertiary 1-OH is least accessible and typically inactive. The secondary 7-OH 
in Ptxl, however, could potentially compete with 2’-OH, the most accessible and active 
hydroxyl group of Ptxl. Although the reaction of Ptxl/SA mediated by Zn catalyst was 
slow, the reaction of Ptxl with MAA in the presence of (BDI)ZnN(TMS)2  at a [MAA]/ 
[Ptxl]/ [(BDI-1)ZnN(TMS)2] ratio of 1.2:1:1 at 40 oC resulted in Ptxl-2’-MAA 
with >98% yield (Table 6.7 entry 5 vs 6).  The 1H- and 2D-NMR experiments confirmed 
that the O-acylation of Ptxl was mediated exclusively by its C2’-OH; wherein the 
chemical shift of 2’-H of Ptxl-2’-MAA noticeably shifted from 4.78 ppm to 5.50 ppm; 3’-
H also from 5.78 to 5.95. Meanwhile, chemical shift of 7-H of Ptxl-2’-MAA maintained 
at 4.40 ppm, exactly same as Ptxl (4.40 ppm) (Table 6.4).  The high O-acylation activity 
and selectivity of (BDI-1)ZnN(TMS)2 were in sharp contrast to the low activity and poor 
selectivity observed with the use of triethylamine in similar reactions (the yield of Ptxl-
2’-MAA was 12.7%). The acylation of Ptxl with ClAA in the presence of (BDI-
1)ZnN(TMS)2 also favoured 2’-OH acylation with the yields over 90% (Table 6.7, entry 
7).  Interesting, the reaction of Ptxl and PA underwent smoothly in the mediation of 
(BDI-1)ZnEt with the yield of 81% in 2 hours (Table 6.7, entry 8). The regio-specific 
tethered alkyne group on Ptxl (Ptxl-2’-PA) enable the employment of bio-orthogonal 
copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) to prepare diverse analogues. A 
small scale CuAAC reaction mixing Ptxl-2’-PA (1 equiv.) with 1-azido-1-deoxy-β-D-
glucopyranoside tetraacetate (2 equiv.) catalyzed by the immobilized CuI catalyst[13] can 
readily generate 1,4-disubstitued 1,2,3-triazoles over nearly quantataive yield with the 
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further employment using commercially copper and azide-capture beads[14] (Figure 6.1), 
showing the potential broad versatility for conjugations. We also found the cytotoxicity 
of Ptxl-2’-site specific prodrugs were decreased for prostate cancer PC-3 cells over 72 
hours. (Table 6.5) 
 
Table 6.3    Site specific ring opening reaction on Ptxl, Dtxl with anhydridea 
Entry initiator R catalyst R-2'-SA %b R%b Other SA form %b
1 Ptxl (BDI-1)Mg 44.40 26.22 29.37
2 Ptxl (BDI-1)Zn 39.68 60.32 0
3 Ptxl (BDI-2)Zn 29.55 15.10 55.35
4 Ptxl (BDI-3)Zn 45.07 41.57 13.36
5 Ptxl (BDI-4)Zn 53.61 46.39 0
6 Ptxl (BDI-5)Zn 5.89 54.34 39.76
7 Dtxl (BDI-1)Zn 71.49 28.51 0
 
a The reaction vial was tightly sealed and immediately moved out from box and heated at 40 oC 
for 4 hours and quenched by 1 ml ice-cold methanol. The resulted solution was immediately 
injected into HPLC for analysis.  
bHPLC condition: analytical Luna C18(2) column (250 × 4.6 mm, 5 μ, Phenomenex, CA, USA) ; 
flow rate: 1ml/min; mobile phase: acetonitrile / water with 0.1% TFA from 50/50 to 80/20 in 40 
min. All spectrums were recorded and analyzed at 227 nm. Ptxl-SA and Dtxl-SA mixture were 
analyzed by low resolution electrospray ionization mass spectrometry (LR-ESI-MS) experiments, 
which were conducted on a Waters Quattro II mass spectrometer.Pure Ptxl-2’-SA and Dtxl-2’-SA 
for NMR analysis were separated by preparative thin layer chromatography 
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Table 6.4   1H-NMR chemical shifts of Ptxl and its derivatives in CDCl3 (500MHz) 
   Ptxl Ptxl-2'-SA (δ, ppm) 
Ptxl-2'-
ClAA (δ, 
ppm) 
Ptxl-2'-
MAA (δ, 
ppm) 
Ptxl-2'-PA (δ, 
ppm) 
3'-NH 7.01 7.01 6.93 6.95 6.96 
10 6.27 6.29 6.29 6.31 6.3 
13 6.23 6.25 6.25 6.28 6.26 
3' 5.78 6.00, 5.98 6.01 5.98, 5.96 5.98, 5.97 
2 5.67 5.69 5.66 5.7 5.69 
5 4.94 4.98 4.96 5 4.98 
2' 4.78 5.55 5.55 5.53 5.55 
7 4.4 4.44 4.43 4.47 4.45 
20 4.30, 4.19 4.31, 4.20 4.3 4.34, 4.20 4.32, 4.20 
3 3.79 3.81 3.81 3.83 3.82 
6 2.54, 1.88 2.54, 1.89 2.54, 1.86 2.58, 1.90 2.54, 1.85 
4-OAc 2.38 2.45 2.45 2.46 2.46 
14 2.35, 2.28 2.37, 2.20 2.35, 2.19 2.36, 2.17 2.34, 2.17 
10-
OAc 2.23 2.23 2.21 2.25 2.23 
18-
CH3 1.79 1.92 1.92 1.96 1.94 
19-
CH3 1.68 1.69 1.67 1.7 1.69 
17-
CH3 1.24 1.23 1.22 1.25 1.24 
16-
CH3 1.14 1.14 1.13 1.16 1.14 
other   2.56 1.95-1.82 6.18 3.57 
1.87 5.71 1.44 
            1.98 2.67 
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Table  6.5 Evaluation of Ptxl and its derivatives anticancer effect using cytotoxic assay 
(MTT assay)  
Drug IC50 (nM) 
Ptxl 87 ± 10 
Ptxl-2'-ClAA 553 ± 12 
Ptxl-2'-MAA 3477 ± 83 
Ptxl-2'-PA 397 ± 11 
 
 
 
 
 
Scheme 6.2 CuAAC reaction scheme mediated by solid bead for reaction catalyst and 
purification scavenger 
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Figure 6.1    LR-ESI-MS of the solution of Ptxl-2’-PA CuAAC reaction with 1-azido-1-deoxy-β-
D-glucopyranoside tetraacetate. The calculated MS of final compounds: [M + H]+ m/z=1308, 
found: 1308. The Ptxl-2’-SA peak ([M+H]+  m/z=934)was not found in the spectrum, indicating 
all the starting materials used up in the reaction. 
 
 
 
3.4 O-acylation reactions of Rapa 
Rapamycin (Rapa) is a macrocyclic polyketide isolated from Streptomyces 
hygroscopicus NRRL5491 as an antifungal agent and later shown as an 
immunosuppressive and antiproliferative agent, and currently approved for use in renal 
transplantation (Sirolimus, Rapamune).[15] Recently Rapa is shown to markedly impair 
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the pluripotency of hESC cell lines, prevents cell proliferation, and enhances mesoderm 
and endoderm activities in hESCs.[16] Rapa can also extend lifespan in old and genetically 
heterogeneous mice through a combination of anti-neoplastic effects.[17] One analogue of 
Rapa, temsirolimus (CCI-779), is a 40-hemiester derivativ and was approved by FDA as 
an mTOR inhibitor for the treatment of renal cell carcinoma [18]. Regioselective acylation 
of Rapa at the 40-OH has proven to be difficult, as there is another secondary hydroxyl 
group at C-28 (Scheme 6.1(b)). Low yields of desired 40-hemiesters are often observed 
due to the poor regioselectivity and the instability of Rapa in the presence of a base.[19] A 
recent study using chemo-enzymatic process for Rapa exhibited excellent yields and 
regioselectivity for some anhydride and vinyl ester.[5d] We explored whether our BDI-
Zn/drug/anhydride system can be potentially applied to Rapa with regioselectivity. First 
the mixture of Rapa and  (BDI)ZnN(TMS)2 was heated at 40 oC for 4 hours and no 
degradation species of Rapa was detected in HPLC spectrum (Figure 6.2), suggesting the 
stability of Rapa in the presence of zinc catalyst. We then examined the reactions of Rapa 
with various anhydrides under the catalysis of (BDI)ZnN(TMS)2 in anhydrous THF. 
Whereas ClAA and IAA showed no activity towards expected ester derivatives of Rapa, 
MAA was found, unexpectly in HPLC spectra, to favor the regioselective acylation with 
the yield of 96% within 6 hours at room temperature. NMR analysis of the product after 
chromatographic separations exhibited the clear C-40 derivative; in 1H NMR spectra 
comparison of Rapa-40-MAA with Rapa (CDCl3), 39-H shifted from 2.9 to 3.1 ppm and 
40-H from 3.4 to 4.7 ppm, whereas 28-H remained at same chemical shift (Table 8).[20] 
The enzymatic reaction of MAA and Rapa in the presence of Novozym 435 in anhydrous 
toluene at 40 oC gave the same regioselective product with the yield of 79% after 48 
hours (Table 6.7, entry 9), confirming our result using (BDI-1)ZnN(TMS)2. Some 
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acylation conditions (TEA, or TEA/N-methylimidazole) replaced (BDI-1)ZnN(TMS)2 for 
Rapa/MAA reaction; lack of regioselectivity and low yield were found for both 
conditions (Table 6.8). It is noticed that the reactions catalyzed by (BDI-1)ZnN(TMS)2 
are generally significantly faster than those promoted by lipase enzyme, and requires 
mild reaction condition. The regioselectivity on 40-OH of Rapa was further demonstrated 
through the reactio.n of Rapa/PA/(BDI-1)ZnEt with the yield of 67% over 4 hours (Table 
6.7, entry 10). Surprisingly, Novozym 435 was inefficient to mediate the acylation 
reaction of Rapa/PA less than 30% conversion over 24 hours. Therefore, our BDI-Zn 
catalysts appeared superior to enzymes for above acylation reaction in terms of the 
efficiency and readily available scale.  A preliminary in vitro study exhibited similar anti-
proliferation profile between Rapa and Rapa-MAA for pluripotent human embryonal 
carcinoma NTera-2 cells,[99] suggesting the regioselective modification on 40-OH of 
Rapa did not affect the activity of binding sites (to mTOR and FKBP12) in Rapa (Figure 
6.3).[21]   
 
Table 6.6   Various acylation conditions for Rapa/MAA 
 
 
 
 
 
 
 
 
 
 
 
Entry Reactant Anhydride  Catalyst Temp. (oC) Time (h) Yield (%) Regioselectivity 
1 Rapa MAA (BDI-1)ZnN(TMS)2 25 6 96 40-OH 
2 Rapa MAA Novozym 435 40 48 79 40-OH 
3 Rapa MAA TEA 40 24 <10 40 and 28-OHs 
4 Rapa MAA TEA/NMI 25 12 20 40 and 28-OHs 
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Table 6.7    O-Acylation reaction of Dasa, Cpt, Ptxl and Rapa mediated by BDI-Zn catalyst 
 
Entry Reactant Anhydride Catalyst 
Temp. 
(oC) 
Time (h) Yield (%) 
1 Dasa MAA (BDI-1)ZnN(TMS)2 25 2 91 
2 CPT SA TEA 40 4 <10 
3 CPT SA (BDI-2)ZnN(TMS)2 40 4 89 
4 CPT MAA (BDI-2)ZnN(TMS)2 40 4 82 
5 Ptxl SA (BDI-1)ZnN(TMS)2 25 4 39 
6 Ptxl MAA (BDI-1)ZnN(TMS)2 25 3 >98 
7 Ptxl ClAA (BDI-1)ZnN(TMS)2 25 4 90 
8 Ptxl PA (BDI-1)ZnEt 40 2 81 
9 Rapa MAA (BDI-1)ZnN(TMS)2 25 6 96 
10 Rapa PA (BDI-1)ZnEt 25 4 67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 184 
Table 6.8    1H-NMR chemical shifts of Rapa, Rapa-MAA and Rapa-PA in CDCl3 (500MHz)  
 
 
Rapa (δ, ppm) Rapa-40-MAA (δ, ppm) Rapa-40-PA (δ, ppm) 
-OH 4.83 4.80 4.77 
19 6.39 6.39 6.38 
20 6.32 6.32 6.29 
21 6.15 6.16 6.14 
18 5.97 5.97 5.98 
22 5.57 5.53 5.52 
30 5.42 5.43 5.32 
2 5.29 5.29 5.30 
34 5.17 5.18 5.16 
28 4.17 4.19 4.14 
14 3.86 3.87 3.92 
27 3.71 3.74 3.75 
16 3.66 3.67 3.68 
6 3.59, 3.44 3.58, 3.44 3.57, 3.47 
51 27-OCH3 3.40 3.40 3.40 
40 3.35 4.73 4.69 
50 16-OCH3 3.32 3.34 3.37 
31 3.30 3.31 3.27 
52 39-OCH3 3.14 3.14 3.13 
39 2.91 3.22 3.16 
25 2.72 2.74 
 
33 2.72, 2.56 2.72, 2.57 
 
12 1.6 1.61 
 
23 2.33 2.33 
 
38 2.10 2.10 
 
     (Table 6.8, continune on page 185) 
 
 185 
     
     
11 1.98 1.95 
 
3 1.92, 1.60 1.92, 1.60 
 
24 1.83, 1.68 1.83, 1.68 
 
4 1.78, 1.47 1.78, 1.47 
 
5 1.75, 1.48 1.75, 1.48 
 
15 1.85, 1.52 1.86, 1.52 
 
47 29-CH3 1.74 1.76 
 
44 17-CH3 1.65 1.66 
 
13 1.62, 1.33 1.62, 1.33 
 
37 1.39 1.37 
 
43 11-CH3 0.95 0.96 
 
45 23-CH3 1.05 1.06 
 
46 25-CH3 1.00 1.00 
 
48 31-CH3 1.11 1.11 
 
49 35-CH3 0.92 0.92 
 
41 1.99, 1.33 2.04, 1.34 1.98, 1.32 
42 1.70, 1.00 1.74, 0.92 
 
36 1.22, 1.12 1.21, 1.16 
 
other H 6.10 
 
 
5.56 
 
 
1.96 
 
     
 
(Table 6.8 continued) 
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Figure 6.2   HPLC spectrum of Rapa mixed with (BDI-1)ZnN(TMS)2 catalyst and heated at 40 
degree over 30 minutes. No degradation species of Rapa was found in the HPLC spectrum. The 
peak at 22.5 min with highest UV absorbance at 280 nm was Rapa. The peaks around 12-14 min 
was BDI-Zn catalyst species.  
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Figure 6.3    Evaluation of Rapa and Rapa-40-MAA anti-proliferation effect using cytotoxic 
assay (MTT assay)  
 
 
 
3.5 O-acylation reactions of Doxo 
Doxorubicin (Doxo) is a significant anti-cancer agent that contains multiple types 
of conjugation-amenable groups (three hydroxyl groups, one amine group and one ketone 
group). Clark and coworkers first showed that facile O-acylation on different OH sites of 
Doxo could be tuned with chemo-selectivity by the careful selection of various 
enzymes.[5b] We previously demonstrated that Doxo can be incorporated into PLA in a 
regio- and chemo-selective manner through its C14-OH to prepare Doxo-PLA 
nanoconjugates.[10a]  Interestingly, Doxo-14-SA was found as the predominant product in 
the reaction mixture of Doxo/SA/(BDI-1)ZnN(TMS)2. Considering MAA and ClAA have 
functional groups potentially reactive towards 3’-NH2 in Doxo, PA was selected to 
exhibit the similar regio- and chemo-selectivity as SA for Doxo. Surprisingly, when PA 
10000 nM 1000 nM 100 nM
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was mixed with Doxo in desalt form, N-acylation on 3’-NH2 proceeded rapidly and all of 
PA was consumed within 60 min. Doxo HCl salt was then mixed with PA in THF to 
eliminate fast N-acylation process. In the mixture of Doxo/PA/(BDI-1)ZnEt, Doxo-PA 
was found as one major product (different peak from the Doxo-3’-NH-PA in HPLC 
spectrum), indicating the acylation was through the hydroxyl groups and most likely on 
14-OH. Small amount of Doxo-2PA (<10%) was found in ESI-MS (Figure 6.4).  The 
profound chemo-selectivity and reasonable regioselectivity will allow for generation of 
diverse derivatives on Doxo. 
 
 
Figure 6.4 LR-ESI-MS of the solution of Doxo/PA/ (BDI-1)ZnEt reaction. 
 
 
3.6 In situ prepared anhydride for O-acylation reactions: expansion of the reaction 
scope 
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Considering the commerical availability of anhydride compared with their 
precursor, carboxylic acid, an improved acylation pathway is devised to in situ prepare 
anhydride from carboxylic acid for acylation. The difficulties were overcome by the 
beauty of the chemistry that use of 1 equivalent of N,N'-dicyclohexylcarbodiimide (DCC) 
allowing almost complete conversion of 2 equivalent acid to anhydride. Since the whole 
process can be monitored by IR (the appearance of anhydride band around 1850-1800 
cm-1), we then examined the acylation method using Ptxl with phenylacetic acid (PhAc). 
PhAc in DCM (2 equiv.) was first mixed with DCC in glove box at -20 degree over 4 
hours until quantitative acid converted to anhydride. (BDI-1)ZnN(TMS)2 reacted with 
Ptxl to generate active Zn-aloxide species before acylation (Figure 6.5). The mixture of 
two solution induce rapid acylation of Ptxl at room temperature in 3 hours, yielding Ptxl-
2’-PhAc with over 99% yield, and no 7-position acylation product was found (Figure 6.5). 
The entry using Ptxl/PhAc/DCC (1/2/1, molar ratio) provided 61% yield of Ptxl-2’-PhAc 
over 12h, suggesting the efficiency using conventional coupling reaction condition lower 
than the protocols using Zinc alkoxide (Table 6.9 entry 3 vs 4). Similar satisfactory result 
was also found for Ptxl/4-azido phenylacetic acid reaction (Table 6.9 entry 5 vs 6, >98% 
over 4 hours). We further investigated the acylation of Rapa adopting this in situ 
DCC/BDI-Zn one pot strategy, tested a selection of carboxylic acid with Rapa, whose 
hydroxyl groups are less reactive compared to Ptxl. Table 6.9 presented the results of the 
yield of acylation and regioselectivity. The acylation products of Rapa have reasonable 
yield and specific regioselectivity on 40-OH.  The outcome of the final yield might relate 
with the anhydride properties (stereo- and electronic-). The method is well-suited for the 
esterification with simple carboxylic acid ; and it may be used  for  the introduction of  
bulky protecting groups  (e.g. benzyl ).  
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Entry   Ptxl   (BDI-1)ZnN(TMS)2    PhAc     DCC  Time(h) / Temp (oC)   
 
 i           +            -                          -                -                    
 
 ii           -            -                          +               - 
 
 iii          -            -                          +               +                    2   / -20 
 
 iv         +            -                          +               +                  12   / 25.          
 
 v          +            +                         +               +                  0.5  / -20 
 
 vi         +            +                         +               +                    3   / 25 
Ptxl-2’-PhAc 
(i) 
 (ii) 
(iii) 
(iv) 
(v) 
(vi) 
PhAc 
Time (min) 
(a) 
(b) 
(c) 
(d) 
 
Figure 6.5 (a) Carboxylic acid reacted with DCC to in situ prepare corresponding anhydride; (b) 
Time line of DCC/BDI-Zn acylation strategy; (c) PhAc/Ptxl reactions setup condition; HPLC 
traces of the corresponding entry was shown in (d). 
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Table 6.9    In situ O-acylation of Ptxl and Rapa by carboxylic acid 
Entry Reactant Acid Catalyst Temp. (oC) Time (h) Yield (%) Regioselectivity 
1 Naph PhAc (BDI-1)ZnN(TMS)2 25 0.5 96 / 
2 Naph AzPhAc (BDI-1)ZnN(TMS)2 25 0.5 94 / 
3 Ptxl PhAc (BDI-1)ZnN(TMS)2 25 4 99 2'-OH 
4 Ptxl PhAc DCC 25 12 61 2'-OH 
5 Ptxl AzPhAc (BDI-1)ZnN(TMS)2 25 4 >98 2'-OH 
6 Ptxl AzPhAc DCC 25 12 48 2'-OH 
7 Rapa PhAc (BDI-1)ZnN(TMS)2 25 4 <15 40-OH 
8 Rapa PhAc (BDI-1)ZnN(TMS)2 40 4 51 40-OH 
8 Rapa PhAc DCC 40 12 <10 / 
9 Rapa PhAc DCC/DMAP/TEA 40 12 <10 / 
10 Rapa PA (BDI-1)ZnEt 40 4 82 40-OH 
 
 
4. Conclusions 
These findings illustrate the potential of site-selective modification of polyol 
natural products. In addition, the discovery of simultaneous functionalization and 
acylation may be of additional utility in the natural product analog generation for both 
medicinal chemistry and biomaterials preparation. We summarize the potential reaction 
of the derivatives mentioned in this paper (Scheme 6.3). In Ringsdorf model of polymer-
drug conjugates, both drugs and active ligands (e.g. the targeting ligand or the imaging 
probe) are attached to the backbones of hydrophilic polymers. This two-step drug 
acylation -conjugation can potentially expand the research scope in both medicinal 
chemistry and biomaterials to generate intriguing therapeutic systems. Currently we are 
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still investigating the origin of the regioselectivity mechanism. The expansion of reaction 
scope and mechanism, the automation of the reaction process, and future application of 
the catalyst with polyfunctional substrates are underway.  
 
 
 
 
 
Scheme 6.3   Potential bioconjugation reactions derived from drug-O-acylation conjugates 
Potential Reaction
Aza-Michael addition
Thiol-ene reaction
Photo-crosslinking
Olefin metathesis
Anhydride Potential Reaction Scheme
Thiol-yne reaction
[3+2] cycloaddition
SN2 reaction
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CHAPTER 7 
REVERSIBLE CELL-SPECIFIC DELIVERY OF CISPLATIN USING 
APTAMER-FUNCTIONALIZED LIPOSOMES 
 
 
1.  Introduction 
Cisplatin, or cis-diamminedichloridoplatinum(II), is a highly potent chemotherapy 
drug for many different forms of cancers. It is believed that aquated form of cisplatin 
inside the cells readily forms adducts with various biomolecules particularly DNAs.[1] 
The cisplatin-DNA adducts interfere with many DNA-mediated cellular functions 
including transcription, which eventually leads to cell apoptosis. Despite the excellent 
pharmacological efficacy of cisplatin, its application is often limited by two factors. First, 
cisplatin has little capability of targeting specific cells. Once in the bodily fluids, cisplatin 
enters cells mostly by passive diffusion.[1a] This means that normal cells are affected by 
cisplatin similarly to the cancer cells. Elevated side effects are often observed 
accompanying cisplatin administration. Second, it is not rare that some tumor cells 
develop resistance to cisplatin,[1b] which results in reduced drug potency. In theory, one 
way to overcome the latter problem is to increase cisplatin dosage. However, because of 
the poor selectivity, this approach can only lead to more serious side effects. Therefore, 
new strategies that facilitate delivery of drug molecules selectively to tumor cells are 
highly desirable. In addition, with targeted delivery, it is possible to use increased drug 
dosage without worrying about severe side effects. 
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We investigated the feasibility of using phospholipid liposomes functionalized 
with site-specific DNA aptamers as a nano-carrier for targeted delivery of cisplatin. 
Liposomes, first described in 1965,[2] are small vesicles formed by phospholipids bilayer 
similar to the cellular membranes. Being able to carry large number of hydrophilic drugs 
inside the aqueous core and hydrophobic drugs in the lipid bilayer, liposomes are among 
the most attractive drug carriers for clinical applications. Since liposomes are normally 
made of naturally existing phospholipids, they are essentially biocompatible and safe, 
with minimum cytotoxicity. Other benefits of liposomes include simple preparation and 
formulation, and easily controllable sizes. Liposomes are particularly useful for cancer 
targeting because of the Enhanced Permeability and Retention (EPR) effect of tumor 
tissues.[3] Generally, blood vessels around tumors exhibit more inconsistency than normal 
vessels and have openings ranging 100 -800 nm in diameter, allowing particles such as 
liposomes to penetrate and accumulate in tumor tissues. However, cancer targeting 
entirely based on EPR effect lacks efficiency because it usually relies on the passive 
diffusion of drug molecules from liposomes to cells. Slow drug release and fast drug 
diffusion into bodily fluids once outside the liposomes pose two major problems for 
efficient drug delivery. For example, Phase I and II studies of a cisplatin-containing 
liposome, SPI-77, showed only poor to moderate therapeutic efficacy.[4] To overcome 
this problem, liposomes have been functionalized with targeting molecules on the surface 
to promote cell-specific binding and internalization of the vesicles. Most targeting 
molecules used so far are antibodies recognizing a variety of cell surface targets.[5] The 
binding of antibodies to the cell membrane receptors triggers the receptor-mediated 
endocytosis, which is an active and site-specific internalization process and allows sub-
μm sized liposomes to enter the target cells. As a result, increased therapeutic efficacy 
 
 197 
has been observed.[6] However, using antibodies as targeting entities also poses some 
challenges. First, coupling antibodies to liposomes is not always simple. Every time an 
antibody is to be used on liposomes, it needs to be chemically conjugated to specialized 
phospholipid or polyethylene glycol (PEG) molecules.[6] Coupling site on the antibody is 
usually not predictable, which could lead to reduced binding capability. Second, it is 
known that antibodies developed in animal hosts or cells can induce immune responses 
when used in human bodies. These antibodies thus require extra humanization steps 
before any clinical applications, making the whole targeted drug delivery process even 
more complex. 
We studied to employ DNA aptamers as targeting ligands for liposome-based 
drug delivery. Aptamers are single-stranded oligonucleotides selected through an in vitro 
selection process, termed System Evolution of Ligands by EXponential enrichment 
(SELEX), to bind specific target molecules.[7] In many cases, aptamers have binding 
affinity and selectivity similar to those of antibodies, but they are produced by more 
straightforward chemical synthesis on automated synthesizers, which allows easy and 
site-specific modification and labeling on the aptamers for a variety of applications. 
Aptamer has been used for targeted drug delivery based on different drug carriers, mostly 
block copolymer nanoparticles and quantum dots (QDs).[8] However, these studies are all 
limited to one RNA aptamer that targets the prostate-specific membrane antigen (PSMA) 
on the prostate tumor cells, and so far no investigation on aptamer directed liposomal 
drug delivery has been reported despite that liposomes are biocompatible, easy to prepare, 
highly efficient, and widely used as drug carriers. In addition, coupling of nucleic acids to 
liposomes is markedly easier then other drug carrying devices. Either antibody-
functionalized liposomes or aptamer-linked nanoparticles/QDs require covalent 
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conjugation of the targeting ligands to the drug carriers. In comparison, aptamers can be 
labeled with a cholesterol moiety at the end during synthesis on an automated synthesizer. 
This cholesterol end group readily inserts into the lipid bilayer of the liposomes via 
hydrophobic interactions, thus placing the aptamer on the surface of the liposomes. With 
recent progress in the development of cell-specific aptamers,[9] especially those based on 
DNA, cell targeting aptamers are becoming more available and economical for 
biomedical research and potentially real clinical applications. Wider application of 
aptamers as targeting ligands for different drug-carrying platforms is expected following 
these new developments. Here we demonstrate that aptamer-functionalized liposomes are 
able to deliver cisplatin into target cancer cells selectively without affecting control cells. 
 More importantly, we have explored, for the first time, the use of complementary 
DNA (cDNA) of the aptamer as an antidote to block, or reverse, aptamer-facilitated drug 
delivery. One unique feature of aptamers that is often overlooked is that aptamers’ 
activity can be easily inhibited by their cDNAs because the strong base pairing between 
two complementary strands disrupts the aptamer’s target-binding conformation. This 
feature is especially useful in therapeutic applications where drug overdosage can have 
severe consequences and a good antidote or neutralizer is often hard to find. Nucleic acid 
based antidotes not only are easy to obtain, but also have predictable toxicity profiles, 
thus eliminating the safety issue associated with the antidotes. There have been reports 
applying cDNA as an effective inhibitor of the aptamer’s therapeutic activity in blood 
plasma, in animals, and even in human body.[10] However, using cDNA to inhibit 
aptamer’s cell-targeting capability as a way to block delivery of other drugs has not been 
demonstrated. Considering drug carriers such as liposomes can carry many different drug 
molecules, in a sense, the cDNA of the targeting aptamer can serve as a “universal” 
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antidote to reduce the efficacy of all these drugs on the target cells. Our results show that 
cDNA of cell-targeting aptamer clearly lowers drug effect of cisplatin encapsulated in the 
liposomes. The clinical implication of our findings is that aptamer-functionalized 
liposomes not only provide simplicity, high selectivity and high efficiency for drug 
delivery, but also offer a practical strategy for convenient and effective drug dosage 
management. 
 
2. Materials and Methods 
2.1 Preparation of DNA functionalized liposomes. 
Chemicals and reagents were from Sigma-Aldrich Corp. (St. Louis, MO) unless 
specified otherwise. The aptamer with sequence 5’- GGT GGT GGT GGT TGT GGT 
GGT GGT GGT TTT TTT TTT TT-3’, a random DNA control, 5’-GAG AAC CTG 
AGT CAG TAT TGC GGA GAT TTT TTT TTT TT-3’, and the cDNA of aptamer in 2'-
O-Methyl RNA bases, 5’-CCA CCA CCA CCA CAA CCA CC-3’, were obtained from 
Integrated DNA Technologies, Inc (Coralville, IA). Labels and modifications on the 
oligonucleotides were incorporated at the time of synthesis. HSPC, cholesterol, 
PEG2000-DSPE, and extruder were from Avanti Polar Lipids, Inc (Alabaster, AL). 
Buffer for liposome preparation contained 25 mM HEPES at pH 7.6, 150 mM NaCl, 5 
mM KCl, 1 mM MgCl2, and 1 mM CaCl2. The elution buffer for column purification of 
liposomes was the same expect containing 35 mM HEPES at pH 7.6. 
HSPC, cholesterol, and PEG2000-DSPE in chloroform were mixed at a 2:1:0.16 
molar ratio in a glass vial, with HSPC at 1.25 mg. This mixture was blown dry under N2 
and placed in a vacuum for at least 6 h. Following that, 100 μL of buffer containing 3 
nmole of cholesterol-tagged DNA was added to hydrate the dry lipids. After at least 6 h 
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at 37 °C, 400 μL buffer containing cisplatin or Calcein was added. This solution was 
gently vortexed and placed at 37 °C for 3 h. Following that, the solution was vortexed, 
and quickly frozen and thawed for at least 5 cycles. The final solution was incubated at 
37 °C overnight. The lipid mixture was then extruded to form liposomes in 200 nm 
diameter according to instructions from Avanti Polar Lipids, Inc. The liposomes were 
finally purified and separated from free cisplatin or Calcein on a column packed with 
Sephadex G-100 medium (Chalfont St. Giles, United Kingdom). 
 
2.2 Cell culture 
MCF-7 and LNCaP (ATCC, Manassas, VA, USA) used for in vitro studies were 
cultured in DMEM and Ham’s F-12K according to the vendor’s recommendation. The 
medium contained 10% FBS (Fetal Bovine Serum), 1000 units/mL aqueous Penicillin G 
and 100 μg/mL streptomycin.  
 
2.3 Confocal imaging 
MCF-7 and LNCaP cells were incubated in chamber slides in medium to allow 
70% confluence in 12-24 hours. On the experiment day, cell medium was removed. Cells 
were washed with 100 μL/well prewarmed 1X PBS and incubated with prewarmed 
OptiMEM (phenol red reduced) for 30 min before the addition of liposome solution. 
Cells were further incubated for 5h or 10 hours at 37 °C. At certain time point, cells was 
washed with prewarmed PBS three times and fixed with 4% paraformaldehyde solution 
for 10 minutes.  The cells were washed again with PBS and visualized by confocal 
fluorescent microscopy. 
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2.4 Cell viability assay 
LNCaP and MCF-7 cell lines were grown in 96-well plates with recommended 
medium at concentrations allowing 70% confluence in 24 h. On the experiment day, cells 
were washed with PBS buffer and incubated with Opti-MEM medium for 30 min at 37 
°C. After the addition of various formulations of liposomes, cells were incubated for 5 
hours and then washed with 100 μL/well PBS twice. Cells were further incubated in 
prewarmed fresh growth medium for 48 h or 96 h. Cell viability was assessed 
colorimetrically with the MTT reagent (Sigma-Aldrich) following standard protocols 
provided by the manufacturer. The absorbance was read with a microplate reader at 570 
nm. Each viability value was the average of readings from 3 wells of cells. 
 
2.5 Flow cytometry analysis 
MCF-7 and LNCaP cells were grown in 24 well plates at about 40,000/cm2 
density overnight. On the experiment day, the medium was replaced by OptiMEM and 
cells were incubated for 30 min before various liposome solutions were added into the 
wells. After 5 hours, cells were washed with 500 μL/well PBS buffer twice and treated 
with 0.25% trypsin with EDTA for 20 min. Cells were centrifuged at 1200 rpm for 5 min 
and trypsin solution was carefully removed by pipette. After washing with PBS twice, 
cells were further fixed by 4% formaldehyde solution for 10 min at room temperature. 
The formaldehyde solution was removed by centrifuge (1200 rpm, 5 min) and cells were 
further washed by PBS once. The resulted cells suspension was analyzed by flow 
cytometry in fluorescein channel. The analysis was gated at 10,000 events. 
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3. Results and Discussion 
Nucleolin is a bcl-2 mRNA-binding protein that is believed to be involved in cell 
proliferation.[11] Nucleolin overexpression has been linked to some human cancer cells 
including breast cancer cells.[12] Even though nucleolin is primarily located in cell 
nucleolus, it is also present on the plasma membrane as a surface receptor, [11] which 
provides a possible target for cancer cell specific drug delivery. A 26-mer DNA aptamer, 
called AS1411, was discovered with high binding affinity to nucleolin.[13] This G-rich 
aptamer forms special G-quadruplex structure under physiological conditions, which is 
resistant to nuclease degradation.[14] AS1411 exhibited antiproliferation activity in a few 
cancer cell lines, presumably through binding to nucleolin.[14] A recent study found that 
AS1411 bound to nucleolin and destabilized the bcl-2 mRNA, which could lead to 
apoptosis in a few breast cancer cell lines including MCF-7 and MDA-MB-231.[15] The 
same report showed that aptamer bound to the cell surface nucleolin could be effectively 
internalized into the cell cytoplasm via endocytosis. Based on these studies, we chose 
AS1411 and MCF-7 breast cancer cells as a model system to demonstrate aptamer-guided 
cisplatin delivery using liposomes. 
The aptamer sequence used in current study (NuApt) is derived from AS1411, 5’- 
GGT GGT GGT GGT TGT GGT GGT GGT GGT TTT TTT TTT TT – Cholesterol -3’. 
The 12 extra T-bases at the 3’ end make sure that the liposome surface is not too close to 
the aptamer as to affect its target binding capability. To confirm the internalization of the 
aptamer by MCF-7 cells, AS1411 was labeled with a TAMRA dye at the 5’ end and 
incubated with MCF-7 cells at 37 °C for 10 hours. Similarly, a TAMRA-labeled random-
sequence DNA underwent the same procedures. On a confocal microscope, the aptamer 
treated cells showed much stronger TAMRA fluorescence in the cytoplasm than the 
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control DNA treated cells (not shown). The fluorescence was seen predominantly in the 
MCF-7 cytoplasm instead of nucleus, in consistence with the endocytosis-based 
internalization mechanism. 
 
3.1 Internalization of aptamer-functionalized liposomes (Apt-lipos) 
The key to cell-specific drug delivery is the selective internalization of the devices 
carrying drug molecules. Endocytosis of the nucleolin aptamer by MCF-7 cells does not 
warrant that much larger liposomes can also be internalized successfully. To test the 
possibility of liposome endocytosis, we prepared aptamer-functionalized liposomes (Apt-
lipos) with a 200 nm diameter. The formula of the liposome was derived from previous 
reports,[5b, 16] and composed of hydrogenated soy phosphatidylcholine (HSPC) : 
cholesterol : methoxy poly(ethylene glycol) (Mr 2000)-derivatized distearoyl-
phosphatidylethanolamine (mPEG2000-DSPE) at a 2:1:0.16 mol ratio. Due to a high 
transition temperature of the HSPC, this composition gives liposomes increased rigidity 
and decreased permeability.[17] The inert and hydrophilic PEG polymer is commonly used 
on liposomes to increase the clearance time of the vesicles in vivo as well as reduce 
immune responses. We also observed decreased non-specific liposome internalization 
with increased PEG content, probably because hydrophilic surface PEG helped shield the 
lipid bilayer from fusing non-specifically with the cell membranes. 
Apt-lipo was prepared by mixing the above liposomal reagents with the 
cholesterol-tagged NuApt in the hydration step of liposome preparation. To monitor the 
internalization of liposomes, the vesicles were encapsulated with 4 mM fluorescent dye 
Calcein. Calcein is a hydrophilic derivative of fluorescein that is often used to trace cell 
fusion and division because it is impermeable to hydrophobic membranes. MCF-7 cells 
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were incubated with Apt-lipo containing Calcein for 5 h, then washed and fixed with 
formaldehyde before being examined on a confocal microscope. As a comparison, a 
prostate cancer cell line LNCaP, not known for having nucleolin, was used as a control. 
Figure 7.1 shows clear fluorescence from Apt-lipo treated MCF-7 cells but notable 
absence of fluorescence from LNCaP cells. In the MCF-7 fluorescence image, the bright 
spots along the outline of the cells are likely intact liposomes bound to the cell surface, 
while the dimmer but more uniform patches of fluorescence are possibly from inside the 
cells. 
To verify that Apt-lipo was indeed internalized and the fluorescence was not just 
due to the surface bound liposomes carrying Calcein, we conducted further tests using 
flow cytometry analysis. MCF-7 cells were similarly treated with Apt-lipo except that 
before formaldehyde fixing, 0.25% trypsin, a common protease, was added to cleave and 
break down any cell surface proteins. This step ensured that no membrane nucleolins 
were available to bind to Apt-lipo, therefore the fluorescence would only come from the 
Calcein dye delivered into the cells. Liposome treated and untreated cells were then 
analyzed in a flow cytometer to measure fluorescence intensity from each individual cell. 
LNCaP cells treated with Apt-lipo and MCF-7 cells treated with a random DNA attached 
liposomes were employed as the control. Figure 7.2 is the histograms showing numbers 
of cells exhibiting different fluorescence intensity. It can be seen that there is a solid shift 
to higher fluorescence on the MCF-7 cells treated with Apt-lipo compared to untreated 
MCF-7. Specifically, the median fluorescence of the treated cells is clearly higher than 
that of the untreated cells. In contrast, MCF-7 cells treated with the liposomes coated 
with a random DNA displayed little difference in fluorescence compared to the untreated 
ones. Although LNCaP cells incubated with Apt-lipo showed slightly increase in 
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numbers of cells with higher fluorescence compared to untreated LNCaP, the overall 
histogram peak did not shift significantly to higher fluorescence, evidenced by a just 
slightly increased median fluorescence. These findings have confirmed that the aptamer-
functionalized liposomes can selectively bind to MCF-7 breast cancer cells and be readily 
internalized. By changing the encapsulated dye to chemotherapy drugs such as cisplatin, 
it would be possible to realize targeted drug delivery and reduced side effects. 
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Figure 7.1 Confocal images of MCF-7 (top) and LNCaP (bottom) cells treated with aptamer-
functionalized liposomes containing Calcein. From left to right: fluorescence image, transmission 
image, and overlay.  
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Figure 7.2  Flow cytometry analysis of untreated cells (red line) and cells treated with DNA-
functionalized liposomes containing Calcein (blue line). From top to bottom: MCF-7 cells treated 
with aptamer-functionalized liposomes, MCF-7 cells treated with random DNA-functionalized 
liposomes, LNCaP cells treated with aptamer-functionalized liposomes. 
 
 
 
3.2 Cell toxicity study 
Apt-lipos were prepared to encapsulate approximately 4 mM cisplatin. The 
solubility of cisplatin in saline at room temperature is roughly 5 mM.[18] Methods to 
increase cisplatin loading in liposomes have been investigated, which include preparing 
liposomes at elevated temperatures.[18] However, cisplatin concentration is not a major 
focus of the current paper, therefore 4 mM cisplatin was used throughout the study. 
For toxicity studies, cells were incubated with Apt-lipo loaded with cisplatin 
(Apt-lipo-cisPt) at 37 °C for 5 h. Following that, the cells were washed and cultured in 
fresh media. At the Day 2 and Day 4 time points of the culturing, cells were subject to 
standard MTT toxicity assay, which measures an enzymatic product produced by viable 
cells.[19] The viability of the cells was obtained by comparing the MTT assay results from 
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treated and untreated cells and assuming the untreated cells had 100% viability. Besides 
MCF-7 cells treated with Apt-lipo-cisPt, we also tested MCF-7 treated with Apt-lipo 
without cisplatin or random DNA modified liposomes containing cisplatin (Ctrl-lipo-
cisPt), and LNCaP cells treated with Apt-lipo-cisPt. Figure 7.3 shows the viability results 
from these tests. Only the Apt-lipo-cisPt treated MCF-7 cells displayed significant cell 
death, more than 20% at Day 2 and about 60% at Day 4. In comparison, the two control 
tests involving cisplatin still had 90% cell viability at Day 4. MCF-7 cells treated with 
Apt-lipos containing no cisplatin showed no noticeable cell death even at Day 4. Even 
though the AS1411 aptamer was reported to have cytotoxicity towards MCF-7 cells,[15] 
the quantity of aptamer used in this paper was obviously not enough to cause any cell 
death. A side note here is that it is probably more economical to use aptamers as the 
targeting agents than therapeutic agents since the quantity needed is much lower and 
aptamers are usually more costly than small molecule drugs. Cytotoxicity of cisplatin 
toward MCF-7 and LNCaP cells has been previously evaluated and the IC50 values of 
about 28 μM and 5.95 μM were reported for MCF-7 and LNCaP respectively.[20] These 
numbers indicate that LNCaP cells are more prone to cisplatin induced cell death than 
MCF-7. However, by constraining cisplatin in liposomal vesicles and functionalizing the 
liposomes with cell-specific aptamers, much greater cell damage was observed for MCF-
7 cells than for LNCaP. This finding demonstrates the successful implementation of 
combining cell-recognizing aptamers with liposomes to effectively deliver cisplatin to 
diseased cells to maximize its therapeutic efficacy and minimize its side effects. 
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Figure 7.3 Cell viability assay of different liposome/cell combination. Viability measured at Day 
2 and Day 4 of liposome/cell incubation. 
 
 
 
 
3.3 Reversed cisplatin delivery 
Following the cell toxicity study, the concept of using the cDNA of aptamer to 
block liposome-based cisplatin delivery was investigated. Our proposition was that by 
forming stable double strand with the aptamer, the cDNA could disrupt the G-quadruplex 
structure of the aptamer that is required for binding nucleolin, thus blocking the delivery 
of cisplatin. The cDNA we used had a 20-base sequence of 5’-CCA CCA CCA CCA 
CAA CCA CC-3’, which was composed of all 2'-O-Methyl modified RNA bases in order 
to improve its resistance to nuclease degradation in cell culturing media. We first tested 
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concentration-dependent effect of the cDNA on cisplatin delivery and cell viability. Cell 
toxicity experiments using Apt-lipo-cisPt were carried out in the same way as mentioned 
earlier. At the beginning of the liposome/MCF-7 incubation, various amounts of cDNA 
were added to range roughly from 0 to 10 equivalents of the aptamer in the cell culture. 
Similarly, cell viability was measured by MTT assay at Day 2 and 4 time points of the 
cell culturing. Titration curves showing cDNA-dependent cell viability is presented in 
Figure 7.4. A clear ascending trend shows that excess cDNA effectively blocked cisplatin 
delivery into the cells and led to reduced cell death. With 10 equivalent of cDNA, the cell 
viability remained above 95% after 4 days. In contrast, absence of cDNA resulted in 
roughly 50% cell death in 4 days. The effect of cDNA on aptamer-based drug delivery is 
evident, which is potentially useful for dosage management in drug administration. 
In the event of drug overdose or drug induced allergic reactions, it is critical to 
apply antidotes as early as possible. The effectiveness of antidotes usually drops as it 
moves further away from the time of drug administration. It is therefore of interest to 
investigate the time dependent antidote effect of the cDNA on aptamer-based drug 
delivery. We designed experiments to mimic the actual drug administration and 
application of antidote. Based on the toxicity test mentioned earlier, at different time 
point of the Apt-lipo-cisPt/MCF-7 incubation, the 20-mer cDNA at 10 equivalents of the 
aptamer was added to the cell culture. MTT assay was done at Day 2 and Day 4. The 
time-dependent effect is shown in Figure 7.5. Cells treated with cDNA at the same time 
of liposome addition remained mostly intact throughout the 4 day period, indicating no 
cisplatin was delivered to cells when the drug carrier was blocked from the beginning. 
The cDNA added after 1 h of liposome/cell incubation still showed strong inhibition of 
cisplatin toxicity, giving cell viability over 80% after 4 days. The cell death was likely 
 
 211 
caused by fraction of drugs internalized in the first 1 h incubation. Later addition of 
cDNA showed further reduced antidote effect. The cDNA added at 5 h, the end of 
liposome/cell incubation, produced almost no effect, similar to the cells treated with no 
cDNA. This time-dependent study suggests that the cDNA of aptamer can be reasonably 
effective as antidote even 1 h after drug administration, thus giving plenty of time to 
reverse or modify the drug’s therapeutic activity. It should be noted though, for drug 
delivery based on endocytosis of aptamers, the time frame in which the cDNA antidote 
can be effective is dependent on how fast the aptamers and drug carriers are internalized 
by the cells. 
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Figure 7.4  Effect of concentration of the cDNA of aptamer on viability of MCF-7 cells 
treated with Apt-lipo-cisPt. Titration curves are constructed using viability data from Day 
2 and Day 4. 
 
 
 
 
 
 
0 2 4 6 8 10
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
1.05
 Day 2
 Day 4
C
el
l v
ia
bi
lit
y
cDNA/aptamer mole ratio
 
 213 
 
 
Figure 7.5 Time-dependent effect of cDNA on viability of MCF-7 cells treated with Apt-
lipo-cisPt. The cDNA at 10 equivalents of the aptamer was added at different time point 
of the Apt-lipo-cisPt/MCF-7 incubation, and the cell viability was measured at Day 2 and 
Day 4. 
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4. Conclusions 
Liposomes have been functionalized for the first time with cell-specific nucleic 
acid aptamers for selective delivery of cisplatin to diseased cells. The poor selectivity of 
cisplatin was largely overcome, evidenced by significant killing of target cancer cells but 
not control cancer cells. Aptamers possess some appealing features as targeting agents for 
liposome-based drug delivery. They are simple to make, can be produced in large 
quantity, and allow easy labeling and modification. Conjugation of aptamers to liposome 
carrier is especially easy compared to current strategies for targeted drug delivery. 
Furthermore, we explored the feasibility of using cDNA of the aptamer to block aptamer 
based drug delivery as a means to counteract drug overdose or drug-induced allergic 
reactions. Cisplain encapsulated in aptamer-functionalized liposomes lost its cell killing 
activity in the presence of excess cDNA of aptamer, due to disruption of the binding 
between aptamer and its cellular membrane target. In summary, aptamer-functionalized 
liposomal drug carriers, combined with therapeutic potency of cisplatin, could provide a 
simple, powerful, versatile, and safe solution to the ever increasing needs for practical 
target-specific drug delivery. 
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CHAPTER 8 
    POLYMERIZATION OF O-CARBOXYANHYDRIDES 
 
1. Introduction 
It has recently witnessed economic and social issues associated with the depletion 
of fossil feedstocks and accumulation of conventional polyolefin plastics (e.g. 
polyethylene, polypropylene and polystyrene). Aliphatic biodegradable polyesters, such 
as poly (lactic acid) (PLA), poly (glycolic acid) (PGA) and poly (hydroxylalkynote) 
(PHA), have emerged as renewable resources materials with huge potential.[1] Although 
concurrent PLA meets the requirement of a broad range of applications in industry, the 
manipulation of the polyester structure, especially in the functional group, is of high 
importance not only to substitute polyolefins with wide variety of mechanical properties 
but also to be applied in sophisticated biomedical fields such as tissue engineering 
implants. In 2002, Langer group synthesized a class of tough polyester by condensation 
of glycerol and sebatic acid.[2] Baker group and Hennink group synthesized a various 
functionalized poly (α-hydroxyl acid)s with improved mechanical properties (varied Tg).[3] 
In 2008, Hillmyer group reported the bifunctional lactide derivative to prepare 
toughening PLA derivatives.[4] The multi-step synthesis of substitute lactide monomer 
might prevent the potential industrial scale production of functionalized polyesters; while 
uncontrolled poly-condensation reaction will raise the problems of repetitive properties of 
the materials. Natural amino acids exist as another large biorenewable resource for the 
preparation of biomaterials such as polypeptides.[5] Here we present a scalable and 
concise synthetic strategy to prepare functionalized polyesters from amino acids through 
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controlled living polymerization. The strategy provides the polyester with mechanical 
toughening properties as potential substituent for polyolefins.  
 
2.     Materials and Methods 
2.1 Polymerization methods 
In a glove box, (BDI-1)ZnEt (3.8mg, 1 equiv) was mixed with Pyr-OH (1.7 mg, 1 
equiv ) in anhydrous THF (300µL). The mixture was stirred over 5-10 min. (solution A) 
PheOCA (142mg) was dissolved in anhydrous THF (1000µL) and mixed with a HMDS 
solution in THF (39mg/mL, 305µL) ([PheOCA]/[HMDS]=10/1, solution B). For 
[PheOCA]/[Zn]=100/1 reaction, solution B (184µL) was added into solution A under 
stirring(41.9µL, [PheOCA]=0.46M for the reaction solution) The conversion of LA was 
monitored by FTIR, by the disappearance of 1812 cm-1 anhydride band. The 
polymerization was completed after 6-8 hours. After diluting the concentration of 
poly(PheOCA) (PFOCA) to 20mg/mL using DMF, the solution was analyzed by GPC to 
obtain the molecular weight and distribution of PFOCA. 
 
 
3. Results and Discussion 
3.1 Synthesis of OCA monomer 
It has been reported all nineteen protected α-amino acid can be converted to 
equivalent α-hydroxyl acid.[6] L-Phenylalanine 1 was initially chosen considering its 
potential enhance of the mechanical property because of its phenyl structure. 
Diazontization of L-phenylalanine with sodium nitrite in acids efficiently provides optic 
pure 2-hydroxyl-3-pheynylpropanoic acid 2 with satisfied yield (>75%). Condensation of 
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the resulted α-hydroxyl acid 2 with phosgene by reported procedures[7] produced 
corresponding 1,3-dioxolane-2,4-diones, so-called O-carboxyanhydrides (PheOCA) 3 . 
The produced 3 is white crystal after recrystalization in glove box with reasonable yield 
(>50%). (Scheme 8.1)  
 
Scheme 8.1 Synthetic scheme of PheOCA monomer and polymerization. 
 
3.2  Screening metals for OCA polymerization 
Bourissou group previously reported the ring opening polymerization (ROP) of 
AlaOCA (or LacOCA) by using DMAP and hydroxyl initiators.[8] However, no 
polymerization proceeded when PheOCA was treated with similar condition using 
DMAP/pyrenemethanol as initiator in similar condition. Complete conversion of 
PheOCA was achieved in 12 hours at 60 oC; however the molecular weight distribution 
(MWD) was broader than expected (Mw/Mn = 1.58).  
We then turned our attention to organometallic catalysts used for PLA 
polymerization (through insertion-coordination mechanism). In this context, we screened 
a variety of metal-amido complexes (Ca, Mg, Zn, Sn) with hydroxyl initiator for their 
capability to ROP of PheOCA.[125] In contrast to the ROP of LA, the most active metal-
amido complexes, Ca[N(TMS)2]2, and Mg[N(TMS)2]2, were not able to initiate PheOCA 
polymerization; Sn[N(TMS)2]2 was also found less active to completely converted 
PheOCA for polymerization (Conv. <50%). Zn[N(TMS)2]2 was eventually found as 
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promising initiator as near quantitative conversion of monomers was detected after 12 
hours at room temperature (r.t.). (Table 8.1) In the control study of Zn[N(TMS)2]2 
without hydroxyl initiator, over 80% of PheOCA remains intact after reacting over 12 
hours, suggesting the polymerization might go through Zn-alkoxide initiated 
polymerization. Other metal alkoxides (Al(OiPr)3, Y(OiPr)3) were examined and no 
polymerization happens over 12 hours.  
 
Table 8.1  Polymerization of PheOCA. 
    
entry a R-OH catalyst  Temp.  Time(h) Conv (%) b Mn (×10
4g/mol) 
c 
MWD 
(Mw/Mn) c 
1 Pyr DMAP r.t. 24 0 -- -- 
2 Pyr DMAP 70 18 >98 2.02 1.58 
3 Pyr Ca[N(TMS)2]2 r.t. 12 0 -- -- 
4 Pyr Mg[N(TMS)2]2 r.t. 12 <50 -- -- 
5 Pyr Sn[N(TMS)2]2 r.t. 12 ~50 -- -- 
6 Pyr Zn[N(TMS)2]2 r.t. 12 >98 1.67 1.71 
7 Bn Zn[N(TMS)2]2 r.t. 12 >98 1.67 1.72 
8 -- Zn[N(TMS)2]2 r.t. 12 <20 -- -- 
9 Pyr (BDI-1)ZnN(TMS)2 r.t. 12 >98 2.34 1.33 
10 Bn (BDI-2)ZnN(TMS)2 r.t. 12 >99 2.79 1.26 
11 Bn (BDI-3)ZnN(TMS)2 r.t. 12 >98 3.21 1.22 
12 Bn (BDI-4)ZnN(TMS)2 r.t. 12 >98 1.45 1.19 
    
 
 a All reactions were performed in glove box with [PheOCA] / [R-OH] / [Catalyst] =100 / 1 / 1 
(molar ratio) in glove box at assigned conditions. Abbreviation: Temp.: temperature; Conv.%: 
conversion of monomer %; MWD: polydispersity index. bDetermined by FT-IR, monitoring the 
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disappearance of PheOCA anhydride peak at 1820-1800 cm-1. cDetermined by gel permeation 
chromatography (GPC). Theoratical molecular weight was 1.49×104g/mol 
 
 
 
3.3 Selection of Single-site Zn catalysts 
In order to eliminated undesired transesterification and other side reaction, single 
site Zn catalyst, (BDI)ZnN(TMS)2 was synthesized accordingly.[9] Since it has been 
reported that subtle modification of BDI ligands structures would affect the centre Zn 
activity for polymerization,[9c] a few of BDI-Zn variations were synthesized for testing 
their catalytic properties. The results indicated the nitrile group substituent (BDI-4) has 
significant effects on control the polymerization due in part to the electron withdrawing 
nature of the nitrile group as reported by Coates etc;[9c] while steric effect of the aryl 
substituent of BDI was not noticeably significant. We attempted the polymerization of 
PheOCA with in situ mixed (BDI-4)ZnN(TMS)2 / BnOH  resulted in quantitative 
conversion of monomer with narrow MWD and predictable Mn. Leaving group seems 
important to the polymerization. Et/ NTMS2 was found to successfully for the 
polymerization; while Zn-acetate cannot initiate polymerization. However, 
polymerization conducting with high monomer/catalyst ratio (>200/1) for all BDI-Zn 
derivative do not happen or at very low monomer conversion ratio.  
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Scheme 8.2    Various of BDI-Zn catalysts structures 
(BDI-m)ZnN(TMS)2
ligand R1 R2 R3
BDI-1 iPr iPr H
BDI-2 Et Et H
BDI-3 Et iPr H
BDI-4 iPr iPr CN
 
Table 8.2  Polymerization of PheOCA with various BDI-Zn catalyst. 
 
        
entry a R-OH catalyst  Temp.  Time(h) Conv (%) b 
Mn (×104g/mol) 
c 
MWD 
(Mw/Mn) c 
1 Pyr (BDI-1)ZnEt r.t. 12 >98 2.34 1.33 
2 Pyr (BDI-1)ZnEt r.t. 12 >98 1.29 1.05 
3 Pyr (BDI-1)ZnEt r.t. 12 <50 N.D. N.D. 
4 Pyr (BDI-1)ZnEt r.t. 12 <10 -- -- 
5 Pyr (BDI-1)ZnEt r.t. 12 <50 N.D. N.D. 
6 Pyr (BDI-2)ZnN(TMS)2 r.t. 12 >99 2.79 1.26 
7 -- (BDI-2)ZnOiPr r.t. 12 <50 N.D. N.D. 
8 Bn (BDI-3)ZnN(TMS)2 r.t. 12 >98 3.21 1.22 
9 Bn (BDI-4)ZnN(TMS)2 r.t. 12 >98 1.45 1.19 
10 Bn (BDI-5)ZnN(TMS)2 r.t. 12 <10 -- -- 
a All reactions were performed in glove at assigned conditions. Abbreviation: Temp.: temperature; 
Conv.%: conversion of monomer %; MWD: polydispersity index. bDetermined by FT-IR, 
monitoring the disappearance of PheOCA anhydride peak at 1820-1800 cm-1. cDetermined by gel 
permeation chromatography (GPC). dn/dc=0.63 based on the 100% mass recovery dn/dc program 
determination by GPC 
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3.4 Cocatalyst: the investigation of HMDS 
It is surprisingly found the BDI-Zn alkoxide has no reactivity towards the 
polymerization. However both in-situ prepared (BDI)ZnN(TMS)2 / alcohol mixture and 
(BDI) ZnEt / alcohol could initiator polymerization at the ratio of [PheOCA]/[Zn]=100/1. 
When the ratio of [PheOCA] /[Zn] was increased at 200/1 and 300/1, the conversion of 
monomer was dramatically dropped below 50% in 12 hours even for all available BDI 
ligand derivatives. In addition, raising the reaction temperature to 40-50 oC resulted in 
complicated phenomon: for (BDI-1)ZnEt the conversion of PheOCA did not increase 
over 40 %; while for (BDI-3)ZnN(TMS)2 the monomer was consumed in 12 hours at 50 
oC, resulting in polymers with relative broad distribution. We hypothesized that the only 
difference for the reaction solution was the existence of HMDS in entry. Our group 
recently developed hexamethyldisilazane (HMDS)-mediated, controlled NCA 
polymerization.  This polymerization proceeds via a unique, trimethylsilyl carbamate 
(TMS-CBM) propagating terminal group and involves the cleavage of the Si-N bond of 
HMDS during the initiation step.  The resulting TMS-amine opens NCA ring at CO-5 to 
form a TMS-amide at the C-end while the TMS group is attached to the N-end to form a 
TMS-CBM, the chain propagating group.  Polypeptide chains are propagated through the 
transfer of the TMS group from the terminal TMS-CBM to the incoming monomer to 
form a new TMS-CBM terminal propagating group. A mixture of BDIZnOiPr/ Pyr-OH 
and HMDS was tested and we surprisingly found to initiate prolymerization with Mn and 
PDI. Similar base TEA was used at the same ratio and no polymerization happens. It is 
also found HMDS ratio is independent of BDI-Zn ratio; the increase of HMDS in the 
reaction mixture significantly promoted the control and reaction rate of the 
polymerization. Even HMDS was at the same equivalent of monomer, polymerization 
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proceeded smoothly with MW nearly identical to the expected MW. The detailed 
mechanism is currently under study.  We preliminarily assumed that there is only one N-
TMS group might regulate the polymerization, similar to the NCA reaction. The mixture 
of [PheOCA]/[allyl-NTMS]/[BDI-Zn-Pyr] (300/1/1) resulted in completely consumption 
of monomer, with broad distribution (PDI=1.36, Mn=15.4 kg/mol). Currently, detailed 
NMR and MS study was conducted to investigate the polymerization mechanism. Kinetic 
study is also planned to resolve the kinetic effect of the addition of HMDS. 
Table 8.3 entries 12-14 showed the preliminary polymerization study of PheOCA 
using mPEG2k-OH as macroinitiator. The MW distribution is slightly broader and the 
MW are relatively identical to the expected MW.  The study showed the potential using 
this synthetic strategy to prepare block copolymers of PEG and various OCA. 
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Table 8.3  Polymerization of PheOCA with cocatalyst combination of (BDI)Zn and HMDS. 
ent
ry a R-OH catalyst  
[M]/[HMDS]/[
Zn] 
Tem
p.  
Time(
h) 
Conv 
(%) b 
Mcal 
(×104g/m
ol)  
Mn 
(×10
4g/m
ol) c 
MWD 
(Mw/
Mn) c 
1 Pyr (BDI-1)ZnEt 100/1/1 r.t 8 >98 1.51 2.69 1.19 
2 Pyr (BDI-1)ZnEt 200/1/1 r.t 8 >98 3.00 3.88 1.15 
3 Pyr (BDI-1)ZnEt 200/0/1 r.t 8 <20 -- -- -- 
4 -- (BDI-1)ZnOiPr 300/30/1 r.t 8 >98 4.49 3.32 1.11 
5 Pyr (BDI-1)ZnN(TMS)2  
200/20/1 r.t 8 >98 3.00 3.71 1.27 
6 Pyr (BDI-1)ZnN(TMS)2  
300/30/1 r.t 8 >98 4.49 4.78 1.21 
7 Pyr (BDI-1)ZnN(TMS)2  
400/40/1 r.t 8 >98 5.98 5.78 1.17 
8 Pyr (BDI-1)ZnOAc 100/10/1 r.t 12 <30 -- -- -- 
9 Pyr (BDI-3)ZnN(TMS)2  
400/400/1 r.t 8 >98 5.98 5.87 1.17 
10 Pyr (BDI-3)ZnN(TMS)2  
200/0/1 50 12 >98 3.00 3.69 1.47 
11 Pyr (BDI-3)ZnN(TMS)2  
200/0/1 r.t 12 <20 -- -- -- 
12 mPEG2k-OH 
(BDI-
3)ZnN(TMS)2  
100/10/1 r.t 12 >98 1.69 1.71 1.30 
13 mPEG2k-OH 
(BDI-
3)ZnN(TMS)2  
200/20/1 r.t 12 >98 3.18 3.82 1.20 
14 mPEG2k-OH 
(BDI-
3)ZnN(TMS)2  
300/30/1 r.t 12 >98 4.67 5.35 1.18 
 
a All reactions were performed in glove at assigned conditions. Abbreviation: Temp.: temperature; 
Conv.%: conversion of monomer %; MWD: polydispersity index. bDetermined by FT-IR, 
monitoring the disappearance of PheOCA anhydride peak at 1820-1800 cm-1. cDetermined by gel 
permeation chromatography (GPC). dn/dc=0.63 based on the 100% mass recovery dn/dc program 
determination by GPC 
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Table 8.4  Polymerization of PheOCA by (BDI-3)ZnN(TMS)2/HMDS. 
          
entr
y a 
R-
OH catalyst  
[M]/[HMDS]
/[Zn] 
Te
mp. 
Time
(h) 
Con
v 
(%) 
b 
Mcal 
(×104g/
mol)  
Mn 
(×104
g/mo
l) c 
M
WD 
(Mw
/Mn) 
c 
1 Pyr (BDI-3)ZnN(TMS)2 
50/5/1 r.t. 8 >98 0.77 0.97 1.13 
2 Pyr (BDI-3)ZnN(TMS)2 
100/10/1 r.t. 8 >98 1.51 1.56 1.14 
3 Pyr (BDI-3)ZnN(TMS)2 
200/20/1 r.t. 8 >98 3.00 3.17 1.11 
4 Pyr (BDI-3)ZnN(TMS)2 
300/30/1 r.t. 8 >98 4.49 4.58 1.12 
5 Pyr (BDI-3)ZnN(TMS)2 
400/40/1 r.t. 12 >98 5.98 5.78 1.19 
          
a All reactions were performed in glove at assigned conditions. Abbreviation: Temp.: temperature; 
Conv.%: conversion of monomer %; MWD: polydispersity index. bDetermined by FT-IR, 
monitoring the disappearance of PheOCA anhydride peak at 1820-1800 cm-1. cDetermined by gel 
permeation chromatography (GPC). dn/dc=0.63 based on the 100% mass recovery dn/dc program 
determination by GPC 
 
3.5 Copolymerization of OCA 
It has been reported by Coates group that the ring opening polymerization can be 
achieved in isotactic stereo-control and living manner with the mediation of BDI-Zn-
alkoxide. Since PheOCA can be also polymerized with the catalyst combination of in-situ 
prepared BDI-Zn-alkoxide/HMDS, it is hypothesized that we can achieved the 
copolymerization of LA (which representative of lactone) and PheOCA with the 
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mediation of BDI-Zn-alkoxide. It is found that the successive addition of 
PheOCA/HMDS (molar ratio 10/1) were consumed within 6 hours after PLA was 
polymerized by (BDI-1)ZnN(TMS)2 / PyrOH; in contrast, for the reverse polymerization 
sequence, monomer LA was intacted after addition to polymerized PheOCA solution. 
Although the detailed mechanism was still under investigation, it is likely the PheOCA 
chain end might not have the capability due to the structure reason to further initiator 
PLA polymerization; while BDI-Zn-alkoxide at PLA terminus remains high activity 
towards the addition of PheOCA. Table 8.5 showed the MW of various LA-co-PheOCA 
block copolymers by both GPC and NMR characterization, which were nearly identical 
to the calculated MW. This strategy potentially allowed the synthesis of various polyester 
copolymer beyond the current selection of cyclic lactones, further diversifying the library 
of polyesters and its copolymers for plastic engineering or biomedical applications. 
 
Scheme 8.3   Proposed PheOCA polymerization mechanism by (BDI)ZnN(TMS)2/HMDS 
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Table 8.5  Copolymerization of LA and PheOCA by HMDS/(BDI)-Zn catalyst 
en
tr
y a 
[LA]/[Zn
]/ [Pyr] Zn catalyst  
[PheOCA]/ 
[LA]/ 
[HMDS] 
Te
mp. 
Time
(h) 
tLA/tO
CA 
Conv 
(%) b 
LA/O
CA 
Mcal  
( ×10
4 
g/mo
l)  
Mn 
(×104
g/mo
l) c 
MW
D 
(Mw/
Mn) c 
1 100/1/1 (BDI-3)ZnN(TMS)2 
100/100/10 r.t. 6/12 96/98 2.95 3.11 1.11 
2 200/1/1 (BDI-3)ZnN(TMS)2 
100/200/10 r.t. 6/12 95/98 4.39 4.52 1.07 
3 300/1/1 (BDI-3)ZnN(TMS)2 
100/300/10 r.t. 6/12 96/98 5.83 5.64 1.03 
4 100/1/1 (BDI-1)ZnN(TMS)2 
100/100/10 r.t. 8/12 98/98 2.95 3.94 1.02 
          
a All reactions were performed in glove at assigned conditions. Abbreviation: Temp.: temperature; 
Conv.%: conversion of monomer %; MWD: polydispersity index. bDetermined by FT-IR, 
monitoring the disappearance of PheOCA anhydride peak at 1820-1800 cm-1. cDetermined by gel 
permeation chromatography (GPC). dn/dc=0.63 based on the 100% mass recovery dn/dc program 
determination by GPC 
 
 
 
4.  Conclusions 
In conclusion, we set up the basis to develop a new polymerization technique to 
synthesize various poly α-hydroxyl esters. It is expected the resulted polymers will have 
potential application for both biomedical and plastic engineering use. 
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 CHAPTER 9 
INITIAL EFFORTS FOR STEM CELL CULTIVATION 
 
1. Introduction 
1.1. Overview of induced pluripotent stem cells 
Groundbreaking work demonstrated that ectopic expression of four transcription 
factors, Oct4, Klf4, Sox2, and c-Myc, could reprogram murine somatic cells to induced 
pluripotent stem cells (iPSCs), and human iPSCs were subsequently generated using 
similar genetic manipulation. To address the safety issues arose from harboring integrated 
exogenous sequences in the target cell genome, a number of modified genetic methods 
have been developed and produced iPSCs with potentially reduced. However, delivery of 
genes to hESCs is limited because there are safety concerns with viral approaches, and 
nonviral methods have low efficacy. For nonviral vectors, testing in the H9 hESC line 
showed that commonly used lipid- and polymer-based transfection agents including 
FuGENE, LipofectAMINE Plus, and ExGen 500 transfected less than 10% of the hESCs.  
In addition, many hESC gene transfer studies lack a reliable marker to separate 
transfected undifferentiated cells from differentiating, differentiated, and feeder cells. 
Among viral gene transfer approaches, adenovirus serotype 5 has been shown to 
transduce just 11% of undifferentiated H9 hESCs, and adeno-associated virus (serotypes 
2, 4, and 5) has been shown to transduce only 0.01% at best. The most effective viral 
strategy to date has been lentiviral vectors, which have 40% transduction efficiency in 
H1 and H9 hESCs. Although the transgene expression can be further enhanced by 
concentrated virus, appropriate promoters, and drug selection after transduction, the 
safety concerns associated with insertional mutagenesis after viral integration are difficult 
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to overcome. This issue limits their potential for human gene therapy. A safe and 
effective method for gene delivery to stem cells would be invaluable to the creation of 
new cell-based therapies. 
One possible way to avoid introducing exogenous genetic modifications to target 
cells would be to deliver the reprogramming proteins directly into cells, rather than 
relying on the transcription from delivered genes. Previous studies have demonstrated 
that various proteins can be delivered into cells in vitro and in vivo by conjugating them 
with a short peptide that mediates protein transduction, such as HIV tat and poly-arginine. 
In addition, various solubilization and refolding techniques for processing inclusion body 
proteins expressed in E. coli to bioactive proteins have been developed to allow facile 
and large-scale production of therapeutic proteins. Ding and coworkers reported the 
generation of protein-induced pluripotent stem cells (piPSCs) from murine embryonic 
fibroblasts using recombinant cell-penetrating reprogramming proteins in 2009 and 
demonstrated that such piPSCs can long-term self-renew and are pluripotent in vitro and 
in vivo. For polymeric delivery system, protein delivery using micro- or nanopraticles has 
been well developed to enhance the absorption, bioavailability, and sustained therapeutic 
actions of proteins. Herein we proposed to use double emulsion method to delivery 
reprogramming proteins to mouse and human fibroblast cells in order to safely and 
efficiently generate iPS cells for potential regenerative medicine application. 
 
1.2. Scaffolds for pluripotent stem cells cultivation 
Hydrogels have attracted considerable attention. They are sometimes called smart 
materials[1] because their physical and chemical properties are subject to change in 
response to  external stimuli, such as pH, temperature, light, and electric fields [2].  Such 
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stimuli-responsive hydrogels have been applied in a range of applications as controlled 
drug delivery vehicles, sensors, and energy-transducing devices [3].  In tissue engineering, 
hydrogel have been used as the scaffolds for cell adhesion and growing; it can also be 
used for delivering therapeutics or presenting other biological cues that are critical to the 
survival and/or differentiation of cells [4]. 
Several studies have explored the culture of hESCs in defined 3D settings by 
using a variety of natural and synthetic scaffolds for cell growth, differentiation, or 
lineage guidance. There has been a considerable effort to replace more biological but less 
controllable native materials with synthetic materials. Hyaluronic acid (HA), a 
nonsulfated linear polysaccharide of (1-β-4)d-glucuronic acid and (1-β-3)N-acetyl-d-
glucosamine, have been demonstrated to support hESC growth in vitro, since it can co-
regulate gene expression, signaling, proliferation, motility, adhesion, metastasis, and 
morphogenesis of hESCs. Besides its known role in embryogenesis, HA scaffolds have 
been reported for the cultivation of hESCs in 2007. HA-based hydrogels can maintain the 
undifferentiated state of hESCs in the presence of conditioned medium from MEFs until 
soluble factors are introduced to direct cell differentiation. The cultivation of hESCs in 
HA hydrogels maintained the state of cell self-renewal and enabled EB formation from 
released cells. However, the culture systems with cues simply added apparently cannot 
mimic the complex extracellular environments where growth factors and other biological 
cues are often secreted at controlled, optimal rates [4e, 5]. Numerous studies have 
demonstrated that the microenvironment and nano-structured hydrogel matrices plays 
significant roles to stem cell cultivation and self-renewal [6].   
Direct ink writing (DIW) is a layer-by-layer assembly technique in which 
materials are patterned in both planar and 3D forms with lateral feature sizes that are at 
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least an order of magnitude smaller than those achieved by ink-jet printing and other 
rapid prototyping approaches, and nearly comparable in size to those produced by two-
photon polymerization and interference holography. Central to this approach is the 
creation of concentrated inks that can be extruded through fine deposition nozzles in 
filamentary form, and then undergo rapid solidification to maintain their shape even as 
they span gaps in the underlying layers. We herein report the creation of hydrogel inks of 
HA that can be printed directly in air using DIW technique, where they undergo 
solidification via photopolymerization. Pluoripotent human testicular embryonal 
carcinoma cell NTera-2 can be cultivated in the resulted 1D and 3D hydrogel scaffolds 
without significant differentiation and the expression of Oct4, one of the key 
reprogramming proteins for pluripotency. Considering the tenability of the nanostructure 
using DIW, this technique for cultivation of human pluripotent stem cells is expected to 
have great potential for the tissue engineering and regenerative medicine. 
 
2. Materials and Methods 
2.1. Preparation of NPs encapsulating proteins by flow cytometry 
Nanoparticles of various sizes were formulated according to the reference. Briefly, 
an aqueous protein solution (10% w/v) was emulsified in PLGA-mPEG (50 mg/mL) in 
DCM solution, using a probe sonicator for 1 min. The emulsion was poured into 1% PVA 
solution and sonicate over an ice bath for 3 min. The resulting emulsion was further 
dilute by 100 mL 0.5% PVA solution. The resulted solution was stirred in fume hood 
over 6 hours to evaporate DCM. The NPs solution was further centrifuged under 3000 
rpm over 30 minutes, washed by DI water twice (50mL). NPs were finally concentrated 
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and collected by ultrafiltration (3000 rpm, Ultracel membrane with 10,000 NMWL, 
Millipore, Billerica, MA).  
 
2.2. Cell uptaking efficiency analysis by flow cytometry 
IMR 90 cells were grown in 24-well plates in DMEM medium (American Type 
Culture Collection), respectively, supplemented with 100 units/ml aqueous penicillin G, 
100 μg/mL streptomycin, and 10% FBS at concentrations to allow 70% confluence in 24 
h (i.e., 40,000 cells per cm2). On the day of experiments, cells were washed with 
prewarmed PBS and incubated with prewarmed phenol-red reduced OptiMEM media for 
30 min before the addition of the PLGA-PEG/BSA-FITC (50 μg) NPs. The cells were 
incubated for 7 h at 37oC, washed with PBS (2× 500 μL per well) and subsequently 
treated with 0.25% trypsin with EDTA for 10 min. The cells were transferred to a 15-mL 
falcon centrifuge tube and centrifuged at 1200 rpm for 5 min followed by removal of the 
trypsin solution using a pipette. After the cells were washed with PBS (2× 500 μL/well), 
they were fixed with 4% formaldehyde for 10 min at room temperature, washed with 
PBS (1× 500 μL) and analyzed by FACS.    
 
2.3. Cell uptaking efficiency analysis by fluorescence microscope 
IMR 90 cells were grown in chamber slides in DMEM medium (American Type 
Culture Collection), respectively, supplemented with 100 units/ml aqueous penicillin G, 
100 μg/mL streptomycin, and 10% FBS at concentrations to allow 70% confluence in 24 
h (i.e., 40,000 cells per cm2). On the day of experiments, the medium was replaced with 
Opti-MEM medium (200 μL) containing PLGA-PEG NPs encapsulating FITC-BSA.  
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The cells and NPs were co-incubated for 7 h, after which the cells were washed with PBS 
(3 × 200 μL), fixed with 4% formaldehyde, mounted and then analyzed on a Leica SP2 
Laser Scanning Confocal Microscope at 10× magnification.  
 
2.4. Synthesis of HA-MA 
Methacrylated hyaluronic acid (HA-MA) was synthesized by the addition of 
methacrylic anhydride (Sigma, 20-fold excess) to a solution of 1 wt % HA (Lifecore, 
MW = 50, 350, and 1100 kDa) in deionized water adjusted to a pH of 8 with 5 M NaOH 
(Aldrich) and reacted on ice for 24 h. This synthesis was previously described, and the 
structure is shown in Figure 9.1. For purification, the macromer solution was dialyzed 
(MW cutoff 5−8 kDa) against deionized water for at least 48 h, and the final product was 
obtained by lyophilization. 
 
2.5. Ink preparation  
The ink was initially formed by mixing 1mL deionized water (Milli-Q, Millipore), 
5 g of glycerol (Sigma Aldrich), and. These constituents were magnetically stirred at 
room temperature until the acrylamide was fully dissolved. 
 
2.6. Direct-writing assembly of HA-MA hydrogel scaffolds 
Micropipette tips (World Precision Instruments) with diameters ranging from 1 to 
10mm were coated with a thin gold film (200 nm thick) to prevent photopolymerization 
of the ink prior to exiting the deposition nozzle. The micropipettes were mounted onto a 
rotating holder to ensure an even coverage, and coated inside ametal evaporator (Denton 
VacuumDV-5024). Coverslip substrates were cleaned in piranha (sulfuric acid, hydrogen 
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peroxide) solution for 1 h, rinsed with deionized water, and dried with nitrogen. 
Coverslips were placed in a 98% toluene (Fisher Scientific), 2% 3-(trimethoxysilyl)- 
propyl methacrylate (Acros) solution for 18 h at 60 8C. The slides were removed just 
prior to drawing, rinsed with isopropanol, and dried. The ink was loaded into a syringe 
with an attached gold-coated tip in place. Once the substrate was leveled, ink flow was 
initiated by applying a pressure of 70–80 psi (1 psi = 6894.76 Pa). After the flow had 
begun, the pressure was reduced to 20–30 psi and the patterning was initiated. The 
printed scaffolds were defined by filament width, spacing between filaments, total 
patterned area, number of layers, and their geometry. We created both planar and 3D 
scaffolds with 1 to 5 mm filaments and a 5 to 20 mm spacing between filaments over 
5mm2 areas with 1–6 layers. A UV lamp (Omnicure S200; Exfo) with a 320–400 nm was 
used to expose the patterned structure to 5mW/cm2 during the deposition process. Once 
patterning was complete, the scaffolds were exposed to a higher-intensity UV light 
source, 400mW/cm2, for 20min to ensure a fully photocured structure. To drive off 
excess water and enhance scaffold rigidity, each scaffold was then heated to 60 oC for 18 
h.  
 
2.7. General cell culture 
NTera-2 cells (pluripotent human embryonal carcinoma cells) were purchased 
from American Type Culture Collection (ATCC) and were cultured according to ATCC 
recommendations. BG01v-Oct4-GFP and NTera-2-Oct4-GFP cell lines were provided by 
Fei Wang lab and cultured in Fei Wang lab with instructed medium. 
 
2.8. Scaffold imaging 
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The printed hydrogel scaffolds were soaked in deionized water for three days 
prior to cell culture to leach out glycerol andany unpolymerized acrylamide. Reflected-
light optical microscopy (IX71; Olympus) was performed prior to cell plating to ensure 
structural integrity of the scaffolds. SEM images were obtained using a Philips 
XL30ESEM-FEG; structures were dried and sputter-coated with gold prior to imaging. 
 
2.9. NTera-2-Oct4-GFP cells cultivated in HA-MA scaffolds 
HA-MA scaffolds were first washed by PBS over 24 hours, and Opti-MEM over 
24 hours before use. HA-MA scaffolds were sterilized prior to cell plating through UV-
light exposure in the laminar flow hood for 20min. On the day of experiment, NTera-2 
cells in culture medium (~5,000/mL) was gently pipetting onto the top of glass slides 
with HA-MA scaffolds. After 24 hours, the medium was removed. The medium was 
replaced everyday. 
 
 
 
3. Results and Discussion 
3.1. Delivery of FITC-albumin to 3T3 and IMR-90 cells 
Various different sizes of NPs were prepared by double emulsion method to 
encapsulate BSA-FITC, which was used as a model protein molecule. We started to 
investigate the uptaking behavior of NPs/BSA-FITC in 3T3 fibroblast cells. Similar to 
the previous work, 160 nm sizes NPs was found to be uptaken by 3T3 cells with higher 
efficiency (47%) than 260 nm size NPs (29%) after 7 hours incubation, characterized by 
flow cytometry. Similar result was also observed through fluorescence microscope. 160 
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nm NPs/BSA-FITC was further tried in the human fibroblast cell line, IMR-90, which is 
the precursor cells used for the generation of iPSC. Satisfactory uptaking efficiency (37%) 
over 7 hours incubation was measured by flow cytometry (Figure 1), suggesting the 
potential of using protein delivery for the iPSC generation and culture. 
 
 
 
Figure 9.1    (a) fluorescence image of IMR-90 cell uptaking 1mg/mL PLGA-PEG/BSA-FITC 
after incubation for 7 hours. Left: fluorescence; right: overlay. (b) FACS analysis of IMR-90 cells 
uptaking different size NPs. 
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3.2. Delivery of Sox2 to MEF cell line 
Sox2 protein was labeled with TAMRA dyes for the flow cytometry and 
fluorescence microscope. NPs encapsulating Sox2 was formulated using above double 
emulsion strategy to provide ~140 nm NPs. Reasonable uptaking efficiency (24%) was 
detected for MEF cells by flow cytometry after incubation over 16 hours. The 
colocalization of Sox2 with cell nucleus is under investigation (Figure 2).  
 
 
Figure 9.2    (a) fluorescence image of MEF cell uptaking 1mg/mL PLGA-PEG/Sox2-TAMRA 
after incubation for 16 hours. Left: fluorescence; right: overlay. (b) FACS analysis of MEF cells 
uptaking NPs for different time. 
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3.3. Preparation and characterization of ink for directed writing 
The ink is prepared by first mixing methacylate- hyaluronic acid (HA-MA), 
glycerol, water, polyethylene glycol-diacylate (PEG-DA, MW=700Da) and photoinitiator 
I-2959 at the ratio of 8/50/50/8/0.1 (w/w). PEGDA was used as the crosslinking agents. 
The solution becomes homogeneous over 12 hours aging. The original ink was found 
occasionally stuck during the printing process. To optimize the ink condition, tween-20 
was added into the ink with 0.1wt % ratio. The improved ink showed the improved 
mechanical properties. We also studied the PEG molecular weight effects different ratios 
on the stability of the HA hydrogels. Without low molecular weight PEG, the gel was not 
stable in DMEM cell medium. HA molecular weight is also critical to the mechanical 
behavior and stability of scaffolds in the cell medium. 
 
(a) (b) 
(c) 
 
 
Figure 9.3 (a) Schematic illustration of direct-writing assembly through a silver-coated 
deposition micronozzle that is simultaneously photopolymerized via UV illumination; structure of 
(b) hyaluronic acid (HA) and (c) methacrylate hyaluronic acid (HA-MA). The acylate group (blue) 
which is used for photopolymerization for crosslinking hydrogel 
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3.4. Preparation of hyaluronic acid hydrogel scaffolds by DIW technology 
Using this modified DIW process, we pattern HA hydrogel scaffolds with 
precisely defined filament diameter, spacing, number of layers, and geometry. As a first 
example, we created hydrogel scaffolds composed of 5mm filaments with a 20mm 
spacing between filaments with 1–4 layers and a total area of 5mm2 (Figure 9.4a and 
Figure 9.5b). To further demonstrate the capability of this novel approach, hydrogel 
scaffolds were printed with nominally 1 mm filaments with 5mm spacing between 
filaments with a total area of 1mm2, as shown in Figure 9.4e. 
  
3.5. NTera-2 cells culture in 1D and 3D hyaluronic acid hydrogel scaffolds 
For this particular cell pluripotency study, it is important to note that some of 
these cells may be differentiated and others may be feeder cells. To avoid this, we made 
NTera-2-Oct4-GFP and hES BG01v-Oct4-GFP cells by introducing the hOct4-GFP-puro 
construct into hESCs. In this construct, the GFP reporter gene is expressed by the Oct4 
promoter that is active when cells are in an undifferentiated state. Upon differentiation, 
the Oct4 promoter is gradually inactivated; therefore, the GFP reporter is downregulated. 
With these cells, pluripotent cells can be clearly distinguished from differentiated stem 
cells and feeder cells.  
To determine their suitability for tissue-engineering applications, NTera-2 cells 
are first plated onto a flat glass substrate (control) as well as 1D and 3D micro periodic 
hydrogel scaffolds using HA-MA and HEMA. The cells plated on the control substrate 
display the typical flattened-out morphology shown in Figure 9.5(e). By contrast, cell 
interactions with the underlying glass substrate and patterned features result in their 
alignment along the patterning direction of the 1D microperiodic hydrogel scaffolds, as 
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shown in Figure 9.4(c-e). This type of elongated morphology is similar to that observed 
by us on 1D periodic patterned surface. We observed atypical fibroblast morphology in 
response to the 3D micro-periodic HA-MA hydrogel scaffolds (Fig. 5c and d), in which 
NTera-2 cells integrate themselves into the regions between interconnecting hydrogel 
filaments. It is found that the cells tend to sit in the square well created by interconnected 
filaments and then grow down into the scaffold towards the underlying glass substrate. 
Additionally, when the fibroblasts are in neighboring compartments, we observe 
interactions between the filaments of adjacent fibroblast cells (Figure 9.5d). In addition, 
for both 1D and 3D micro-periodic hydrogel scaffolds, green fluorescence was observed 
almost for every NTera-2 cells. The sustainable growth of NTera-2 cells was also 
noticeable shown in Figure 9.4(c-d) from 1 to 9 days. Some NTera-2 cells even expanded 
upon the periodic filaments (Figure 9.4d). These microscopy imaging study demonstrate 
the HA-MA scaffolds with well defined nanostructures have the capacity to support the 
growth and self-renewal of NTera-2 cells without disturbing the expression of Oct4. In 
contrast, synthetic pHEMA scaffolds lacked the biological capability for the plating and 
cultivation of Ntera-2 cells (Figure 9.5 e and f). 
 
 
 244 
(e) 
(d) (c) 
(a) (b) 
 
Figure 9.4  Optical image of a 1D hydrogel scaffold (a) during and (b) after using direct ink 
writing with the ink of  HA-MA (350k) ; Overlay images (light and green fluorescence) of 1D 
HA-MA scaffolds plated with Ntera-2-Oct4-GFP cells over (c) 1  day and (d) 9 days; (e) Overlay 
images (light and green fluorescence) of 1D large area HA-MA scaffolds with Ntera-2-Oct4-GFP 
cells over 4 days. The color in the green fluorescence channel indicated the expression of OCT4. 
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(b) (a) 
(c) 
(f) 
(d) 
(e) 
 
Figure 9.5  Optical image of a 3D hydrogel scaffold during direct ink writing using the ink of (a) 
HA-MA 50k and (b) HA-MA 350k (the composition and other components are the same); (c) and 
(d) Overlay images (light and green fluorescence) of 3D HA-MA scaffolds plated with Ntera-2-
Oct4-GFP cells over 4 days; (e) and (f) Overlay images (light and green fluorescence) of 3D 
HEMA scaffolds plated with Ntera-2-Oct4-GFP cells over 4 days. The color in the green 
fluorescence channel indicated the expression of OCT4. 
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4. Conclusions 
The initial study explored the possibility to use NPs delivering proteins to various 
fibroblast cells in order to generate iPSC. The combination of cell penetration peptide and 
nanotechnology for protein delivery would be expected to benefit the stem cell culturing 
and generation. 
We present the development of constructing 3D HA scaffolds using DIW 
techniques. BG01 human embryonic stem cells are planned to be further plated on the 
scaffolds. This technique for cultivation of human pluripotent stem cells is expected to 
have control on the hESC self-renewal process and cell colony size. The exploration of 
3D nanostructure parameter and ESC behavior will be investigated in the near future. 
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